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Evolution of incidence of glomerulonephritis in Spain during 1987 and
1988. Spanish Glomerulonephritis Registry (REGN). The Spanish Gb-
merulonephritis (GN) Registry (REGN) has done an epidemiobogical
study about the overall incidence of GN in Spain during 1987 and 1988.
Patients were classified according to their kidney histological features
into 8 categories of primary GN (PON) and 4 of secondary GN (SON).
Patients were considered as "adults" when they were 15 years old and
over, and "children" if they were younger. Excluded from the study
were patients with a functioning kidney allograft. The incidence of
hospital request response was 77%. Biopsies were obtained in 74
hospitals with an adherent estimated population of about 22 million
inhabitants. The number of biopsies-patients registered during 1987 was
1036 and 1087 during 1988. PGN were 73,2% in 1987 and 74.8% in 1988.
During the study it became apparent that there were some regional
differences in classifying into primary or secondary GN. Adult results:
Annual ratio of membranoproliferative GN/PGN kept decreasing ac-
cording to the expected behavior proposed by the ON Cooperative
Study in previous reports: 8.991o-'—1987 and 8.3%—l988. In the northern
Spain MPGN frequency remained stable, about 13%. The percentage of
MPGN type l1/PGN has not changed during these years. IgA nephrop-
athy incidence remained without significant variation, about 23%, being
the most frequent PGN in Spain. A significant increase in membranous
nephropathy incidence has been observed, 13.9% with respect to
previous periods, 10.2%, P < 0.01. The frequency of idiopathic
nephrotic syndrome (INS) remained unchanged, 23%, with 11% of
minimal change lesion (MChL) and 12% of focal gbomerulosclerosis and
hyalinosis (FGS). Extracapillary ON is more frequent in northern than
in the rest of Spain. An overall annual incidence of 43 new ON per
million of adult inhabitants was found, of whom 32 belonged to PGN.
Lupus erythematosus nephropathy represents a 33.5% of SON in
Spain, and is significantly more frequent in the southern Spain. Sys-
temic vasculitis, with 23.5%, is the second most frequent cause of SON.
GN associated with neoplasia were found only in 3.7% of SGN.
Children results: MPGN frequency continued to decrease during 1987—
88, 4.3%. IgA nephropathy represents 20% of PON, and INS 48.7%,
with 33% for MChL and 15.7% for FGS. Vasculitis was the first cause
of SON, 51.5% (Schonlein-Henoch purpura) and LES 18.2% the second
one.
Bicarbonate biofiltration (BBF). C. Sanz-Moreno, F. Fdez-Giron, E.
Armada, J. Fdez-Fdez, D. Sanz-Guajardo, J. Botellu, Hospital Puerta
de Hierro, University Autónoma, Madrid, Spain. The biofiltration
technique (BF) corrects acidosis in RDT patients by reinfusing bicar-
bonate. However, as acetate is still used in the dialysate the side effects
it causes are not eliminated. In order to correct this, the BF technique
was modified and the acetate in the dialysate was replaced by bicar-
bonate. In this paper we analyzed the data of 10 patients who showed
poor tolerance to the acetate BF, probably due to the existence of other
associated illnesses: diabetes, cardiopathy, hepatopathy and old age. In
these patients the acetate in the dialysate was replaced by bicarbonate
(39 mEq/liter) and the reinfusion of sodium bicarbonate was reduced
from 300 to 180 mEq/session. The clinical and biochemical data during
the last two months of treatment with acetate BF and the first two
months with BBF treatment were studied. No statistically significant
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differences were found as far as the pre-session bicarbonate figures are
concerned (18.6 1.9 with acetate vs. 21.1 1.6 and 20.1 1.7 after
one and two months on BBF), or post-session (23.0 2.4vs. 26.1 2.1
and 25.1 1.7); neither were differences found in the other acid-base
parameter. Tolerance to the sessions improved considerably, the num-
ber of symptomatic hypotensions decreased from 5.2/patients/month on
acetate BF to 1.1 and 0.3/patients/month after one and two months on
BFF and the incidence of vomiting went from 2.5 to 0.6 and 0.8
patients/month. From these results we can conclude that bicarbonate
biofiltration improves tolerance to blood purification techniques and
maintains the correction of acidosis obtained by conventional biofiltra-
tion.
Analysis of the hypothalamic-pituitary-gonadal axis (HPG) in hemodi-
alysis patients receiving erythropoietin treatment. E. Armada, C. Sanz-
Moreno, J. Estrada, J. Fdez-Giron, J. Alcañiz, D. Sanz-Guajardo, J.
Botella, Hospital Puerta de Hierro, University Aufônoma, Madrid,
Spain. Improved sexual activity has been reported in RDT patients
treated with EPO. Some authors have related this to the correction of
hyperprolactinemia, the normalization in the release of gonadotropins
and/or the increase in the level of testosterone (T). Therefore, we
studied the HPG axis in 22 patients on HD, IS male (age 38.3 6.9)and
7 female (age 33.4 8.7), before treatment with EPO and after 3 and 6
months. The following parameters were studied: Free T, Estradiol (E2),
progesterone, LH and FSH basal and after 20 and 60 mm of stimulation
with LHRH (100 g i.v.), Prolactine (PRL) basal and after 20 and 60
mm of stimulation with TRH (200 g i.v.). The results after 3 and 6
months of treatment were: Males: The hematocrit increased signifi-
cantly (19.3 2.6 vs. 29.5 5.3 and 30.2 2.9). Neither the basal PRL
(14.5 11.2 ng/ml vs. 13.9 9.5) (normal 0—15), nor the abnormal
response to TRH (PRL 20 mm: 19.7 11.9 vs. 18.5 11.9 vs. 19.5
9.7; PRL 60 mins: 20.6 12.3 vs. 18.3 11.4 vs. 19.4 10.5); Neither
the basal LH (14.2 13.8 mU/mI vs. 10.8 7.5 vs. 11.6 8) (normal
1—8), nor the abnormal to LHRH (LH 20 mm: 30.3 15.6vs. 30 14.2
vs. 30.9 17.8; LH 60 mm: 37.56 21.2 vs. 34.9 14.2 vs. 43.7 21.4)
were significantly modified. The Free T was within the normal range
throughout the study (31.5 5.9 pg/mI vs. 32.9 9.1 vs. 20.5 4.9)
(normal 14—40). Females: The hematocrit increased significantly (20.5
1.5 vs. 29.4 3.5 vs. 31.6 1.3). The basal PRL was worse in two
patients after six months, there was no change in the rest (11.6 2.9
ng/ml vs. 10.6 3.1 vs. 26.3 20.9) (normal 0—20) and the response to
TRH continued to be abnormal (PRL 20 mm: 20.8 9.2 vs. 18.6 6.6
vs. 40.3 30.2; PRL 60 mm: 20.5 8.6 vs. 18.7 5.8 vs. 30.1 28.5);
there was no significant change in either the basal LH (22.4 16.1
mU/mI vs. 21.1 10.1 vs. 14.9 7.8) (normal 1.5—9.5), or the abnormal
response to LHRH or the E. Conclusion: The anomalies in the HPG
axis and the PRL release are not corrected by an improvement in the
anemia of RDT patients treated with EPO.
Lipid metabolism abnormalities after renal transplantation (RTX)
under cyclosporin A (CsA) and prednisone (PNS) treatment. A.M.
Castelao, J. Bover, M.J. Barberá, C. Fiol, A. Blanco, f.M. GriM, S.
GilVernet, E. Andrés, D. SerOn, M.J. Castineiras, J. Alsina, Nephrol-
ogy and Biochemical Departments, Hospital Universitario de Bellvitge,
Barcelona, Spain. Hyperlipidemia (HLIP) is a risk factor for cardio-
vascular mortality, an important cause of death after RTX. In order to
elucidate the possible risk factors to develop HLIP we studied 74
patients, 40 men, 34 female, mean age 38 10 years, treated with CsA
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(maintenance dose 2—6 mg/kbw/day) and PNS (maintenance dose 0,25—
0.1 mg/kbw/day). We determined Tcholesterol (TCHOL), HDL,
HDL2, HDL3, LDL, VLDL, atherogenic rate (AR), and Al and B
apolipoproteins before and at 6, 12, 24 and 48 months after RTX. Only
statistically significant results are summarized in the table:
TC}-IOL HDL HDL2 LDL
mmollliter
Before RTX 4.47 1 1.2 0.3 0.32 0.04 2.87 0.78
6 months 6.38 1.68a 1.58 0.4k' 0.62 04d 4.19 1,56b
12 months 6.04 2.03a 0.88 0.4c 0.66 0.3" 3.6 1.01
24 months 6.52 1.52k 1.54 0.5" 0.68 O.S' 4.08 1.77'-'
t-test: a p = 0.0001, "P = 0.001, P = 0.01, d p = 0.02.
Results are compared to that observed in two control groups (GI
psoriasis patients maintained on CsA monotherapy and G2 lupus
erythematosus patients maintained on PNS monotherapy). There was
no correlation between lipidic parameters and age, sex, CsA dose, CsA
levels, maintenance PNS dose, plasma creatinine or plasma glucose.
Sixty-six patients were hypertensive after RTX. In conclusion, T Chol,
HDL-HDL2 and LDL seem to be frequent and persistent complications
in our clinically stable RTX recipients, and multiple factors could been
to be involved.
Effect of the treatment with desferrioxamine on the aluminium content
in bone marrow and its influence on the anemia of hemodialysis. P.
Abaigar, B. Mendiguren, M.L. Carrasco, J. Santos, M. T. Barroso, S.
Pascual, G. Torres, SecciOn de NefrologIa, Hospital G. Y. Burgos,
Spain. We selected 22 patients from our population on hemodialysis
according to a positive desferrioxamine test. We considered positive a
delta aluminium  150. Aluminium-containing drugs were withdrawn
one week before the tests were made. All patients were treated with i.v.
D.F.O. 10 mg/kg at the end of each dialysis for four months. Blood was
drawn before, monthly during and at the end of treatment. We could
find no variations of the Hgb, during or at the end of the study (10.04
2.2 vs. 10,3 2.8%). A significant increase of mean MCV was found
during and at the end (89.6 7.4 vs. 95.4 7.3 fi, P < 0.001) and there
was a significant negative relationship between serum aluminium and
MCV (r = 0.54, P < 0.05). A decrease of ferritin was observed (125
186 vs. 84.2 129 ng/ml, NS). The reticulocyte count corrected to the
degree of anemia decreased significantly (3.2 1.5 vs. 2.3 1.4%).
There was a significant positive relationship between cell packet
aluminium content and reticulocyte count (r = 0.45, P < 0.05). Delta
aluminium value decreased significantly (291.3 155 vs. 125 81.4
pg/liter, P < 0.01). Bone marrow aluminium content decreased to near
the level of significance (508.3 702 vs. 348.0 420 pg/liter, NS).
MCV is a good marker of the medular aluminium deposits. The
decrease of the aluminium content in the bone marrow cell packet could
be taken as an argument in favor of local toxicity of the aluminium.
Treatment of urinary tract infection during pregnancy: Single doses
versus conventional therapy. E. Ojeda, P. Abaigar, C. Cortes, M.L.
Carrasco, J. Santos, S. Pascual, G. Torres, S. Bacteriologia, S.
Ginecologla, and S. NefrologIa, Hospital General Yague, Burgos,
Spain. A total of 1251 pregnant women were studied for eighteen
months. Culture of urine was made in the first trimester of their
gestations, and at the minimum four cultures more during their preg-
nancies. Four therapeutic groups were done: A (Cephalexin, single
doses: 3 g), B (Amoxicilin, single doses: 3 g), C (Cephalexin, standard
treatment 500 mg, q 8 hr, 10 days) and D (Amoxicilin, standard
treatment 500 mg, q 8 hr 10 days). According both to the age and
therapeutic group a random stratification was done, In this sense 91
urinary tract infections (U.T.I) were observed, of which 20 were
excluded for different reasons (5 insensible to the some of the antibiot-
ics, 8 were lost, 5 who did not follow our instructions and 2 abortions).
In the end the composition of the groups was: group A, N = 15;group
B, N = IS; group C, N = 22; and group D, N = 19. The prevalence of
bacteriuria in this group of pregnant women was 7.2%. Most of the
U.T.I were caused by Escherichia coli (65%). Therapeutical success
was observed in 9 patients of group A, 11 of group B, 18 of group C and
11 of group D. Comparing these results with the method significant
differences were not observed. We think that the U.T.1 of pregnant
women could be treated with single doses which, as it is well known,
has a better cost-effective approach, offers less toxicity and, finally, has
higher compliance than the standard treatment.
Value of ecocardiography in the determination of dry weight ion
hemodialysis. M.L. Carrasco, M.J. Lopez, f.M. Ayuela, P. Abaigar, S.
Pascual, S. Santos, G. Torres, S. Nefrologia, Cuidados Intensivos,
H.G. Yagüe, Burgos, Spain. Usually, dry weight is calculated accord-
ing to clinical parameters. We attempted to find an incruent, easy and
objective method to measure it. We chose nineteen patients from our
population who were on hemodialysis without showing cardiac dis-
eases. The dry weight of these patients was established according to
clinical parameters. A 2-dimensional and M-mode echocardiography
was performed to measure the diameter of the inferior vena cava (IVC)
and the collapsability index (Cl) (inspiratory decrease in diameter), in
the first dialytic session of the week both before and after hemodialysis.
The l.V,C. diameter (1.V.C.D) was measured next to its junction with
the right atrium, during a normal respiratory cycle, maximal inspiration
and expiration. The transducer was placed in a subxiphoid or right
subcostal position to get a long axis view. This procedure was made by
two independent observers, Changes in plasma volume were measured
according to changes in hematocrit,
Results I.V.C.D C.!
Predialysis 9.8 3.7 mm/rn2
(95%c.l.:8.0—ll.5)
P=0.000
51.7 23%
(95%c.l.:40.6—62.8)
P=0.000
Postdialysis 3.9 2.2 mm/rn2
(95%c.l.:2.8—4.9)
85.7 20.6%
(95%c.l.:75.3—95.6)
Besides, a positive significant correlation was found between the
difference of 1.V.C.D and the difference plasma volume both before and
after the hernodialysis (r = 0.73, P = 0.004). According to our research,
and others previously been reported, we think that our patients are
slightly hypovolemic primarily at the end of the dialysis. Echocardiog-
raphy is a good method to know the hemodynamic state of the patients
on hemodialysis and could help to calculate, in a better way, the
patient's dry weight.
Kidney transplants in elderly cyclosporine-treated receptors (AR). J.
Bover, D. SerOn, L. Riera, A.M. Caste!ao, f.M. GriñO, J. Torras, J.
Alsina, Hospital Pr(ncipes de Espana, Belivilge, Hospitalet de Llobre-
gat, Barcelona, Spain. The aim of this study is to review the results of
kidney transplant in receptors over 50 years old (ER) under cyclospo-
rine-based immunosuppressive therapy. In our study, 210 kidney trans-
plants performed throughout 1984-88 were included; 152 were younger
than 50 years (YR) (72.4%), mean age 35.3 8.8 years; 58 were older
than 50 years (ER) (27.6%), mean age: 54.7 3.5 years (P < 0.0001).
Both groups were matched for sex, number of transplant (first or
second), immunosuppressive therapy (CsA + prednisone, CsA +
prednisone ÷ antilinfocitic globulin, CsA ÷ prednisone + OKT3),
number of transfusions, number of HLA mismatches and the percent-
age of linfocitotoxic antibodies. Results: During the three month period
after kidney transplant, the incidence of rejection was significantly
lower in the ER group (0.43 0.59 vs. 0.28 0.49; P < 0.03). The
incidence of total rejections was also significantly lower in this group
(0.52 0.7 vs. 0.28 0.49; P < 0.02). Nevertheless, the mortality rate
was higher in the ER group (1.9% vs. 13.8%; YR N 3, AR N = 8; P
< 0.002) due mainly to cardiovascular and infectious complications.
The actuarial graft survival (considering patient's death as a loss of the
graft) was similar in both groups. No significant differences were found
in the number of days of oliguria, number of hemodialysis, plasma
creatinine levels at 24 hours, I, 3, 6, 12 and 24 months after transplant.
Moreover, the incidence of acute tubular necrosis, surgical complica-
tions and hypertension was also similar in both groups. Conclusions: I)
Elderly patients have a lower incidence of graft rejection. 2) The
two-year graft survival rate is similar in both groups, but the mortality
rate is significantly higher in ER, 3) Our results suggest that ER could
receive less immunosuppressive treatment.
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Percutaneous transluminal angioplasty (PTA) for treatment of allograft
renal artery stenosis (ARAS). J. Bover, f.M. Grifló, J. Montana, A.M.
Castelao, 1. Camps, S. Gil Vernet, E. Andrés, D. Serón, E. Franco, N.
Serrallach, J. Alsina, Hospital PrIncipes de Espana, Bellvitge, L'Hos-
pitalet de Llobregat, Barcelona, Spain. ARAS is one of the causes of
arterial hypertension and graft dysfunction after kidney transplant.
There is an outstanding disparity among the results obtained by
different groups performing PTA for treatment of ARAS. Thirty-two
out of 454 patients (7%) transplanted in our department throughout June
1980—September 1989, were diagnosed with ARAS. Mean time of
diagnosis was 10 months (range: 2—45). PTA was performed in 27
patients. Two out of these 27 procedures were technically unsuccessful.
Among the treated patients mean blood pressure fell from 123 0.8mm
Hg before PTA to 107 13 mm Hg six months after the procedure (P
= 0.0002). The mean plasma creatinine level before PTA was 202 127
mol/liter and it was 168 79 mol/liter six months afterwards (P
0.027). Before and after PTA, the mean number of antihypertensive
agents was 1.7 and 1.08 (P = 0.026). Three recurrent stenoses were
seen. A second PTA was indicated in one of them and a saphenous
bypass was performed in two. These procedures were successful. We
conclude that PTA emerges as the first choice treatment of renal graft
artery stenosis because of its technical simplicity, good tolerance and
effectiveness. Furthermore, PTA does not preclude following with a
successful saphenous bypass if it is necessary.
Cardiac surgery in hemodialysis patients (HP). S. Gil Vernet, J. Bover,
E. Andrés, E. Castells, f.M. Grinó, AM. Castelao, J. Alsina, Depart-
ment of Nephrology and Cardiac Surgery, Hospital de Beilvilge,
Hospitalet de Llobregat, Barcelona, Spain. Cardiac surgery with
extracorporeal circulation is usually considered a high risk procedure in
HP. In order to establish the real risk, 11 HP have been compared to a
control group of4l patients without renal insufficiency (CP). They were
matched for age, sex, kind of surgery and date of procedure. Obviously
there were significant differences between both groups for hematocrit,
K and plasma volume used to achieve an hematocrit above 26%, prior
to surgery. In the postoperative period there were no significant
differences (HP vs. CP) for: bleeding (329 234 ml vs. 519 789),
volume of transfusion (576 391 ml vs. 788 861), mechanical
ventilation (19 IS hours vs. 13 7.5), inotrope drugs (1.8 0.4 vs.
1.8 0.4), days in the intensive care unit (6 2 vs. 4.27 4.7) and days
admitted to the hospital (15.4 7.3 vs. 15.6 9). The perioperative
mortality rate was a little bit higher in HP (9%) than in controls (7%),
but this difference was not statistically significant. Nevertheless, the
actuarial survival was lower (67%) in the hemodialysis group. This was
not necessarily related to cardiac problems but related to HP. In
conclusion, it is our experience that HP are not a special high risk group
for cardiac surgery if there is an adequate selection of patients before
surgery.
Calcium acetate (CH3COO)Ca2 as intestinal phosphorus binder in
dialysis patients. f. Bestard, D. Torán, E. Fuentespina, R. Coil, L.
Ladaria, J. Gascó, A. Morey, J. Marco, 1. Martin, A. Alarcón,
Nephroiogy Service and Laboratory Departement, Hospital Gral. S.
Dureta, Palma de Mallorca, Spain. in chronic renal failure and
especially in dialysis patients, phosphorus retention plays a major role
in the development of secondary hyperparathyroidism; consequently
the use of phosphate binders is of obligatory use in the majority of
patients. Intestinal phosphorus binders are associated commonly with
deleterious effects on bone, gastrointestinal tract, brain and metabolic
effects such as hypercalcemia and acidosis, with uncontrolled plasma
phosphorus. We attempted to find more efficient binder with less
toxicity using calcium acetate during a period of eight weeks. We
selected 10 patients with previous consent (5 males, 5 fern) aged 44
years (32—61) with a dialysis time of 61.3 34 months (16—117).
Aluminium containing gel, carbonate calcium gel and calcitiol were
previously discontinued. The hemodialysis schedule was 8 patients with
cuprophan and 2 with An-69 between 12—15 hr/week, Ca dialysate of 2.5
mmol/liter. The acetate was used in doses between 3—5 g/day after
meals adjusted to maintain serum Pi below 6.5 mg% and serum Ca less
than 11 mg%. Serum Ca, Pi, AF, pH, pCO2, C01H, Ub were
measured at weekly intervals and serum Al, Pb and PTH at monthly
intervals. Serum calcium increased without exceeding 11.5 mg% in any
case (P < 0.05); serum Pi level decreased significantly in the second
week (P < 0.001) but did not achieve the normal range (<6 mg%); we
observed an increase in the pH (P < 0.001) in the second week without
a parallel in the serum C03H (P = NS). We did not observe any
significant change in the serum levels of PTH, AF, serum Al, Pb and
Hb with respect to the pre-study serum levels. The results of these
studies demonstrate that the oral administration of calcium acetate is a
safe procedure for control of hyperphosphatemia in dialysis patients,
although with these doses we could not obtain serum levels below 6
mg%. On the other hand, we did not observe adverse reactions such as
hypercalcemia, acidosis or gastrointestinal disturbance.
Risk factors in the development of dialysis encephalopathy by acute
aluminum overload in dialysate. f.M. Monfd, F. Sousa, M. Saivd, E.
Pastor, J.L. Perez, A. Garcia, A. Acebal, Rio Carrion General Hospi-
tal, Palencia, Spain. Dialysis encephalopathy (DE) is the most severe
manifestation of aluminum (AL) toxicity in hemodialysis. The condi-
tions which favor the development of this syndrome are not clearly
established. Various lines of investigation have been undertaken, such
as the study of spinal fluid Al values and the relationship of Al with iron
metabolism. Twenty-nine chronic hemodialysis patients suffering an
acute Al overload by dysfunction of the water treatment system were
studied. Their serum Al values showed a 400% increase over previous
levels. They underwent neurologic (including lumbar puncture) and
electroencephalographic examination. Six patients showed DE symp-
toms while 23 did not. The presence of DE is related to several clinical
and analytical parameters by means of the ANOVA test. There is a
direct, statistically significant relationship between the development of
DE and serum Al prior to the overload (P < 0.01), maximum serum Al
detected during overload (P < 0.05), spinal fluid Al (P < 0.01) and age
(P < 0.05), while there exists an inverse relationship with serum ferritin(P < 0.05) and transferrin saturation percentage (P < 0.05). No
relationship was established between DE and time on dialysis, doses of
Al hydroxide, serum Al extracted at the moment of the lumbar puncture
and serum transferrin values. We conclude that DE caused by acute Al
overload is related to the highest value of serum Al reached, to previous
serum Al values, to spinal fluid Al levels, to the patient's age and to the
state of iron deficiency measured by the decrease of ferritin and by the
transferrin saturation percentage.
Parathyroid sonography in secondary hyperparathyroidism: Correla-
tions between ultrasonic and clinical findings. N. Esparza, L. Mesa, F.
Madueil, J. Longo, L. Bolaños, C. VOzquez, P. Errasti, A. Purroy,
Servicio de Nefrologia y Departamenlo de Radiodiagnostico, Clinica
Universitaria, Pamplona, Spain. We present the results of ultrasonic
neck examination in 24 patients (13 males, 11 females) on chronic
hemodialysis with clinical and biochemical signs of increased function
of the parathyroid glands (PG). Ultrasonic neck examination was
performed with a linear transducer of 7.5 MHz. In 8 patients PG were
not visible, in 12 patients there were one or two enlarged PG, and in the
remaining 4 patients three or four of the glands were enlarged. The
number of enlarged PG was correlated with the serum level of PTH (r
= 0.60, P < 0.01). The patients with one or more enlarged PG had a
higher PTH (748.5 640.0 vs. 295.7 101.7, P < 0.05) and alkaline
phosphatase levels (413.7 468.2 vs. 115.8 42.2, P <0.05) than the
patients with PG not visible; there were no significant differences in the
age nor in the duration of dialysis. Women had a higher number of
enlarged PG (1.9 1.1 vs. 0.7 1.1, P <0.05) and showed a tendency
to have higher PTH levels than men (815.9 739.2 vs. 359.9 261.2,P < 0.1). There were no significant differences in the age nor in the
duration of dialysis between the sexes. We conclude, that ultrasonic
neck examination is a method of first choice in patients on chronic
hemodialysis with secondary hyperparathyroidism. Ultrasonography is
non-invasive and simple to carry out, and permits us to establish a
correlation between anatomic and clinical findings in the patients with
secondary hyperparathyroidism.
Effects of captopril on the plasma levels of uric acid in essential
hypertensive patients. J.A. Oliva, P. Fernandez, Nephrology Section
HCR, T.H.E.M.A Study Group. Hyperuricemia constitutes a common
side effect which can limit the use of diuretics, both as monotherapy or
in therapeutic association with other hypotensive agents. We have
studied the effect of captopril (CPT) and hydrochiorothiazide (HCT) on
plasma uric acid at various dosages, as monotherapy and in therapeutic
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combination. We studied 1361 patients, 666 and 695 9, aged between
22—86 (X = 52 10), bearing an essential HBP, with pressure values
prior to the study of 169.5 16.6/103.9 9.69 mm Hg. Uric acid was
5.11 1.2. After a washout period of 15 days, they were distributed into
2 groups: Group A: 936 patients, 484 d and 452 9, aged 22—86 (X = 52
10), serum blood pressure 171.08 16.9, diastolic blood pressure
104.15 9.6, uric acid 5.13 1.2 mg/dl, whose dosage was being
increased by 50 mg/day/month up to a maximum of 150 mg/day if
normotension was not obtained (144/90). Group B: 425 patients, 182 ,
243 9, aged 24—86 (X = 52 9.7), serum blood pressure 166.2 15.5,
diastolic blood pressure 103.4 9.7, uric acid 5.07 1.2, to whom we
administered HCT at an initial dosage of 25 mg/day, increasing it by 50
mg/day after I month if normotension was not attained. After three
months, the patients from both groups who remained hypertensive were
included in a third group. Group Cl: CPT 50 mg + HCT 25 mg, 38
patients, 15 , 23 9, aged 29—70 (X = 55 8.78); uric acid at I month
5.39 1.2. Group C2: HCT 25 + CPT 50,45 patients, 15 and 30 9,
aged 34—66 (X = 52 8.9), uric acid at I month 4.9 1.2. After 5
months of study we evaluated the changes in blood pressure and plasma
uric acid.
Group
Blood
pressure Uric acid
Signifi-
cance
CPT 50 —25.7 18.6 —0.14 0.09 P = 0.05
CPT 100 —28.9 19.9 0.00 0.12 No change
CPT 150 —24.8 18.2 0.01 0.32 No change
HCT 25 —23.6 17.4 0.36 0.15 P = 0.05
HCT 50 —22.1 17.9 0.40 0.19 P = 0.05
CPT 50 + HCT 25 —24.6 15.7 —0.01 0.49 No change
HCT 25 + CPT 50 —25.5 17.2 0.29 0.32 No change
Conclusions: (I) Captopril in the three dosages studied does not cause
changes or a slight decrease in uric acid. (2) Hydrochlorotiazide in its
two dosages studied causes an increase in the level of uric acid. (3) The
combination of CPT + HCT, or vice versa, does not change the levels
of uric acid. (4) Both CPT and HCT are effective as monotherapy,
although the reductions in pressure are more relevant in the CPT group.
Activated protein C inhibitor: Its probable role in hypercoagulability of
the nephrotic syndrome. 1. Parramón, N. Tibau, A. Oliver, F. Rousaud,
F. Calero, J.M. DIaz, P. BarcelO, J.A. BallarIn, Hemathology and
Nephrology Departments, Fundació Puigvert, Barcelona, Spain. Hy-
percoagulable state is one of the characteristics of nephrotic syndrome
(NS), where some natural plasma anticoagulants are decreased. One of
them, protein C (that inactivates procoagulant factors V and VIII, as
well as PAl-i) has two well known inhibitors: activated protein C
inhibitor (PCI) and al-antitrypsin (al-AT). The former is immunologi-
cally identical to PAI-3, heparin-dependent and inactivates activated
protein C (APC) and u-PA. The latter, which is non-heparin-dependent,
nonspecifically inhibits other serum proteases. To investigate the role of
these protein C inhibitors in NS hypercoagulability, we measured them
in the plasma of 70 nephrotic patients, with proteinurias ranging 3 and
26.4 g/24 hours. PCI was estimated by a functional method based on its
APC inhibitory ability in the presence of heparin, while al-AT had been
determined by nephelometry. Antithrombin III (AT III), protein C (PC)
and free protein S (FPS) were measured by routine laboratory methods.
AT III
%
PC
%
FPS
%
PAI-3
%
al-AT
g/liter
5 2sr 91.5 20.8 125 25 90 27.4 126 54 2.76 0.79
VN 80 120 94 12 109 25 104 21 2.60 0.35
P <0.001 <0.001 <0.001 <0.001 NS
We found, as in other previous studies, an AT III and FPS decrease
characteristic of these patients. We have also observed a significant PC
and PCI increase, al-AT was not altered, probaly due to excessive
urinary losses. These high PCI levels suggest that PC increase cannot
be considered as a compensatory mechanism for the hypercoagulability
caused by losses of other anticoagulants like AT III, as has been
described by some authors.
Lupus anticoagulant-type antibodies (LA) in patients without diagnos-
tic criteria of systemic lupus erythematosus (SLE). C. Quereda, A.
Pardo, A. Gonzalo, R. Marcén, F. Liano, M. Rivera, J. Pascual, J.
Ortuño, Nephrology and Hematology Departments, Hospital Ramón y
Caja!, Madrid, Spain. LA has been found in patients with SLE, and is
associated with neoplasia or drugs even in an otherwise healthy
population. The association between thrombotic events and abortions is
well known. In SLE patients with LA there is a higher incidence of
glomerular thrombosis and worse functional prognosis. A causal rela-
tionship between these antibodies and non-lupus glomerular nephrop-
athy has been recently reported to be microangiopathic thrombotic
forms. The aim of this work is to analyze clinical and histological
features of patients with LA and nephropathy, excluding SLE cases
(ARA criteria). All of them had prolonged cephalin time (mean 54 mm,
control 33 mm, P < 0.001), partial thromboplastin time and a Russell
test. Prothrombin activity and platelet count were normal in all cases.
Anticardiolipin antibodies (AC) were positive in 5 patients. Antinuclear
antibodies were positive in 5 patients. Anti-DNA, ENA and comple-
ment were normal in all cases. Main clinical and histological features
are summarized in the Table. A patient presented with pericarditis of
unknown etiology. Only one patient (with scleroderma) had glomerular
and small vessel thrombotic lesions.
Age/
Case sex Diagnosis LA AC ANA CRF NS Thrombosis
1 21/M Membranous
ON
IgG IgO — No Yes Pulmonary
2 38/M Membranous
ON
lgG IgG 1:640 Yes Yes Graft vein
3 33/M Unknown
ON
JgG IgG 1:125 Yes No Graft
artery
4 70/M FSGN lgG-
1gM
IgG 1:160 No Yes Myocardial
5 18/F Mesangial
ON
IgG-
1gM
1gM 1:320 No No No
6 49/F Scleroderma IgG — 1:80 Yes No Phlebitis
We conclude that, excluding SLE, there is great clinical and histological
heterogenicity in patients with glomerular nephropathies associated
with LA. Three of our patients could have atypical forms of SLE. The
association of scleroderma with thrombotic microangiopathic lesions
has not been described so far. We confirm the high incidence of
thrombotic events.
Isotopic morphofunctional study of arterial hypertension (AH) of
adrenal origin. J. Pascual, L. Orte, L. DomInguez, M. Mitjavila, C.
Gdmez, C. Quereda, J. Ortuño, Nephrology and Nuclear Medicine
Departments, Hospital Ramón y Cajal, Madrid, Spain. We assessed
the diagnostic value of two isotopic methods in a study of adrenal AH.
Group I (labelled cholesterol) was 13 patients with strict clinico-
analytical criteria of primary hyperaldosteronism and unilateral mass in
5 cases. Group II (metaiodidebencyl-guanidin, MIBG) was 12 patients,
9 with clinico-radiological suspicion of pheocromocytoma and 3 screen-
ing cases (2 severe childhood AH and I MEN II). In group I,
6-selenium-methyl-norcholesterol (6 cases) or 6-iodide-demethyl-nor-
cholesterol (7 cases) were injected after a week suppression with
dexametasone. In group II, MIBG-I-l3I was injected in 6 cases and
MIBG-i-l23 in other 6; the thyroid gland was blocked with lugol
solution. Plannar gamma-camera images were sequentially obtained at
different time intervals according to the isotope. Clinical data were
contrasted with conventional and gammagraphic images. Adenoma was
diagnosed twice in group I (histologically confirmed) and bilateral
suprarrenal hyperplasia in 9; 2 studies were normal. These last 11
patients remain normotensive with diuretics after 6.2 yr of follow-up. In
group II sensitivity of the technique was 71%; the 2 false negatives were
with 1-131 (one of them necrotic pheocromocytoma with previous
normal metanephrins). Specificity and positive predictive value were
100%, being true negatives all the cases indicated for the screening
cases with negative metanephrins. We can conclude that isotopic study
of AH of probable adrenal origin (primary hyperaldosteronism or
pheocromocytoma) indicated with strict clinical criteria allows correct
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morphofunctional evaluation and therapeutic orientation of adrenal
pathology.
Regression of left ventricular hypertrophy (LVH) in patients on hemo-
dialysis (HD) after a year of treatment with erythropoietin (EPO). J.L.
Terue!, J. Pascual, F. Liano, M. Jiménez, J,L. Moya, C. Gámez, M.
Rivera, J. Ortuno, Nephrology and Cardiology Departments, Hospital
Ramón y Cajal, Madrid, Spain. LVH is the most frequent echocardio-
graphic finding in patients on HD. It is a parameter of much prognostic
importance, whose severity usually increases with time on HD and has
a multifactorial origin. In the present work, we studied evolution of
LVH after partial correction of anemia, one of the etiologic factors
implicated in LVH. Fifteen patients (8 males), aged 39 14 yr, treated
with HD during 54 45 months, received EPO during a year (mainte-
nance dose: 165 53 lU/kg per week). All of them underwent
echocardiographic studies (Doppler, bidimensional and M-mode) im-
mediately prior to starting EPO therapy and after a year. The studies
were performed within half an hour of mid-week HD session, with the
patients on theoretical lean body weight. Interventricular septum thick-
ness (IVST), left ventricular posterior wall thickness (LVPWT) and left
ventricular mass (LVM) were considered as parameters of LVH.
Cardiac index (CI) was also studied. Hemoglobin concentration in-
creased within the first 3 months (6.4 0.9 vs. JO 1.1 g/dl), stabilizing
thereafter (10.5 0.9 g/dl within a year). Echocardiographic evolution
was:
CL
liter/minIm2
IVST
cm
LVPWT
cm
LVM
g/m2
Basal 5.49 1.55 1.42 0.33 1,28 0.21 210.7 48.3
I year 3.98 0.94 1.07 0.13 1.01 0.11 139.5 50.4
Of the 15 patients, 7 remained normotensive and 8 required antihyper-
tensive drugs. In both groups CL and morphological LV parameters
diminished, but LVM was lower in normotensive group (106 24 vs.
168 50 P < 0.025). Partial correction of anemia during a year is
associated with impressively decreased LV mass not only in normoten-
sive but also in hypertensive patients on HD. Anemia is the principal
factor that induces LVH in HD patients.
Treatment of iron deficiency in hemodialysis with intravenous ferric
gluconate. J. Pascual, J.L. Teruel, MT. Naya, A. Sureda, C. Gámez,
P. Serrano, J. Ortuño, Nephrology and Hematology Departments,
Hospital Ramón y Cajal, Madrid, Spain. Iron deficiency (ID) is an
increasing complication in HD patients, and frequently oral supplemen-
tation is not enough for adequate repletion of iron stores. Iron dextran
has usually been given i.v. for ID treatment. However, this form of
therapy is accompanied by an excess of adverse reactions, including
fatal or life-threatening anaphylactic ones. We have given sodium ferric
gluconate complex (Ferriecit, Nattermann, Germany), I g divided into
8 doses post-HD to 3 groups of patients: (I) 8 with renal anemia and ID;
(II) 6 with renal anemia, ID and concomitant treatment with nandrolone
decanoate im (200 mg weekly); (III) 5 with ID associated with poor
response to treatment of renal anemia with EPO. All patients had been
taking oral ferrous glutamate with poor response in hematological
parameters. Significant rises in hemoglobin were obvious after 3 months
(m) in all groups, Serum ferritin levels also had risen within I m and
slowly declined from the 3rd to 6th month (table).
Hemogloblin gIdI Serum ferritin /.Lglliter
Before Before
Group iron 3 ma 6 ma iron lma 3 ma 6 ma
I 7.7 8.9 8.6 23 149 163 III
II 8.4 9.3 9.6 28 130 231 199
111 8.5 11.2 10.3 26 193 213 154
A total of 152 infusions were performed, and there were no immediate
or delayed reactions or adverse side effects. Our data support that i.v.
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ferric gluconate is safe and efficient treatment for severe ID in HD. ID
will become an increasing problem as EPO is used more widely unless
prophylactic iron is given i.v. when serum ferritin falls below adequate
levels.
Detection of cytomegalovirus (CMV) genome by in situ hybridization in
renal transplantation (RI). J. Pascual, F. Mampaso, L. Orofino, R.
Marcén, A. Molina, F. Liaño, C. Quereda, J. Ortuño, Nephrology and
Pathology Departments, Hospital RamOn y Cajal, Madrid, Spain.
CMV continues to be the most important viral pathogen in RI,
promoting severe infections and even graft function impairment. In situ
hybridization techniques applied to diagnosis of viral processes have
been proposed as an alternative to common methods (cultures, serology
and immunohistochemistry) for reasons of rapidity and specificity. The
use of biotinylated probes in formalin-fixed paraffin-embedded tissue
sections allows specific histological localization of viral genome. Graft
biopsies were studied in 5 patients with subacute graft function deteri-
oration (5Cr 3 0.4 vs. 3.5 1.2 mg/dl) and probable CMV infection
defined by detection of CMV in culture (2 cases), seroconversion (2
cases) or both (I case), with or without symptoms. DNA probes of
CMV labelled with biotin were used, being detected after addition of
avidin-biotin-peroxidase complex. After hybridization with these
probes, positive homogeneous nuclear colored images were observed in
all cases. Except for nuclear inclusions observed in one case by means
of common methods, CMV inclusions were only demonstrated after
hybridization. Biopsy showed probable acute rejection in 2 cases, while
lesions responsible for graft function impairment could not be defined in
the other 3. Without specific antiviral treatment, renal function mildly
improved after 4 2 months (Sr 3.5 1.2 vs. 3 1.7 mg/dl) but
remained worsened with respect to basal one. We conclude that in situ
hybridization technique is the most specific method to diagnose CMV
infection in RT, as it allows direct observation of viral genome. Several
clinico-pathological aspects suggest the role of CMV in functional
impairment episodes, albeit possible efficacy of antiviral treatment
warrants controlled studies.
Study of the nature of cytotoxic antibodies in hyperimmunized patients.
P. Sanchez Mozo, C. Alonso, J. Amigo, M. Cao, J. Oliver, A. Alonso,
F. Valdés Canedo, Nephrology and Immunology Department, Juan
Canalejo Hospital, La Coruna, Spain. The differentiation between
autoantibodies and anti-HLA antibodies must improve the strategy of
the control for hyperimmunized patients who are on a waiting list, and
increase their possibilities to receive a transplant. For that purpose, 12
patients with 75% of reactivity of the panel cells (12% of the whole
waiting list), 5 women and 7 men, with an average age of 44 (17—58) and
23 transfusions, have been controlled. Among them 6(50%) had at least
one previous transplant. The patients' serum has been compared and its
reactivity has been studied with autological cells, chronic lymphoid
leukemia cells (CCL) (20) and panel cells (30), with or without
Dithioteitrol (DIT) treatment of the sample.
Results
Case I 234 56789101112
%ofPanelC 77 100 100 93 90 93 90 93 75 75 100 77
% of Panel C + 63 97 97 87 80 90 83 100 66 66 100 60
DTT
AutoiC 000000000000
CCL 100 95 95 100 95 100 95 100 100 84 68 80
Conclusions: (I.) It is necessary to know the prevalence and nature of
the cytotoxic antibodies and their clinical relevance in the crossed test
and patient prognosis. (2.) Within our series, no autoantibodies have
been detected as no-reactivity in the presence of autological cells. (3.)
The antibodies were in IgG preferent form since they kept their
reactivity in the presence of panel cells in spite of DTT treatment. (4.)
All of them were directed against antigens of class I and II since their
reactivity in presence of panel cells and chronic lymphoid leukemia
cells has been verified.
HLA compatibility and blood transfusion effect in renal transplant
patients treated with cyclosporine. L.M. Pallardó, P. Sanchez, J.L.
Górriz, J. Sanchez, J. Garcia, E. Orero, I. Beneyto, f.M. Cruz,
P < 0.01 in all comparisons
a All values were higher than basal ones (t-test, P < 0.05).
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Nephrology Department, La Fe General Hospital, Valencia, Spain.
Immunosuppressive efficacy of cyclosporine (CsA) has questioned the
transfusion effect and the value of HLA compatibility in renal trans-
plant patients. Since the introduction of CsA in our Unit in December
1985, we reduced pretransplant blood transfusions to two units, having
HLA DR compatibility as the major criteria for selection of recipients.
We have analyzed the prognostic factors of graft survival in the 255
consecutive kidney transplant patients treated with a triple drug ther-
apy, including CsA, azathioprine and prednisone. Graft survival was
correlated with age (P = 0.001) and sex of recipient (P = 0.003), HLA
lymphocytotoxic antibodies (P = 0.002) and HLA DR compatibility
measured as HLA DR identities (P = 0.003), HLA DR incompatibilities
(P = 0.007) or HLA DR+B incompatibilities (P = 0.002). However,
graft survival did not correlate with the number of blood transfusions,
as there were not significant differences whether the patients received
two blood units, three to five, or more than fine blood transfusions (P =
0.66). Multivariate analysis confirmed the prognostic value of HLA DR
compatibility (P = 0.007). In relation to the postransplant events, graft
survival did not correlate either with ATN (P 0.10) or acute rejection
episodes (P = 0.28). In conclusion, in CsA treated patients we obtained
the transfusion effect with two blood transfusions, and graft survival
correlated with HLA DR compatibility.
Antivirus C antibodies in hemodialysis patients. M. Gimenez, E.
Garrigos, J. Martin, E. Ajenjo, E. Roma, C. Tuset, A. Perez, Nephrol-
ogy Section, General Hospital, Valencia, Spain. Hepatitis C virus
(HCV) has been isolated recently, and a inmunoassay to detect anti-
HCV antibodies has been developed. This study's aim was to establish
the incidence of this infection due to HCV in our patients under
hemodialysis treatment. One hundred and thirty-eight patients were
studied: 120 males and 63 females, mean age of 54.4 years (x = 20—81).
Anti-HCV antibodies were detected by the ORTO HCV ELISA test,
and hepatitis B serologic markers and clinical signs of hepatitis were
monitored as well. Results: VHC seropositivity was detected in 34 of
the 183 patients studied (18.57%). Patients who were found to be HCV
positive were the ones who received more transfusions (x = 9.35), and
spent more time under dialysis treatment (78.7 months), compared with
the seronegative patients (x = 5.5 and 42.3 months), which was
statistically significant (P <0.01 and P <0.001). In 69 patients we found
serologic signs of present or former infection due to HBV, 18 of them
were anti-HCV positive (26.09%). In the group of 114 patients who were
HBV negative, 16 were HCV positive (14.03%). In 31 patients, clinical
signs of hepatitis were detected, 21 of them were considered non-A-
non-B. In the last group, 10 patients were anti-HCV positive (47.6%),
and 2 developed chronic hepatitits. Discussion: The incidence of
seropositivity for HCV in our patients is less important than the one
issued in other high risk groups, and similar to the referred one in other,
comparatively similar groups in our environment. Seropositivity for
HCV has been related to the amount of transfusions received, and time
under dialysis treatment. From the detected non-A-non-B hepatitis in
our patients, 46.6% are probably hepatitis C, and 20% of them have
developed chronic hepatitis.
Anemia and deferroxiamine in chronic renal failure. A study about the
erythrocytes antioxidant mechanisms and response to treatment. R. Moll,
M.J. Martin, A. Miguel Sosa, A. Miguel Garcia, E. Ajenjo, E. Roma,
A. Perez, Nephrology Section, General Hospital, Valencia, Spain.
Erythrocytes from uremic patients develop enhanced levels of the
antioxidant enzymes superoxide-dismutase (SOD) and glutathion per-
oxidase (GPX), as well as the substrate reduced gluthathion (GSH),
which we regard as secondary to the oxidative damage caused by
uremia, but which isn't important enough to avoid the increased
susceptibility described in these erythrocytes for peroxidation of their
membrane lipids, measured as levels of malonyl dialdehide (MDA).
This fact can contribute to the diminished half life of erythrocytes. An
improvement of anemia has been described with DFO treatment in
patients without increased aluminium deposits which has been attrib-
uted to enhanced erythropoiesis. With the purpose of studying the
effect of DFO as a chelant of ionic iron, (which catalyzes the interec-
tions among the free oxygen radicals), on the antioxidant systems and
membrane lipid peroxidation, we have studied 10 patients with hemo-
globin levels less than 9 g, and ferritin levels more than 300, who had
been under dialysis treatment for 6.1 3 years, without aluminium
toxicity signs, determining the following parameters: hemoglobin, fer-
ritin, transfusional requirements (TR, cc per month), MDA, GSH,
SOD, and GPX pre- and post-six months of I g DFO post-dialysis
treatment.
Hg Fer MDA GSH SOD GPX NT
Pre 6,61
1.5
NS
861
822
NS
489
46
NS
92
20
0.05
2914
805
NS
43
18
NS
148
193
NS
Post 7.4
2.1
844
956
492
72
106
17
2709
546
46
22
147
194
In 4 patients a moderate improvement of anemia, with clinical signifi-
cance, was found, without variation of ferritin and basal aluminium
levels post-DFO compared with the previous levels, as well as levels of
MDA, SOD, GPX or GSH. DFO makes some patients' hemoglobin
increase, but not for an action of decreased peroxidation, nor an
improvement of the antioxidant system.
Urinary elimination of two indicators of renal proximal tubular lesions
in adult hypercalciuria. J. Chahin, V. Garcia Nieto, M. Muros, C.
Leon, A. Torres Ram frez, E. Gallego, M.L. Mendez, J. Garcia Perez,
Nephrology Section, Nuestra Señora de Ia Candelaria Hospital, Santa
Cruz de Tenerife, Spain. The urinary elimination of certain proteins of
low molecular weight, such as beta2-microglobulin, and of lysosomal
enzymes, such as N-acetyl-glucosaminidase (NAG), increases early in
the progression of renal proximal tubular function disease. We studied
the urinary excretion of these two proteins in 23 adults (7 m; 16 f)
diagnosed with idiopathic hypercalciuria (IHC). The results were com-
pared with those of 17 controls and expressed as ratios with respect to
creatinine (Cr). Patients with IHC presented higher NAG:Cr ratios than
the controls (3.3 1.8 vs. 1.9 0.7 mU/mg; P < 0.01). No significant
differences were observed for the 132m:Cr ratios, (115.4 85.3 vs. 73.6
59.4 ng/mg.) A high correlation was observed between calciuria
(FEca) and the urinary elimination of NAG (r:0.74) and of f32m (r:0.79),
as well as between the values of PTH C/MM and both ratios (r: 0.84 and
0.61, respectively). Similar results, although with somewhat lower
correlation coefficients, were obtained with respect to the urinary
elimination of cyclic AMP. Conclusions: The urinary elimination of
NAG is increased in adult patients with IHC, and bears a relation with
the urinary elimination of calcium and with PTH levels. NAG is a better
indicator of tubular lesion in IHC than beta 2-microglobulin.
Clinical implications of the presence of antibody to hepatitis C positive
after renal transplantation. f.M. Morales, A. Andres, C. Campo, G.
Castellano, F. Colina, A. Fuertes, F. Moreno, fL. Rodicio, Nephrol-
ogy Department, Hospital 12 de Octubre, Madrid, Spain. Chronic liver
disease (CLD) is a severe complication after renal transplantation (RT).
In order to know the clinical importance of hepatitis C after RT we
measured antibody (anti-HCV) to hepatitis C virus by immunoenzyme
assay (ELISA) in 200 functioning renal transplants (RTS) for longer
than 12 months. In 66 of them (33%) anti-HCV was positive. Fifty-eight
were on cyclosporine and 8 on azatioprine (Aza). Twenty RTS with
positive anti-HCV had CLD (persistent abnormal liver test for longer
than 6 months) before RT, and in 5 of them clinical remission was
evident after RT, while 15 exhibited chronic liver biochemical alter-
ations. From the remaining 46 anti-HCV positive RTS, 24 developed
CLD after RT (although in 4 of them clinical remission was seen) while
22 never had any liver biochemical alteration. Active chronic hepatitis
was the most frequent histopathological diagnosis, especially in Aza
therapy. In summary, after RT one-third of patients had anti-HCV
positive, and remarkably more than sixty percent of these anti-HCV
positive patients had CLD, some of them with a severe histopatholog-
ical pattern.
Effect of captopril, an angiotensin converting enzyme inhibitor (ACEI),
on the massive proteinuria (MP) of chronic rejection (CR) after renal
transplantation (RT). A prospective study. f.M. Morales, A. Andres,
f.M. Alcazar, C. Montoyo, M. Praga, L. Algranari, J.L. Rodicio,
Nephrology Department, Hospital 12 de Octubre, Madrid, Spain. It has
been reported that captopril, an ACE!, can decrease MP in hyperfiltra-
Abstracts
tion states. The purpose of this work was to study the influence of
captopril on MP due to CR, a clinical situation that could be suggestive
of hyperfiltration. We selected 7 patients, under steroids and azathio-
prine therapy, who were diagnosed of CR by clinical and histological
parameters. All of them had renal failure and MP (more than 3.5 g/day)
without hypoalbuminemia. Prospectively we had evaluated the re-
sponse to captopril therapy during 6 months.
0 month 3 months 6 months
Proteinuriag/dl 5.57 1.71 4,76 1.96 6.18 3.77
Serum creatinine mg% 3.4 1.37 4 1.8 4.48 1.99
Albumin g/dl 3.8 0.2 3.7 0.32 3.77 0.20
Total proteins g/dl 6.5 0.5 6.64 0.44 6.22 0.14
Cholesterol mg/dl 248 43 229.7 36.5 268 71.3
Captopril dose mg/dl 50 14.4 68.7 18.9 87.5 58.6
There was no difference between proteinuria and renal function after
captopril was started. Our work indicates that captopril did not have a
beneficial effect on proteinuria associated with CR. These results are
against the possibility that hyperfiltration plays a fundamental role in
the pathogenesis of CR after RT.
Short-term effects of late steroid withdrawal in renal transplant recip-
ients over fifty years old with a protocol of low cyclosporine doses. A
prospective study. f.M. Morales, M.A. Muños Cepeda, S. Sancho, A.
Andres, f.M. Alcazar, C. Montoyo, C. Campo, J.L. Rodicio, Nephrol-
ogy Department, Hospital 12 de Octubre, Madrid, Spain. It has been
reported that cyclosporine (CsA) monotherapy can be an effective
treatment in aged renal transplant patients. The aim of the study was, in
a group of patients over fifty years old with at least one year of graft
functioning, to switch from double therapy to CsA monotherapy
analyzing the short-term clinical consequences after steroids were
stopped. Prospectively in 18 patients, group I aged 56.6 6 years, a
slow steroid withdrawal was performed maintaining low CsA doses.
The clinical results in the first nine months after steroid interruption
were compared with a group of 20 patients, group II aged 54.3 2.2
years who were maintained with low steroid and CsA doses. Both
groups were comparable in the time of graft functioning (group 1 20.9
11.5 vs. group II 24.6 12 months, P NS), acute rejection and
transitory CsA nephrotoxicity incidence, number of second grafts,
frequency of hyperimmunized and degree of renal function. Two
patients of group I developed an episode of late acute rejection (11.1%
vs. 25%, P NS), one was controlled with steroids and the other was
steroid and OKT3 resistent. In the remaining 16 patients of group I the
clinical course was excellent, maintaining a stable renal function during
the follow-up (Sr 1.28 0.43 mg/dl) with low CsA doses, 2.7 0.98
mg/kg/day. The incidence of transitory CsA nephrotoxicity and the
association of azathioprine were similar to the group LI. Graft survival
in group I was 94.5% vs. 90% in group H, P NS, and patient survival
was 100% in both groups. Also, a tendency to present less infections
and readmissions together with a diminution of cholesterol and triglic-
erydes was evident in the group I, while in the group H there were no
changes. In conclusion, our results suggest that in patients over 50
years old with a functioning graft more than one year, CsA monother-
apy can be a short-term, useful immunosuppressive protocol that can
permit avoidance of the undesirable effects of steroids.
Calcium antagonist (CA) therapy prevents chronic cyclosporine (CsA)
nephrotoxicity (N) after renal transplantation (RT). A prospective study.
J.M. Morales, A. Andres, J.M. Alcazar, M. Praga, C. Montoyo, E.
Rodriguez Paternina, J.L. Rodicio, Nephrology Department, Hospital
12 de Octubre, Madrid, Spain. It has been reported that CA may
ameliorate CsAN. The aim of the study was to investigate whether
long-term CA therapy can prevent chronic CsAN after RT. Prospec-
tively we studied the clinical course of 97 cadaveric renal transplant
patients. All had high blood pressure at the end of first postRT month
(mo): group I, N = 47, treated with nifedipine retard (80 mg/day), and
group II, N = 50, were treated with other antihypertensive drugs. All
were on steroids and CsA 10 mg/kg/day in slowly decreasing doses.
Donor and receptor age, HLA-DR mismatching, cold ischemia time,
postRT acute tubular necrosis, early CsAN and acute rejection (AR),
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first RT and frequency of hyperimmunization were comparable in both
groups.
Group 6 mo 12 mo 24 mo
Scra
mg/dl
CCra
mI/mm
1
II
I
II
1.28 0.37
1.45 0.46
89.3 51.8
75.5 51.8
1.23 0.35
1.60 0.49
89.1 25.5
73.5 28
1.25 0.37
1.58 0.45
90.3 29
85.8 28
Doses CsA 1 4.6 0.9 4 1.1 3.2 0.9
mg/kg/day II 4.4 0.8 3.7 0.8 3 0.76
During the follow-up, renal function was better in group I without
differences in blood levels and CsA doses, blood pressure control,
frequency of late AR or change to conventional/triple therapy. Also in
CA patients, a tendency to show higher natriuresis in the first year was
observed. In conclusion, our results suggest that long-term CA treat-
ment could be beneficial in order to avoid chronic CsAN after RT, in
patients with low CsA doses.
Efficacy of low-dose human erythropoietin in chronic hemodialysis
patients. C. Solozabal, F. Maduell, F. Fonseca, J. Unzue, J. Asin,
Department of Nephrology, Virgen del Camino Hospital, University
Clinic, Pamplona, Spain. Recombinant human erythropoietin has been
shown to be effective in correcting anemia in uremic patients. In the
literature the initial endovenous dose to raise the hematocnt to a target
level 35% varies from 40 U/kg body weight or above. Elevation blood
pressure and hypertensive encephalopathy are the more frequent se-
vere complications. In order to minimize complications we studied the
effect of low dose erythropoietin in renal anemia. Fourteen patients on
hemodialysis were included in this study, 6 males and 8 females, who
had an average age of 58.4 16.5 years. All patients presented
moderate to severe anemia; transfusional requirements were 6.29
2.08 concentrates/patient-year. They were treated with recombinant
human erythropoietin endovenously, three times a week, for five
months with a constant dose of 13.61 1.71 U/kg body weight (range
10.5—16.3). All patients responded to the treatment. It was enough to
slowly increase hematocrit (23.4 2 vs. 30.2 2.8%) and hemoglobin
(7.46 0.59 vs. 9.76 0.9). After 5 months, 8 patients had a good
responses (hematocrit >30%). Treatment was well tolerated without
severe side effects. No hypertension, seizures or thrombosis were
observed. Increased antihypertensive medication was not necessary.
The results suggest that endovenous low-dose erythropoietin could be
an effective and safe alternative treatment for renal anemia in hemodi-
alysis patients.
Liver transplantation (LTx) in children: Renal dysfunction and hyper-
tension. M. Navarro, C. Camarena, C. Sanchez Peinado, M.L. Picazo,
P. Jara, Renal and Liver Divisions, Hospital Infantil "La Paz",
Madrid, Spain. We analyzed renal dysfunction and hypertension in 14
children with LTx with a mean follow-up of 28 months (range 17—48
months). They received continuous immunosuppression with cyclospo-
rifle (CsA) and Methylprednisolone. Glomerular filtration rate (GFR)
estimated by the height formula (Schwartz, 1984) was normal in all prior
to LTx (125 48 ml/min/l.73 m2). Serum CsA levels were measured by
RIA. Hypertension was present within the first month in 13 (93%), and
became normal in 12 (92%) two to three months post-LTx. Continuous
hypertension was present in 3 (23%), was associated with normal GFR
in 2, and with slight reduction in one. Renal function during the first
month post-LTx GFR decreased from 152 48 to 64 46, with figures
less than normal in 10 (71%), being necessary to change to continuous
haemofiltration in 2. There was correlation (r =
—0.6, P < 0.05)
between GFR and a hepatic phase during surgery but not with CsA
levels. On continuous long-term therapy (mean 28 months), there was
correlation (r =
—0.5, P < 0.05) between GFR and CsA levels at 6
months but not at 12 and 48 months. Two years after LTx, 4 children
had persistent decrease of GFR (58 12 ml/min/l.73); all of them had
a P < 0.01
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higher acumulative CsA doses but without significance. In 3 out of the
4, CsA daily dose was reduced and azathioprine added. A significant
decrease of CsA levels was achieved (227 57 vs. 83 70 ng/ml, P <
0.05), but the increase in GFR (61 3 to 74 8 ml/min/l.73), was not
significant. Hyperkalemic acidosis was present in 3 out of the 4 with
decreased GFR. Reversible impairment of GFR was seen in 3 children
with toxic levels of CsA. Histological study of the kidnay has been
made in two children dying at 16 and 18 months post-LTx, showing
slight focal interstitial fibrosis and tubular atrophy in the child with
normal GFR and blood pressure. The other with GFG of 63 ml/min/l.73
m2 and continuous hypertension has focal and severe tubular atrophy,
interstitial fibrosis and also artenolar hyalinosis with lumen narrowing.
Conclusions: Early and transient hypertension may be in relationship
with steroid therapy and vascular volume changes but not with CsA
levels. Persistent hypertension present in 23% was not in relationship
with GFR. Early renal dysfunction had a slight correlation with the
hepatic phase during surgery. Persistent decrease of GFR and hyper-
kaliemic acidosis may be due to nephrotoxicity mainly secondary to
CsA.
Efficacy of recombinant human growth hormone (rGII) in children with
chronic renal failure (CRF). A. Alonso, M. Navarro, C.G. Meseguer,
M.J. Martinez, R. Gracia, Hospital Infant!! "La Paz", Madrid, Spain.
We analyzed rGH treatment in eight children (GH and 2F) with severe
growth retardation and CRF (2 hemodialysis, I CAPD and 4 with
conservative treatment). The mean age was 10.46 3.1 years. Each
patient received 30 i.v./m2/week of rGH at night, 7 days/wk subcuta-
neously. Before rGH treatment there wasn't a peak GH response to
stimulation (insulin-hypoglycemia) in 71% of patients. Results (mean
and SD):
Basal
After 12
months of
treatment Significance
Height (SD) —2.86 0.69 —2.07 0.6 P < 0.05
Height velocity (SDS) —2.87 2.1 +3.74 3.2 P < 0.01
IGF I U/mi 1.95 1.5 5.6 2.6 P <0.01
EGFR ml/min/1.73 m2 14.37 1.9 11.25 1.7 P < 0.1
There was a significant correlation between growth retardation and
height velocity during treatment (P < 0.01; r = —0.81). We found a
significant correlation (P < 0.05; r = 0.58) between height velocity and
increase of IGF I. We also found a negative correlation between
nutritional state and the peak GH response to stimulation (insulin-
hypoglycemia) (P < 0.05; r = —0.86). A seven-year-old female with
Fanconi syndrome and EGFR of 64 mI/mm/I .73 m2 had a decrease to
48.7 ml/min/l.73 m2 (P < 0.01) during treatment, with increase of
proteinuria from 48 mg/m2/hr to 133 mg/m2/hr (P < 0.01) and with a
negative correlation between EGFR and proteinuria. Summary: (1.) A
significant increase of growth was achieved in stunted children with
CRF (predialysis and dialysis), with supraphysiological doses of rGH,
without aceleration of bone age. (2.) IGF1 increased significantly, as
there was a positive correlation between height velocity and 1GFI. (3.)
Higher growth velocity was found in children with the most severe
growth retardation. (4.) rGH may have contributed in decreasing EGFR
due to hyperfiltration in the child with slight reduction in renal function
prior to treatment.
Effect of furosemide on the urinary acidification in the kidney trans-
plant. J. Ocharan, P. GOmez-Uiiate, J. Rodriguez-Soriano, A. Vailo,
J.J. Amenabar, L. Ruiz, R. Mufliz, I. Lampreabe, Nephroiogy and
Department of Paediatric, Hospital de Cruces, Bilbao, Spain. Urinary
acidification occurs mainly in the cortical collecting tubules. The
properties of furosemide (F) have permitted us to study a test of urinary
acidification in the cortical collector tubule, as well as the state of
renin-aldosterone axis with F. All study subjects (N = 48) were given
intravenous F (I mg/kd body wt) over 2 minutes. Urine volumes were
measured. All urine was collected by spontaneous voiding during the
following time intervals: 0 to 30, 31 to 60, 61 to 120 and 121 to 180
minutes. Plasma samples were obtained at 0 and 180 minutes for
determination of plasma renin activity and plasma aldosterone levels.
N = 48 Basal Maximum P <
UpH 6.38 5.82 0.001
Amonium 100 GFR 27.5 45.7 0.001
A. Titulable 100 GFR 21.9 30.5 0.001
C Na 100 GFR 2.09 18.12 0.001
C K 100 GFR 18.5 66.1 0.001
C Cl 100 GFR 2.02 24.5 0.001
Renin 1.17 2.39 0.001
Aldosterone 145 343 0.001
The acute administration of F is necessary to study the urinary
acidification and to value the renin-aldosterone axis in a group of
transplant subjects, excessively, in the hyperkaliemia secondary to the
hypoaldosteronism hyporenin or the non-response of aldosterone in
kidney tubule.
Seroepidemiologic study of hepatitis C virus (VHC) antibodies in a
hemodialysis unit. J. Garcia-Valdecasas, M.C. Bernal, N. Montiei, M.
Manjón, M.J. Garcia Cones, S. Cerezo, Department of Nephroiogy,
University Hospital, Granada, Spain. We measured the titers of VHC
antibodies in 107 patients on dialysis to determine the possible relation-
ship between these antibody expressions and the following: sex,
duration of dialysis, previous transfusions and transaminase levels. We
used an enzymoinmunoassay with Ortho reagents. (1) Twenty-seven
out of 107 hemodialysis patients (25.2%) were positive for VHC
antibodies. (2) We found no relationship between sex and antibodies.
(3) Patients on dialysis more than 5 years were more likely to contract
VI-IC (5 1.8%) than patients with less than 5 years on dialysis (16.2%).
(4) There was a clear relationship between blood transfusions and VHC
seropositivity: 40.4% with a history of blood transfusions vs. 10.9%
with no blood transfusion history. (5) Patients with 3 or more blood
transfusions were more likely to contract VHC (47%) than patients with
less than 3 blood transfusions (27.8%). (6) Patients with episodes of high
transaminase levels during this study showed a higher percentage of
VHC positivity (50%) than patients with no transaminase elevation
(15.6%).
Acquired cystic renal disease (ACRD) in renal failure. A. Covarsi, 0.
Sanchez, N. Manigliano, R. Novillo, J. Ganin, J.R. Gonzalez, Hospital
"San Pedro de Aicántara," Caceres, Spain. ACRD is an HD entity
characterized by the progressive substitution of the atrophic renal
parenchima by multiple bilateral cysts. Sixty-six patients included in
dialysis programs; 59 in HD and 7 in CAPD were studied with
echographs and T.A.C. The existence of 3 or more cysts on each kidney
was taken as the yardstick for ACRD. Statistical analysis was carried
out (ANOVA). Of the 66 patients studied, 8 had polycystosis and were
excluded; of the remaining 58, 22 (37.9%) fulfilled the ACRD criterion
and 36 (61.2%) did not. Of the 22 with ACRD, 18 (81%) were male
patients; of those without ACRD, 16 (44%) were males. The age range
was 47.3 15.7 yrs and 44.6 16.6 with P = 0.54. Dialysis time was
80.3 46.3 and 53.8 45.8 with P = 0.052. IR time (Cr greater than 2
mg%) was 43.3 36.6 months, and 26.5 .± 25.5 with significant
differences, P < 0.05. No difference in ethyological causes was found
except in diabetes (7 cases) which were included in the non-ACRD
group. In the ACRD group 19 had no symptoms, one showed an
increase in Ht2, another suffered pain in the lumbar region and a third
person suffered abdominal pain and hematuria. Radiological study
revealed neoplastic lesions in 4 (18%) of the ACRD group and in I
(2.7%) of the non-ACRD group. It can be concluded that (I) ACRD is
frequent in dialysis. (2) The time in IR is a favoring factor. (3) There is
a male predominance. (4) ACRD reveals on appreciable incidence of
tumoral degeneration (18.1%).
Study of cellular and humoral immunity In dialysis patients suffering
from j32-microglobulin amyloidosis. J. Fort, J. Aliaga, M.T. Español, J.
Rosello, I. Camps, A. Olmos, L. Piera, Nephrology, Pneumology,
Immunology and Preventive Medicine Departments, Hospital General
Vail D'hebrón, Barcelona, Spain. Although the pathogenesis of dialysis
amyloidosis is still unknown, seeming to be multifactorial, several
authors have suggested its relationship to a greater deterioration of
immune status of patients who have been on dialysis for a long time.
The different incidence of this pathology in patients of similar age and
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similar length of time on dialysis and its infrequent occurrence in young
dialysis patients have encouraged us to carry out this study. We studied
36 patients who had been on dialysis for an average of 10 years, who we
divided up in to three groups. Group 1: patients with dialysis-related
amyloidosis and pathologic evidence of amyloid deposition, with an
average age of 61.5 years. Groups 2 and 3: patients without amyloid
arthropathy with an average age of 62.2 years and 44.3 years. As a
control we studied two groups of healthy patients from the Plastic
Surgery Department with an average age of 60 and 39.3 years. We
tested serum levels of immunoglobulins, lymphocyte subpopulations
with monoclonal antibodies and we carried out skin tests with five
different antigens. Results: When we compared lymphocyte subpopula-
tions in groups I, 2, 3, first separately, then together with the control
group, patients from group I had a T4/T8 ratio of 1.1 which was
significantly lower (P = 0.04) than that of patients from group 2 (P =
1.71) and group 4 (P = 1.62). No differences were found either in T4/T8
ratio or in absolute number of T3, T4, T8 cells between patients from
groups 3 and 5. We did not find any differences in the immunoglobulin
levels. Higher levels of 1gM were found in patients from group 5 than
from group 3. Skin tests: We found a greater cutaneous reaction in
control groups related to PPD, Varidase and Staphylococcus Toxoid. A
greater cutaneous reaction to PPD was detected in asymptomatic
patients (groups 2—3; P = 0.01) in comparison with amyloid arthropathy
patients (group I). In summary, in our patients for the same length of
time on dialysis, those who developed amyloid arthropathy had a
greater worsening of the cellular immunity in comparison with patients
of similar age or younger, who remained amyloid-symptom free.
Renal lesions in AIDS patients from Sanitary Area 6 of Catalonia. M.
Borrás, J. Bonet, P. Torguet, F. Cofan, J. Mate, B. Clotet, A. Caraips,
Hospital Germans Trias I Pujol, Badalona, Spain. A spectrum of renal
abnormalities has been described in patients infected with the human
immunodeficiency virus (HIV) and acquired immunodeficiency syn-
drome (AIDS), in particular the HIV-associated nephropathy. Clinico-
pathological studies in USA show a discrepancy in prevalence of renal
lesions; from Europe there are sporadic reports. The aim of the present
study was to analyze renal lesions presented in patients infected HIV
from our area. Clinical and pathological findings in the kidneys of 38
consecutive AIDS autopsies performed at our institution between
November '85 and August '90 were studied. The autopsied population
included 36 males and 2 females, all of them white. Risk factors for HIV
included: intravenous drug abuse (26) homosexuality (8) and others (4).
Overt clinical renal manifestations were not found. At autopsy 25
patients had no renal morphologic abnormalities; in any case glomerular
pathology was found. A mild degree of nephrocalcinosis in I case was
attributed to amphotericin therapy. The infections included septic renal
infarcts (2), one of them by aspergillous, disseminated infections
cryptococcus (1), and Mycobacterium tuberculosis (I); immunoblastic
lymphoma (I). Mild degree of intersticial fibrosis was in 6 cases and
severe in I. In our AIDS patients, important clinico- and pathologic
renal features were absent. The findings included renal involvement by
infections and neoplasms. These results are in agreement with the low
prevalence of glomerular pathology reported in several autopsy studies
from the USA. The difference from those studies is the large amount of
intravenous drug abusers in our studied population.
Structural and functional alterations of the Cl/NaCO3 anion ex-
changer in erythrocytes of uremic patients. F. Maduell, J. Fernandez, J.
DIez, Department of Nephrology and Hemalology, University Clinic,
Pamplona, Spain. There are several proteins involved in anion trans-
port in erythrocytes. The C1/NaCO3 anion exchanger protein is
localized in electrophoretic band 3 of erythrocyte membrane. This
transport mechanism accepts Li instead of Na and is inhibited by
DIDS. We have studied the transport activity of the erythrocyte anion
exchanger by measuring the DIDS sensitive, Li influx in fresh red
blood cells incubated in HC03 medium. In addition, the amount of
erythrocyte band 3 protein was determined by electrophoretic analysis.
The study was performed in 20 uremic patients in hemodialysis (12
males and 8 females, mean age 47.9 years). Mean time on hemodialysis
was 63.9 months (range 6—170 months). The DIDS-sensitive Li influx
was decreased in erythrocytes from uremic patients as compared to
erythrocytes from controls (619.6 34.1 vs. 761.2 36.6 tmol/liter cell
x hr, P < 0.01). The content of band 3 protein was decreased in
erythrocytes from uremic patients as compared to erythrocytes from
controls (30.01 0.39 vs. 32.12 0.48%, P < 0.01). These results
indicate that the Cl/NaCO3 anion exchanger is altered in erythro-
cytes from uremic patients in chronic hemodialysis and suggest that the
regulation of ion content may be compromised in the red blood cells of
these patients.
Biological study with low molecular weight heparin (LMWH) and
unfractionated heparin (UFH) in chronic hemodialysis (HD). F.
Siguenza, E. Grau, A. Caridad, F. Maduell, I. NerbOn, M. Linares,
Department of Nephrology and Hematology, Hospital SVS Xdtiva,
Spain. It has been postulated that LMWH has less hemorrhagic risk
than UFN due to its selective inhibition of factor X activated with a
slight modification on cefaline-kaolin time (aPTT). Study objective: (I)
to assess the relationship between antithrombotic markers and an-
tithrombotic efficacy of LMWH and UFH; (2) to investigate the
coagulation and fibrinolysis activation markers. We designed a prospec-
tive study using 14 patients undergoing HD with first UFH (4 weeks)
and second LMWH (CY-216) (6 weeks). In each phase blood samples
were taken the first and the last week at the beginning (B) and at the end
(E) of the HD. The following coagulation parameters were investigated:
aPTT, thrombin time (iT), Anti-Xa, TAT and D-Dimer. Results:
aPT
B
T (sec)
E
iT
B
(sec)
E
Anti-Xa
lU/mI
E
TAT
ng/ml
E
UFH 27.0 43.6 23.4 84.9 0.28 37.2
LMWH 28.753 32.4÷39b 24.8 35.6206b 0.51 28.9
P NS NS c a
a p <o.os, b P <0.01, " P <0.001.
D-Dimer was <200 ng!ml in 23 (83%) of 28 samples in the UFH phase
and in 23 (69%) of 33 samples in the LMWH phase. Conclusions: (I)
There is a relationship between anti-Xa levels and antithrombotic
efficacy of LMWH. (2) Anti-Xa levels should exceed 0.4 U/mI to
minimize thrombus formation. (3) Activation of coagulation is frequent
during HD with both UFN and LMWH, but clots are rarely detected.
ALG, cyclosporine (CsA) and steroids (ST) vs. OKT3, CsA and ST in
kidney cadaveric transplant (TR). Evaluation at two years. C. Gonzalez,
f.M. Griño, A.M. Casteiao, S. Gil-Vernet, D. Serón, E Andrés, I
Sabaté, M. Mestre, J. Aisina, Hospital de Beilvitge, Hospitalet de
Liobregat, Barcelona, Spain. Prophylactic use of both, ALG or OKT3
associated with CsA and ST has been useful in kidney cadaveric
transplantation. The administration of ALG before transplantation
induces allograft acceptance in transplant animals models. Two groups
of first cadaver transplant recipients (R) were prospectively docu-
mented based on immunosuppression regime used. Group 1 (N = 48):
Horse ALG IS mg/kg just before TR, ALG 12 mg/kg the first day after
TR, followed by 4 doses of 10 mg/kg on alternate days. CsA i.v. 2
mg/kg/day until oral route was started at 8 mg/kg/day. ST 0.25 mg/kg!
day. Group 2 (N = 53); OKT3 5 mgjust before TR, followed by 4 doses
of 5 mg/day. CyA and ST were administered using the same schedule of
the Group I. Results: The incidence of acute rejection during the first 3
months (m) was, Group I: 13%; Group 2: 17% (NS). The probability
that the patients evolve free of rejection 24 m after TR (Kaplan-Meier)
was: Group I 89% and Group 2 79%. The actuarial patient survival at 24
m was: Group I 95%; Group 2 98% (NS), and the graft at 24 m was
Group 1 86%, Group 289% (NS). The monitoring of CD3+ and CD2+
peripheral cells displayed the CD3 modulation under OKT3 treatment
(CD3+ cells 7.7 9%, CD2+ cells 31.6 17% the day of the last dose
of OKT3) which disappeared beyond 5 days of the withdrawal of OKT3.
Conclusions: (I) Similar low incidence of rejection was obtained with
both treatments, and the probability to evolve free of rejection is very
high in both groups two years after TR. (2) The OKT3 group has CD3
antigenic modulation which persists after the withdrawal of this mono-
clonal antibody. (3) Two years after TR, the patient and the graft
survival are very high in both regimes.
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Clinical, diagnostic and therapeutical aspects in intrinsic renovascular
hypertension in children: 27 cases. L. Garcia, J.A. Camacho, A.
Gimenez, E. Guardia, Service of Nephrology, Hospital Infantil San
Juan de Dios, Barcelona, Spain. Hypertensive patients (N = 122)
represent 1.7% of all nephrologic patients in our service (1974—1989).
We present 27 cases (22.1%) (12 male, 15 female, ages ranging from 5
months to 18 years) whose hypertension was related to a variety of
renovascular anomalities. They were divided up into two groups as
follows: Group A (N = 20) changes in intrarrenal arteries: 6 chronic
glomerulonephritis (CGN); 4 neurofibromatosis (NF); 4 policystic kid-
ney disease; 2 lupic nephritis; I hemolytic-uremic syndrome (HUS); I
segmentary hypoplasia; I oligomeganephron; I PAN. Group B: (N = 7)
changes in renovascular stems; 4 fibromuscular displasia (FMD); 3 NF.
Systolic and diastolic blood pressure ranged from 140 to 255 mm Hg
(mean 180) and from 100 to 170 (mean 118), respectively. General
symptoms included headache, abdominal pain, vomiting, epistaxis,
facial nerve paralysis, failure to drive, appearing severe affectation of
target organs in several cases (acute pulmonary edema, retinopathy,
hypertensive encephalopathy, intracranial hemorrhage). A rise in renin
and aldosterone blood levels was confirmed in 23 cases. We point out
the preferable interest of different diagnostic procedures in renovascu-
lar hypertension. Treatment was given according to the etiology and
pathophysiology of hypertension: Group A underwent medical dietetic
and drug therapy (diuretics, antihypertensive agents, remarking in all
cases control with captopril). Group B received medical therapy as
support to surgical intervention that was performed in 6 cases [percu-
taneous angioplasty (PA) in 2 subjects and restorative surgery in all 6]
with satisfactory results. Average control time was 9 years. Conclu-
sions: (I) FMD and NF are the most frequent causes of renovascular
disease-induced hypertension. (2) Severe signs of target organs are
common in the onset of renal hypertension. (3) Individualized therapy
according to etiology, location and severity of the lesion must be the
rule. (4) We must remark on the outstanding therapeutic advances in
both medical management of hypertension and surgical procedures (PA
and revasculanzation).
Control of hyperphosphatemia: Aluminum hydroxide [Al(OLI)3] and
desferrioxamine (DFO) versus magnesium carbonate (MgCO3). P. Arriz-
abalaga, f.M. Pons, M. Pocino, M. Carrera, M. Garcia, L. Revert,
Centro de Diálisis, Hospital Cilnico, Barcelona, Spain. We compare
the effects of Al(OH)3 plus DFO versus MgCO3 as phosphate binder
successively prescribed for aluminum-calcium-phosphate metabolism,
and its clinical tolerance in the same patients. Thirteen patients aged 54
7 (x SD), on hemodialysis 9 4 years, received Al(OH)3 at doses
of 4.8 I g/day plus DFO at doses of 6 g/week (period I) during 12.3
7.5 months; immediately at 9.7 8 months all patients received MgCO3
at doses of 4 0.8 g/day with magnesium-free dialysate fluid (period 2).
The mean serum phosphate decreased from 5.8 1.3 mg/dl to 4.9 1.3
mg/dl in period I, and remained at 5.6 0.7 mg/dl in period 2. The mean
serum aluminium decreased from 127.2 32.5 pg/liter to 70.6 39
zg/liter (t = 3.3294, P < 0.02) (period 1) and to 55.3 27.8 sg/liter
(period 2). There were no significant changes in magnesium, calcium,
alkaline phosphatases, intact parathyroid hormone, or potassium serum
mean values. The treatment with AL(OH)3 plus DFO was performed by
84.6% of the patients, and it was discontinued because of reversible
visual and auditory toxicity in 2 cases. The administration of MgCO3
was performed by 70% of the patients, and it was discontinued because
diarrhea in 4 cases (Pr = 0.989, P = NS). In conclusion: hyperphos-
phatemia and hyperaluminemia can be controlled with Al(OH)3 plus
DRO or MgCO3; both treatments present complications which limit
their clinical utility.
Organ procurement in the Basque autonomous community (B.A.C.):
Organization and development. I. MUares, J. de los Mows, J. Arrieta,
M. T. Neyro, J. Aranzabal, Transplant Coordination Team-Osakidetza/
Basque Health Service-Bilbao, Spain. The organ procurement infra-
structure in B.A.C. (2,130,000 inhabitants) has been established in this
way: seven public hospitals are authorized for organ harvesting, one is
able to perform renal transplantation and four are engaged in donor
detection. Each public hospital has its own surgical and medical units.
The coordination team is made up of two interhospital coordinators and
four intrahospital ones. In the last three years 213 potential donors have
been reported; there were 110 real donors (52%). The causes of
rejection of donors were multiorganic failure (14.5%), infection (8%),
old age (3.5%), detection failure (3%), family refusal (13.5%) and others
(5.5%).The donor detection rates were:
Reported donor/
1000 deaths
Reported donor/
100 hospital deaths
1987 4.13
1988 4.52
1989 5.1
0.91
1
1.2
The organ procurement rateslPMP were:
Heart Liver Kidney
1985 0.5
1986 1.4
1987 2.8
1988 2.4
1989 4.7
0.5
1.4
2.8
4
7
25.3
33.8
31
31
41.3
Conclusion: The current organization has achieved an important in-
crease in donor detection in organ procurement. Our ratios between
potential donors and organs obtained are similar to other groups. An
effort must be made in donor detection and organ preservation to
increase the organ procurement.
Effect of recombinant human erythropoletin (rHuEPO) on porphyrin
metabolism. A. Fontanellas, J.A. Herrero, M.J. Moran, F. Coronel,
J.L. Santos, F. Tornero, E. Enriquez de Salamanca, A. Barrientos,
Porphyria Unit and D. of Nephrology, Hospital ClInico San Carols,
Madrid, Spain. We have analyzed the erythrocytic activities of the
enzymes aminolevulinic-dehydratase (ALA-D) (J Clin Chem Clin Bio-
chem 12:389—390, 1974) and porphobilinogen-deaminase (PBG-D) (En-
zyme 28:146—157, 1982) and plasmatic and erythrocytic porphyrin levels
in 8 anemic HD patients during rHuEPO treatment. Initial doses of
rHuEPO (40 U/kg/session, i.v.) were increased (to 180 U) and modified
taking into account hemoglobin (Hb) and hematocrit (Htc) values. Prior
to treatment we observed a Hb 8.3 g/dl, Htc 24.4%, hypoactivity of
ALA-D (12.4 jsmol/liter/min; normal 29 9 U) and a compensatory
hyperactivity of PBG-D (66.1 nmol/ml/hr; normal 39 10 U) with an
increment of plasmatic porphyrin (1.53 g/dl; normal 0.5 0.25) and
erythrocytic porphyrin levels (40.8 tg/dl; normal 22 10). At the third
month of treatment 1-lb and Htc levels were 10 g/dl and 30%, respec-
tively. Reticulocytic count increased to 18% within the first thirty days,
then at the fourth month it decreased to basal values (13%). At the same
time there was an increment in ALA-D activity from 18.3 U at the first
month to 20.7 U at the third month, and it persisted at stable levels (19
U) until fifth month. This phenomena occurred despite a reduction of
doses in most of the patients since their third month. Compensatory
hyperactivity of PBG-B was corrected from the fourth month. During
the second and third months of treatment there were an increase in
plasmatic and erythrocytic levels of porphyrins. We conclude that
rHuEPO treatment stimulates porphyrin synthesis and produces a
partial correction of erythrocytic ALA-D hypoactivity. From these
results we can conclude that the alterations observed in heme-biosyn-
thesis could play an additional role in the development of anemia of
end-stage renal disease patients.
Fructosamine assay as an index of glycemic control in diabetic patients
on dialysis. F. Coronel, A. Cidoncha, M. Macia, A. Sanchez, J.
Torrente, L. Hidalgo, A. Barrientos, R. Valor, Hospital Clinico San
Carlos, Madrid, Spain. The value of hemoglobin glycosilated (HbAI) in
uremia is controversial, depending of the method used and the fraction
measured. Fructosamines (F) is considered to be a good indicator of
glycemic control in diabetics. We measured F (colorimetric method),
HbAl (c-fraction, HPLC method), mean blood glucose (MBG) and total
proteins (T-Prot) in 20 healthy subjects and 62 patients divided in the
following groups: 12 non-diabetics pre-dialysis, 10 non-diabetics on
hemodialysis (ND-HD), 8 non-diabetics on CAPD (ND-CAPD), 8
diabetics pre-dialysis, 8 diabetics on HD (D-HD), 8 diabetics on CAPD
(D-CAPD) and 8 diabetics with renal transplant. The levels of F and
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HbAlc were in normal range in all the groups of uremic non-diabetics.
In all the groups of diabetics F and HbAlc were elevated. In D-HD, the
F and F/T-Prot ratio were significantly correlated with the MBG of the
previous 21 days (r = 0.73, P < 0.05; r = 0.80, P < 0.05). HbAIc
correlated significantly with MBG (r = 0.89, P < 0.01). In D-CAPD,
there was a tendency of correlation between MBG with F and HbAlc (r
= 0.60, r = 0.63, NS). There was a good correlation between F and
HbAlc in both D-HD and D-CAPD (r = 0.82, P < 0.01; r = 0.75, P <
0.05). We can conclude that (I) F and HbAlc (HPLC method) seem to
be useful parameters in the glycemic status of diabetics on dialysis. (2)
Uremia per se does not seem to influence F and HbAlc levels.
Urinary-blood pCO2 difference (U-B pCO2) after furosemide. M.
Macia, A. Barrientos, A. Cruceira, A. Glez-Maie, P. 0/ivan, A.
Sanchez, J.A. Herrero, A. Torralbo, Hospital Clinico San Car/os,
Madrid, Spain. U-B pCO2 has been used as an H secretion index after
sodium-bicarbonate and sodium-phosphate infusion. Furosemide is a
potent stimulus for urinary acidification. It also has an inhibitory effect
on carbonic anhydrase at the brush border of the proximal tubule,
inducing bicarbonaturia. Based on these data it is tempting to expect an
increase in U-B pCO2 during furosemide testing. In eight healthy
volunteers (age X = 28 3 years) we measured U-B pCO2 at 0, 60, 90,
120, 150, and 180 minutes, after 80 mg p.o. of furosemide. This
parameter reached its maximal level at 90 minutes (10.5 2.1 mm Hg;
X SE) in seven cases, coinciding with the maximal urine volume (14.9
3.5 mI/mm). Fractional bicarbonate excretion increased from 1.4
I.! at 0 mm to 46.5 34 at 180 mm. From these findings we conclude
that in spite of the huge increment in urinary volume that should blunt
U-B pCO2 elevation after furosemide, this value increases. It occurred
along with an elevation in urinary bicarbonate secretion.
Shortening of furosemide test by the determination of urinary pH and
net acid excretion. A. Barrientos, M. Macia, A. Cruceira, P. 0/ivan, A.
Glez-Mate, F. Coronel, P. DeO/eo, P. Naranjo, Hospital Clinico San
Carlos, Madrid, Spain. Furosemide stimulates urinary acidification(UA) without previous acid load. As a matter of fact, furosemide in
chronic therapy induces metabolic alkalosis. It works increasing distal
sodium delivery. However, it is surprising that U-pH is minimal by the
time when sodium excretion is not at its maximum level. Also the role
of aldosterone (A) is controversial during the test. The aim of our study
is to shorten furosemide test, by the determination of net acid excretion
during the assay. In 8 healthy volunteers (age X = 28 3 years) we
studied UA during 180 minutes after 80 mg p.o. of furosemide.
Abbreviations are: urinary volume (U), NAE, NH4, fractional excre-
tion of bicarbonate (FEe), FENa, blood-pH (b-pH), U-pH. U-pH was
minimal at 180 mm. However NAE and distal sodium delivery were
maximal at 90 mm; afterwards all of them decreased. Blood pH
increases during the test.
v
mi/mm
NAE NH4
nEqimin FEB FENa U-pH
0 mm 0.7 0.1 45 14 13 3 1.4 1.1 0.5 0.1 5.28
90 mm 15 3 114 53 76 43 46 34 6.7 3.4 4.9
180 mm 6.5 4 69 20 37 17 4.3 4.1 3.3 2.1 4.3
P ace abe acc ace d
a 0 vs. 90 mm; b 0 vs. 180 mm; c 90 mm vs. 180 mm; a <0.05; <0.01
B-pH went from 7.386 to 7.429 (ce). Aldosterone increased from 214 +
77 to 443 + 53 to 702 + 37 (abce).
We conclude that: (I) maximal NAE and Na delivery were coincidental,
so the test could be shortened by one half; (2) U-pH decreased at 180
mm related to a NH4 decrement; (3) NH4 decrease could be related to
the increment in B-PH; (4) Aldosterone increased from 90 minutes.
Distal tubular renal acidosis (DTRA) in kidney transplants: Incidence
and pathogenic mechanism. P. Naranjo, F. Tornero, F. Coronel, M.
Macia, A. Cruceira, A. Sanchez, J.A. Herrero, A. Barrientos, Hospital
Clinico San Car/os, Madrid, Spain. To study the frequency and
patterns of DTRA in 120 kidney transplants (Tx), we selected those
patients with a trend for: metabolic acidosis, serum potassium alter-
ations and/or maintained urinary pH > 5.5. Minimum elapsed time after
Tx was 3 months. Exclusion criteria were: hepatic disorders, obstruc-
tive uropathy, urinary infection, recent rejection episode, serum creat-
mine (Sr) > 2.5 mg/dl and those treated with drugs able to interfere
with tubular function. Patient should have non-toxic serum levels of
CsA. In 21 patients (17.5%) an i.v. infusion of CINH4 was performed.
Twelve of them shown DTRA (7 males; 5 females. Tx time X = 29.4
months. Sr = 1.37 0.53 mg/dl). We did a furosemide test in 8 patients
and we measured pCO2 urinary generation after an iv. I M infusion of
CO3HNa in 4. Type I DTRA was observed in 7 (58%) (4 complete; 3
incomplete) divided in: 4 gradient type, 2 pump failure and 1 difficult to
classify. Type IV DTRA was observed in 5 (42%), divided in: 3
aldosterone deficiency and 2 tubular resistance to aldosterone. There
were no significant relationships between DTRA presence and CsA
treatment (X = 0.04). We conclude: (I) DTRA is a frequent complica-
tion in Tx, in spite of good graft function. (2) It does not seem to be
related to CsA. (3) Different types and mechanisms of DTRA could be
present in Tx.
Liposoluble vitamins (A and E) in uremic patients and those undergoing
dialysis. J. Bonal, C. Sierra, MC. Pastor, J. Bonet, P. Torguet, M.
Borràs, R. Lauzurica, A. Serra, J. TeixidO, R. Romero, A. Caraips,
Hospital de Badalona Germans Trias I Pujol," Barcelona, Spain.
Plasma levels of vitamins A and E in patients on dialysis are occasion-
ally contradictory. Vitamin E (tocopherol) is one of the chief antioxi-
dizing agents (cell membrane stabilizer) and has been implicated in the
risk of atherogenesis. Plasma levels of vitamin A (retinol) and plasma
and intraerythrocytic levels of vitamin E (tocopherol) are determined
by high resolution liquid chromatography. Likewise, the retinol binding
protein (RBP), pre-albumin, creatinine, cholesterol, triglycerides,
HDL-cholesterol and atherogenic index were determined. Healthy
subjects (N = 30), patients with renal failure on a supplemented
hypoproteic diet (N = 17), on chronic haemodialysis (HD) (N 20), on
peritoneal dialysis (CAPD) (N 12) and one year after renal transplan-
tation (RT) (N = 12) were analyzed. The results show that the plasma
levels of vitamin A (retinol) are significantly increased in patients with
renal failure undergoing dialysis. The vitamin A and RBP levels
significantly correlate with plasma creatinine levels. The alterations in
the union of vitamin A-RBP-prealbumin depend on the degree of renal
failure. Plasma levels of vitamin E (tocopherol) are significantly in-
creased in patients on a supplemented hypoproteic diet and on CAPD.
Nevertheless, they are normal in patients on HD and RT. The absolute
levels of vitamin E correlate significantly with the total cholesterol,
HDL-cholesterol and triglyceride levels. The fraction of vitamin E
bound to the HDL is significantly reduced in all patients with renal
failure. The level of intraerythocytic vitamin E is significantly reduced
in patients on HD (in contrast to those on CAPD). We conclude that the
liposoluble vitamins A and E are increased in renal failure and do not
require supplements. The highest levels of vitamin E (tocopherol) are
seen in patients on CAPD and on a hypoproteic diet, the two groups
likewise having a higher atherogenic index.
Use of pantethine in the treatment of hyperlipidemia in renal transplant
(RTx) patients. F. Coronel, F. Tornero, M. Macia, P. DeOleo, A.
Sanchez, A. Touchard, A. Barrientos, Hospital Clinico San Car/os,
Madrid, Spain. Hyperlipidemia is a frequent complication in RTx,
associated with mmmunosuppression therapy. We studied 92 functioning
RTx patients during one year period. Twenty-seven (29.3%) presenting
hyperlipidemia were treated with hypolipidemic diet. Five of them
achieved an adequate control, in the remaining 22 (3 diabetics)
pantethine was administered, given orally in 900 mg/day doses.
Pantethine is a natural substance derivated from pantothenic acid, and
is a precursor of CoA in the Krebs cycle. We evaluated its effect on the
lipmd spectrum after 2, 4, and 6 months. There were a significant
decrease mn: total cholesterol (300 49 vs. 262 39 mg/dl; P < 0.01),
triglycerides (238.3 127 vs. 186 79 mg/dl; P < 0.05), VLDL-Chol
(47.6 25.4 vs. 37.3 15.8 mg/dl; P < 0.05) and total-chol/HDL-Chol
ratmo (6.8 2 vs. 5.8 1.6; P < 0.01) after 2 months, and was
maintained at 4 and 6 months. There was a significant reduction in
LDL-ChoI (197.8 63.9 vs. 163 41.8 mg/dI; P <0.05) after 4 months
and it continued to 6 months. No significant changes were observed in:
HDL-Chol, blood glucose, SGOT, SGPT, serum creatinine (Sr) CsA
doses and levels. Three patients abandoned the treatment, 2 because of
gastric intolerance and I due an unexplained increase of Sr. We
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conclude that pantethine can be used as an effective and well-tolerated
hypolipemic substance in renal transplantation. It does not interfere
with CsA treatment.
Interleukin-2 in IgA nephropathy. M. Parera, A. Campos, F. Rivera,
Hospital de Alicante and Hospital de Elda (SVS), Centro de Transfu-
siones, Facultad Medicina, Departamento M. Interna, Alicante, Spain.
Interleukin 2 (IL-2) plays a central role in the immune response and may
be involved in the cellular immunoregulation of idiopathic IgA nephrop-
athy (IgAN). The aim of this study was to investigate the production of
IL-2 by peripheral blood mononuclear cells (PBMC) and the distribu-
tion of T cell surface receptors (IL-2R) in patients with IgAN. Twenty-
three patients with IgAN and 11 healthy controls (age and sex matched)
were studied during an infection-free period and without macroscopic
hematuria at the moment of the study. IL-2 was measured by ELISA
(GenzymeR) in serum and supernatants taken from 24-hr cultures of
PBMC stimulated with phytohemaglutinin and tumor necrosis factor.
The expression of cellular IL-2R was identified by flow cytometry using
murine monoclonal antibody anti-CD25. Serum IL-2 concentration did
not differ among patients and controls. The levels of IL-2 in the culture
supernatants were also similar in patients and in controls. In contrast,
the percentage of IL-2R positive cells was increased in patients com-
pared with controls (12.2 8.6% vs. 3.6 3.3%, respectively; P =
0.004). Moreover, IgAN patients had an increased number of activated
CD4+ lymphocytes when compared to the controls (52.1 10.5% vs.
39 8%, respectively; P = 0.001), There were no correlations between
serum and supernatant levels of IL-2 and cellular expression of IL-2R.
The percentage of CD25+ cells, clinical manifestations and serum IgA
levels were also unrelated. We conclude that IL-2 is involved in the
altered cellular immune response of IgAN and may be related with the
increased activity of helper T cells. Probably, serum IL-2 is used by
CD4+CD25+ cells in their activation.
Prevalence and causes of anemia in a population of renal transplanted
patients treated with cyclosporin A. A. Segarra, M. Morlans, LI.
Capdevila, J. Munne, S. Aiguade, A. Carrera, L. Biera, Nephrology,
Radionuclear laboratory, Hae,nathology Departments, H. general ValI
D'hebrón, Barcelona, Spain. The prevalence of anemia was determined
in 82 patients who carried a functioning renal graft and were on
immunosuppressor treatment with CsA. The responsible clinical factors
were analyzed with CsA. The responsible clinical factors were analyzed
also. The study of anemia included an hemogram and erythrocyte
index, reticulocytes, transferrin, transferrin sat., B12 and folic, Coobs
test and EPO plasmatic level (RIA). The clinical factors which may be
related to anemia were analyzed as follows: creatinine, donor and
receiver ages, the period of staying in hemodialysis, cold ischemia, a
prolonged acute tubular necrosis, pre-transplant hemoglobin, total dose
of accumulated CsA and existing systemic diseases which lead to
anemia. Twelve patients (15%) had levels of Hb <12 g/liter. In one
patient whose renal function was normal, the anemia was secondary to
a Fe deficit. The other eleven patients had RI (creatinine >1.5 mg/dl).
The patient parameters of Fe metabolism, folic and B 12 were similar to
those observed in patients with no anemia and in the general popula-
tion. The levels of EPO and the relation Hb/EPO were lower than those
observed in general population. Only the pre-transpiant level of Hb was
correlated with the level of Hb twenty months after the transplant. In
conclusion, the presence of renal failure is a necessary condition for the
occurrence of post-transplant anemia, but it is not enough. The main-
tenance of EPO secretion or any other factors related to the mainte-
nance of the levels of pre-transplant hemoglobin seems to be important
to keep the levels of post-transplant Hb in patients with renal failure
steady.
Plasma levels of cholesterol (C), HDL-C, LDL-C and tryglycerides
(TG) in renal trasplanted patients treated with CsA. A. Segarra, J. Vila,
Li. Capdevila, P. Chacon, M. Vilardell, L. Piera, Nephrology, Lipid
Research Unit, Hospital General VaIl D'HebrOn, Barcelona, Spain.
The plasma levels of C, HDL-C, LDL-C and TG were determined in
120 patients who were carrying an over six-month-evolution renal graft
and were on immunosuppressor treatment with CsA and steroids. The
aims of the study were as follows: (1) to define the prevalence of
dyslipidemia; 2) to analyze the clinical factors related to the alterations
of the lipid metabolism observed in this population. The prevalence of
hypercholesterolemia in patients with no risk of dyslipidemia was of
28% with an average C levels of 232 40, and did not differ from that
observed in patients with one or more risk factors. The average levels
of HDL-C in the total population was 65 25 and the average level of
LDL-C was 126 46. In patients with one or more risk factors the level
of HDL-C was never lower than 45, and that of LDL-C was not higher
than 150. The average level of TO in patients with no risk factors was
130 72 with an hypertryglyceridemia prevalence of 14%. In patients
with renal failure there was an increase in the levels of TG in relation to
the levels of creatinine. In the population with renal failure the
prevalence of hypertryglyceridemia was of 45% similar to that observed
in patients with more than one risk factor. In conclusion, the high
prevalence of hypercholesterolemia observed in these patients does not
seem to be attributable to the deterioration of the renal function over
weight or beta-blocker treatment. The deterioration of the renal func-
tion is a factor of great importance to the level of TO, In the population
we studied, though there were several risk factors leading to the
development of a dyslipidemia, the levels of HDL-C and LDL-C did not
seem to be among the high risk values which lead to development of
atheromatous vascular disease.
Single dose of low-molecular-weight heparin (LMWH) in hemodialysis:
A prospective clinical study. M. Ramirez, J. Bartolome, J. Rodriguez, A.
Olmos, M. Pico, 1'. Monasterio, Nehrology and Haemosthasia Depart-
ments, Hospital General Vail D'HebrOn, Barcelona, Spain. LMWH
has an antithrombotic action due to its anti-FXIOA activity. A prospec-
tive clinical study was done comparing conventional and LMWH in six
ESRD patients dialyzed with a cuprophan filter. The coagulation
parameters are TTPA, Ti', the parameters of platelet activation (FP4
and beta TO), TPA and D dimer. We analyzed the results obtained from
every heparinization model, the required doses of heparin and the
secondary effects. We conclude that LMWH when given only as a
intravenous dose before hemodialysis is a suitable method to prevent
thrombosis from the dialysis device in these patients.
Low molecular weight heparin (LMWH) in hemodialysis (HD). A.
Bondia RomOn, I. Aiberca Silva, L. Vazquez Lopez, B. De LeOn
Gomez, L. Corbacho Becerra, Hospital Clinico Universitario, P° de
Dan Vicente, Salamanca, Spain. To discover the degree of efficacy and
to establish the ideal dose of a LMWH (FraxiparinR) in our patients on
HD with a Cuprophan membrane, we carried out a 28 day follow-up of
3 groups of 4 patients each receiving 7500, 10000 and 12500 anti-X-
activated (A-X-a) U of LMWH on a i.v. monodose regimen at the
presence of clots in the lines or in the dialyzer at the end of the HD
session: no clots, score I; 1 or 2 clots, score 2; 2 clots, score 3.
Tolerance was evaluated according to the pressure time (PT) elapsed to
reach hemostasis in the arterial and venous punctures and according to
the activated arterial thromboplastin time (APT!') with a single-time
technique on an automated ACL system. For doses of the circulating
LMWH the technique of chromogenic substrates was used (Kabi,
Stockholm, Sweden) adapted to an ACL automatized system according
to the usual techniques followed in a coagulation laboratory. The results
are shown in lU. (1st International Standard).
Clots
Venous
PT
mm
Art.
PT
mm A-X-a
APT!'
mm
Control
with Sod. Hep. 1.66 3.08 2.7 — —
7.500 U. Choay A-X-a
(3.075 lU.) 1.39 4.44 3.72 0.76 IIJ 1.16
10.000 U.Choay A-X-a
(4.100 1.U.) 1.46 2.38 2.77 0.87 LU 1.39
12.500 U.Choay A-X-a
(5.125 L.U.) 1.39 3.06 2.95 0.97 LU 1.27
Although these data cannot be used in statistical terms, it may be
deduced that the degree of efficacy of LMWH is similar to that of
sodium heparin as well as tolerance on the basis of bleeding time. No
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appreciable alterations were seen in the clotting test since the APT!' did
not reach pathological values and the levels of A-X-a activity remained
sufficient to attain anticoagulation with no modification in other param-
eters (APT'!'). Additionally, we believe that a dose of 7500 U should be
used since higher doses do not alter either efficacy or tolerance.
Anti-hepatitis C antibodies in hemodialysis. M. Cordero Sanchez, A.
Bondia Roman, J. Lopez Ochoa, A.M. Martin Sanchez, J. Nuñez
Garcia, Hospital Clinico Universitario, Paseo de San Vicente, Sala-
manca, Spain. With a view to clarifying the epidemiology of hepatitis C
in hemodialysis (HD) and using an inmunoenzymatic technique for the
detection of antibodies against the hepatitis C virus (HCVAc), the sera
from 116 patients on hospital HD were analyzed; the patients had been
receiving treatment for periods ranging from 2 to 162 months. Twenty-
eight of them (24.13%) were carriers of HCVAc. Upon observing the
levels of aminotransferases (AT), retrospectively there were clear
differences between the carriers and non-carriers:
No I AT
I AT Episodic
asymptomatic
1' AT with
Clinic of
acute
hepatitis
f AT in
bouts
I AT
Sustained
HVCAc(+)
HCVAc(—)
6.25%
93.75%
31.25%
68.75%
75%
25%
93.33%
6.67%
100%
0%
According to analysis of variance or the chi-squared test a clear
association was detected between the presence of cytolysis and HC-
VAc (+): this was more patent in the cases of sustained elevated
enzyme levels and in those appearing in bouts. Upon studying the
correlation of the presence of HVCAC with epidemiological factors
associated with risk, a clear relationship was observed between the time
of dialysis in months (P = 0.0001) and, although not so pronounced,
with the number of units of blood transfused since the beginning of the
condition (P = 0.048). From these findings its be inferred that there is
probably a high incidence of hepatitis C in HD (it is not possible to
detect antigens) related with sustained raised levels and/or in bouts of
AT; this is clearly correlated epidemiologically with the overall time the
patients had been undergoing dialysis and, though to a lesser extent,
with the units of blood transfused, factors which in themselves might be
correlated.
Anti-OKT3 antibodies in responder and non-responder patients from
the waiting list for kidney transplant without OKT3 treatment. G. de
Masdevall, A. Arrieta, C. Altés, M. RihOn, C. Arranz, P. Gomez-
Ullate, S. Zarraga, SecciOn de Inmunologia y Servicio de Nefrologia,
Hospital de Cruces, Baracaldo, Vizcaya, Spain. We have developed an
ELISA technique to detect anti-OKT3 Ab in patients who received
OKT3 treatment. Studying normal polulation and patients from the
waiting list as controls we have found anti-OKT3 Ab in responder
patients (who developed Ab against a panel of cells) more frequently
than in normal individuals and no-responder patients. In our ELISA I
mg/mI OKT3 (Cillag) was used for coating the microplates, then
incubated with serum samples, and subsequently incubated with per-
oxidase conjugated antisera. The amount of anti-OKT3 Ab for each
sample was calculated with respect to a previously calibrated sera. All
the sera of our study were determined for anti-OKT3 Ab and for the FR
isotype (1gM-FR, IgA-FR, IgG-FR) by an ELISA technique. Study
groups: Control N = 49 (laboratory staff, blood donors); systemic lupus
erythematosus, N = 29; seropositive rheumatoid arthritis, N = 22;
no-responders from the waiting list, N = 56; responders from the
waiting list, N = 34.
OKT3 FR+ OKT3/FR+
Control 4.1% 10.2% 0%
No-resp W.L. 5.3% 19.6% 1,85%
Resp W.L. 26.4% 41.2% 17.6%
Lupus 10.3% 41.4% 10.3%
Rheum. arthr. 40.9% 100% 40.9%
We can see that the responders from the waiting list have a major
incidence of OKT3 than the no-responders. There is no association
between FR and OKT3 in kidneys of patients who are on the waiting
list. However, the association between anti-OKT3 Ab and responders
has a significant value (P < 0.01) when compared with controls and (P
<0.05) with no-responders.
Effect of DTT on the antilymphocite antibody levels in patients on the
waiting list for kidney transplantation: variation in the level of antilym.
phocyte B antibodies.G. de Masdevall, A. Arrieta, M. RinOn, R. Campo,
P. Gomez-Ullate, J.J. Amenabar, SecciOn de InmunologIa y Nefrolo-
gIa, Hospital de Cruces, Baracaldo, Vizcaya, Spain. We selected 42
patients in our transplantation program who presented with anti-
lymphocyte antibodies in a total of 288 sera. We studied those sera
against a panel of T and B cells (those ones separated by nylon wool).
All the sera were treated with DTT. DTT inactivates 1gM antibodies by
reducing the disulphide bonds, but leaving IgG reactivity intact. The
treated and the untreated sera were studied in parallel against the same
panel employing the normal microlymphocytotoxicity technique. In the
untreated sera we found 7 sera (3%) negative against B lymphocites and
221 sera (97%) positives. In the treated sera we considered that PRA
decreased only when it was equal to or higher than 10%. We found that
55 sera (24%) decreased PRA and only in 14 sera (6%) did PRA become
negative. Those sera that became negative with DTT had previous
levels of antibodies in the untreated sera higher than against T cells.
Only 14 sera became negative against T and B cells when treated with
DTT. Comparing the antibody levels against T and B cells in untreated
sera, we found that the level of anti-B antibodies was higher than anti-T
in 77 sera (34.8%), lower in 19 sera (8.5%) and without changing in 125
sera (56%). The media of the PRA levels against B cells were higher
than those against T cells (57% vs. 52%). In both cases the media of the
PRA levels were reduced to 5% when treated with DTT.
Hepatitis C in dialysis and transplantation. P. GOmez-Ullate, J.
Ocha ran, J. Corral, I. Sancha, L.M. Ruiz, S. ZOrraga, J.J. Amenabar,
1. Lampreabe, Nephrology and Bacteriology Departments, Hospital de
Cruces, Bilbao, Spain. We measured antibodies against hepatitis C
virus (anti-HCs) by the immunoassay method (ELISA) in 117 dialysis
patients (pts) undergoing hemodiatysis (HD) and in 200 pts with
functioning renal transplantation (RT), finding a prevalence of 16% in
HD (19 pts) and 16.5% in RT (33 pts). In pts in HD we did not find
significant differences between the anti-HCs positive and anti-HCs
negative groups as to age, sex, the cause of nephropathy, hepatic
disease measured by a sustained increase of transaminases, or the
number of blood transfusions, in pts in RT we found significant
differences between the anti-HCs positive and the anti-HCs negative
groups as to the number of transfusions (13 23 vs. 8 13, P < 0.05)
and an increase of transaminases (61% vs. 19%, P <0.001). There were
no differences regarding age, sex or the cause of nephropathy. The
retrospective analysis of pre-transplantation sera made in 10 pts in RT
with anti-HCs antibodies showed 8 cases with positive anti-HCs titers
before transplantation. Conclusion: the prevalence of anti-HCs antibod-
ies in our population in dialysis and transplantation is similar (16% and
16.5%). We found a larger number of blood transfusions and more
severe hepatic disease in the transplanted population with anti-HCs
antibodies positive. Most of the trasplanted patients with anti-HCs
antibodies were already carriers during their dialysis period.
Study of intradialytic interleukin-1 production with live different
membranes. Comcomitant evaluation of beta2-microglobulin levels. L.M.
Ruiz, J. Ocharan, G. Garcia Erauzkin, D. Garcia Masdevall, A.
Arrieta, M. RinOn, J.J. Amenabar, P. GOmez-Ullate, I. Lampreabe,
Divisions of Nephrology and Inmunology, Cruces Hospital, Bilbao,
Spain. Nine hemodialysis patients were sequentially treated during a 5
week follow-up time with 5 different membranes: Cuprophan (CU),
polyacrilonitrile type AN-69 (PAN), polysulfone (PSF), Ethinylvinylal-
cohol (EVAL) and cellulose acetate (CA). We determined by ELISA
the basal and intradialytic plasma levels of alfa lnterleu kin-I (IL-I) and
beta2-microglobulin (f32-m) at 3 moments, initial (I), half (H) and final
(F), of every week until the last dialysis. PAN, CU, and CA membranes
induced a significative intradialytic IL-I production: I = 98.5 57.46;
129 5l.11;F= 98.5 54.6 for PAN. 1= 86. 1± 27.48;H= 104.6
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28.84; F = 81.4 20.04 for CU. I = 56.42 14.96; H = 75.14
20.78; F = 75.42 26.49 for CA (Wilcoxon test: P < 0.05 for H vs. I;
level measures in pg/mi). EVAL and PSF membranes did not show
significant changes:! = 69.62 17.95;H = 72.12 15.51;F = 75.5
16.66 for EVAL. I = 75.28 10; H = 76 17.43; F = 84 13.67 for
PSF. Intradialytic /32m levels significantly decreased with PSF: I = 35
12.13; H = 27.3 12.2; F = 24 10.4. On the other hand they
increased with CU: I = 32.7 11.02; H = 37.2 10.4; F = 39.4 10.3(Wilcoxon test: P < 0.05 for H vs. 1; level measures in mg/liter). No
significant changes were seen with PAN (1 = 32.12 8.06; H = 30.6
10.9; F = 29.7 10.5), EVAL (30.3 10.1; H = 32.8 7.07; F = 33.6
7) and CA (I = 38 10.4; H = 43.1 13.9; F = 45.2 13.4).
Conclusion. Membrane-monocyte interaction can be a inducer of IL-i
intradialytic production. EVAL and PSF membranes are the most
biocompatible membranes from this point of view. In our experience,
there is not an apparent correlation between intradialytic p2m changes
and acute IL-I production.
Continuous arteriovenous hemodialysis (CAVHD) in severe acute renal
failure (ARF). R.1. Muñoz, J. Gainza, F. Garcia, 0. Garcia Erauzkin,
S. Zárraga, f.M. Martinez, J.J. Amenabar, R. Mufliz, I. Lampreabe,
Nephrology Department, Hospital de Cruces, Bilbao, Spain. CAVHD
achieves better clearances than continuous hemofiltration because of
the addition of diffusion to convection, since dialysate is flowing
through the filter. We reviewed our experience in applying CAVHD to
15 patients (pt) (5 females and 10 males), with ages from 32 to 79 years
(x = 63) admitted to the Intensive Care Ward, with oliguric ARF and
multiorganic failure, 14 of them with mechanical ventilation and all with
vasoactive drugs. A 0.5 m2 polyacrylonitrile (AN69) filter was used,
making blood flow without pump from the femoral artery to the femoral
vein. Dianeal 1.5% at 1000 mI/hr was used as the dialysate and the
ultrafiltrate replacement was made with Ringer's lactate in the venous
line. Heparinization was continuous, at 3—10 mg/hr (in 10 pt at 5 mg/hr).
We studied their clinical and their usual analytical parameters. One
patient died in the first 24 hours and other 10 died during the treatment.
At the beginning of CAVHD BUN was 100 37 mg/dl and creatinine
was 5.9 1.8 mg/dl. This latter decreased 33% in 72 hours (P < 0.05,
paired data, in 14 pt) and 45% in one week (8 Pt alive). Hyperkalemia
and hyponatremia were normalized in all patients but one in one week,
and bicarbonate was greater than 18 mEq/liter in all. The ultrafiltration
mean was 330 147 mI/hr. Treatment lasted from 1 to 18 days (x = 7)
and the mean duration of filters was 41 + 14 hours. Ten patients had
digestive hemorrhage (4 before CAVHD); the 4 patients who survived
were transferred to conventional hemodialysis after 4—12 days of
CAVHD and recovered a normal renal function. We conclude that
CAVHD is an efficacious therapeutic alternative in the management of
serious ARF. Digestive hemorrhage, not imputed exclusively to this
technique, has been the most common complication.
Results of kidney transplantation in sensitized patients treated with
cyclosporine A and prednisone. J.J. Amenabar, P. GOmez-Ullate, G,
Garcia Erauzkin, S. Zdrraga, L. Ruiz, J. Gainza, D, Garcia Masdevall,
I. Lampreabe, Nephrology and Inmunology Services, Cruces Hospital,
Bilbao, Spain. Since the prognosis of kidney transplantation in sensi-
tized patients has important therapeutic implications, we report our
experience in our center. From July 1986 to January 1990, 161 kidney
transplanted patients, all of them with a negative crossmatch in a
current serum, were treated with cyclosporin A and prednisone. We
divided them into three groups according to panel-reactive lymphocy-
totoxic antibodies (PRA), in their last serum pre-transplant. Group A,
highly sensitized, was defined by PRA > 50% (N = 18, 15 > 75%).
Group B, lowly sensitized, had PRA 50% (N = 17). Group C,
controls, were without antibodies (N = 126). Patients from groups A
and B, sensitized, received more blood transfusions than controls (A:
24.7 31, B: 19.9 34 and C: 7.9 10; P < 0.01). A total of 8.6% of
patients from group A, 33% from group B and 16% from C shared three
to four B+DR identities (NS). Also, there were no differences in age,
cold ischemia and graft number. Results: (I.) Actuarial graft survival in
the first year was: A, 87%; B, 88%; and C, 85%. Second year was A,
87%: B, 81%; and C, 82%. Third year A, 87%; B, 81%; and C, 82%
(NS). (2.) Immunologic graft losses: 0/18 in A, 1/17 in B and 7/126 in C.
(3.) Acute rejection incidence, A 46%, B 29.5%, and C 24% (A> B, C;
P <0.05), (4.) Serum creatinine levels were first year A 1.4 0.5; B, 1.7
0.7; and C, 1.6 0.8 (NS). Second year were A 1.4 0.3; B, 1.6
0.4 and C, 1.4 0.4 (NS). Conclusions: In a two-three year period of
time, the survival and renal function of grafts in our sensitized kidney
recipients were similar to the control group. The highly sensitized
patients showed a higher incidence of acute renal rejection.
Early detection of cytomegalovirus (CMV) on kidney transplantation
(KT). R. So/a, R. Mouzo, F. Sanchez, N. Margall, FundaciO Puigvert,
S. Microbiologia, Hospital Sta, Creu i Sant Pau, Barcelona, Spain.
The number of CMV infections (first or reactivated) is very common in
KT and its importance is not known. We presented our experience in a
new method of identification of CMV by evaluation of serology and
tGM measurement in patients affected of this infection. Methods:
Nineteen patients with KT were studied in a 6 month time period after
KT. Anti-CMV serology was measured in all patients, and detection of
antibodies and cellular cultures of urine immediately before transplan-
tation and every 2 weeks for 6 months. Blood cellular culture was done
when there was a virus infection. Serology was measured by comple-
ment fixation. Negative results were comprobated by latex. 1gM was
measured by indirect immunofluorescence. Cellular culture was made
in fibroblasts from human embrionic lung (MRC5). Results: All patients
were serum positive before kidney transplantation. In 3 patients blood
culture was positive to CMV. One had no observation of any increment
of 1gM, and the patient died from CMV sepsis. In the other, an acute
kidney rejection was established. Urinary virus and serology increased
their values. In the third blood virus sepsis was appeared with fever and
increase of serology, 1gM and urinary virus. In II patients an increase
of urinary virus and increase of blood antibody with negative 1gM was
observed. Only in two patients was the increase of tubular antibody
observed or preceded by an increase of 1gM. In 2 patients an increase
of blood antibody titers was observed, in 1 patient the titer of antibody
was not modified during all the time of the study. Conclusions: Blood
virus was detected in 3 patients with different prognosis importance.
Serology and 1gM detection were nonspecific and we could not relate
clinical or cellular culture to CMV. All patients were previously serum
positive but two presented a severe clinical form of CMV illness.
Effect of captopril and hypoprotein diet on diabetic nephrotic syndrome
in type II (noninsulin dependent, NIDOM) diabetic patients treated with
combined therapy. f.M. Mallafre, f.M. Pou, R. So/a, J.A. Arroyo, X.
Ampudia, S. Nefrologia H.Cruz Roja, S. Endocrinologia, H.Sta.Cruz y
S. Pablo, S. Nefrologia F. Puigvert, Barcelona, Spain. In this paper the
therapy of several NIDDM patients affected of diabetic nephrotic
syndrome was evaluated with a history of high blood pressure (HBP)
and normal glomerular function. Seven NIDDM (SM, 2F) were treated
with a combined therapy of hypoprotein diet (0.6/g/kg/day) plus capto-
pril (mean 118 27 mg/day) and furosemide (40—80 mg/day). Their
mean age and known diabetes duration were 58 7 and 5.65 24 years.
Biochemical studies: HbA1C 7.78 1.3%, creatinine 148 31 mol/
liter. Urinary protein excretion and albumin plasma levels were 7045
1437 mg/24 hr and 30 g/liter. After 90 days of combined therapy we
observed: HbAIC 7.7 .2%, creatinine 151 12 mol/liter, urinary
protein excretion 2882 528 mg/24 hrs (P < 0.005), plasma albumin
37.4 3.2 g/liter (P < 0.05). Colesterol, tryglicerides, LDL, VLDL
were maintained at high levels. HDL increased from 0.175 0.3 to 1.31
0.29 mmol/liter (P > 0.05). Normal BP pius hypoprotein diet could
partially regulate the diabetic nephrotic syndrome in NIDDM patients.
This therapy promoted an important rise of HDL at the same time that
there was a decrease in urinary protein filtration. Captopril is an
interesting drug in the therapy of HBP in diabetic patients with normal
glomerular function.
Effect of hypoprotein diet and captopril In the development of diabetic
nephropathy. R. So/a, f.M. Mallafre, M. Ba/sells, J.M. Pou, F.
Puigverl, S. Nefrologia, S. Nefrologia de Cruz Roja, S. Endocrinolog(a
de Hospital Sta.Cruz y S. Pablo, Barcelona, Spain. The most important
syndrome in diabetes is the late complication of nephropathy. In this
paper the effect of protein reduction in diet or angiotensin conversion
enzyme inhibitors (ACE) in the establishment of diabetic nephropathy
was studied. Twelve selected type I (insulin dependent) diabetic pa-
tients (6 M, 6 F) were studied. The mean age and diabetes duration were
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for5.64 1.5 years. Serum creatinine was 128 30 mmol/liter, urinary
protein excretion (UPE) 12853408, colesterol 7.31 .88, TGE 2.4
.81, HDL 1.18 .45, LDL 3.77 1.41, VLDL 1.76 0.72 mmol/liter,
respectively. We used two therapies in a cross-over study: A-restriction
of proteins (0.6 g/kg/day), or B-Captopril 100 mg/day. Five patients in
group and 4 in B needed nifedipine (A + N1 and B + N2) for HBP
stabilization. The two therapies were used for 90 days with a wash-out
time of 2 months in between.
Results Basal 1St month 3rd month
A creatinine 181 26 178 37 171 25
UPE 1205 362 857 285 837 l73
A+N, creatinine 173 32 177 14 169 31
UPE 1383 185 1021 240 960 I61
B creatinine 181 27 189 16
UPE 1317 241 816 177
B+N2 creatinine 165 12 173 13
UPE 1123 404 938 88
a P < 0.01.
Lipids and lipoprotein fractions did not change. Hypoprotein diet
promoted an important decrease in UPE at the same range as captopril
without glomerular function alteration. Nifedipine could interfered in
the UPE reduction. We need more time and experience for several
definitive conclusions.
Kinetics of rHuEPO in ESRD patients. J. Bravo Solo, M. Benitez
Sanchez, J. Hernandez Magdalena, M.A. Fernandez Fe:jóo, A. Mon-
ies Puerta, MAD. Del Pino y Pino, f.M. Osorio Moratalla, C. Asensio
Peinado, CCSS "Virgen de las Nieves", Granada, Spain. In a previous
study of over 17 ESRD patients treated with rHuEPO intravenously,
the levels of this protein before the hemodialisis session after the
weekend did not correlate to hematocrit improvement, and they were
not useful to control the therapy. In addition, these levels were much
lower, at least at the beginning, than those found in non-uremic
anemias. Because of this, we designed a study to characterize the
kinetics of this hormone in ESRD. Methods: Group A: 12 patients
treated intravenously (I man; 11 women), aged 45.5 18.7 years,
weight = 49.5241 10.2 kg; rHuEPO dose 25—120 U/Kg. Group B: 9
patients treated subcutaneously (3 men, 6 women), aged 56.4 12.9
years, weight = 59,8 10.4 kg; rHuEPO dose 17—80 U/kg. We
measured EPO by RIA (INCSTAR) in all patients at a certain time
during the therapy (Group A from 1st to 26th week; Group B from 1st
to 10th week) at times 0,-, 1, 2,4, 8, 16, 24 and 48 hours. We calculated
the usual kinetics parameters, residual creatinine clearance, predialysis
serum creatinine, prothrombin activity, GOT and hematocrit increase—
after 4 weeks of study—, the latter only in patients who were main-
tained with the same dosage.
Results Group A
Plasma concentration (t = 0): Kel: 0.118 0.05 hr'
755.4 432.9 mU/mI
Plasma concentration (48 hr):
0.57 0.41 mU/mI
T: 6.44 2.82 hr
Time in which plasma levels are Creatinine: 10.9 2.3 mg%
maintained 100 mU/mi:
14.8 3.95 hr
Creatinine clearance: 0.84 rHuEPO Cl: 7.79 3.9 cc/mn
1.089 cc/mm V.d.: 0.08 12 0.037 1/kg
Group B No correlation of creatinine
Highest concentration time: clearance, serum creatinine,
11.58 7.71 hr (± 10%) of prothrombin activity, GOT
highest concentration time: and hematocrit increase to
12 hr kinetic parameters have been
Creatinine clearance: 0.82 0.95 found
cc/mm
Creatinine: 12.07 2.6 mg%
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Conclusions: (1) The kinetics of intravenous rHuEPO fits a mono-
exponential elimination. (2) The curve of subcutaneous rHuEPO shows
a delayed absorption, and elimination is not completed after 48 hr. 3)
The clearance and T! of the hormone are unrelated to residual renal
function. (4) Pharmac2okinetic data are not useful to assess the response
to the therapy.
Study of the lymphocyte populations in kidney transplantation with
stable renal function vs. healthy individuals and hemodialysis patients. A.
Monies Puerto, F. Ruiz Cabello, J. Bravo Soto, J.M. Osorio Moratalla,
MaD. Del Pino y Pino, F. Garrido, C. Asensio Peinado, CCSS Virgen
de las Nieves," Granada, Spain. New human differentiation antigens
have recently been described, CD45R and CD29, which allow us to
distinguish between T-helper suppressor and T-helper inductor lympho-
cytes. We studied several lymphocyte subpopulations in patients
treated with CsA and azathioprine after transplantation. Methods: 20
healthy subjects were used as controls; IS patients undergoing he-
modyalysis and 46 transplanted patients were included in the study (41
treated with CsA and 5 with azathioprine). A number of lymphocyte
subsets were analyzed using a flow cytometer (FACS) and a panel of
monocional antibodies: CD-20 (pan-B), CD.3 (pan-T), CD4 (helper
lymphocytes), CD-8 (cytotoxic-suppressor lymphocytes), CD-25 (IL-2
receptor), CD4-CD29 (T-helper inductor) CD-4-CD45R (T-helper sup-
pressor). In addition, cells from healthy subjects were estimalted in
vitro with PHA in presence/absence of CsA. The relationship between
HLA compatibilities and CD-25 expression was also investigated.
Results: When comparing results from healthy subjects and trans-
planted patients, a lower number of CD2O(+), CD4(+)CD29(+) cells
and an increase of CD3(+), CD8(+), CD4(+)CD25(+), and CD8(+)
CD25(+) cells were found in the second group. When analyzing subsets
from patients undergoing hemodialysis and transplanted patients,
the latter group presented an increase in the number of CD3(+) and
CD8(+) cells, and a decrease of CD4(+), CD4(+)CD2S(+), and
CD4(+)CD29(+) cells. Conclusions: (I.) Transplanted patients have
lowlevels of CD2O(+) cells (P <0.01), because of immunosuppression.
(2.) Transplanted patients have a greater number of CD3(+) cells,
mainly because of an increase of the CD8(+) cell population (P <
0.001). Perhaps CD8 suppressor cells enhance tolerance. (3.) There is
an increase in the expression of CD25 in transplanted patients when
compared with controls (P < 0.001), but is lower than hemodialyzed
patients, and the increase is not associated with HLA compatibility. (4.)
We found a decrease in the number of CD4(+) CD29(+) cells in
transplanted patients compared with controls, which may improve graft
survival CsA blocks T-helper inducer cells as the in vitro tests show us.
(5.) There are no differences between lymphocyte populations from
transplanted patients treated either with CsA or those treated with
azathioprine.
Hemostasis in ESRD patients treated with rHuEPO. J. Bravo Solo,
J.M. Osorio Moratalla, M.J. Gutierrez Pimentel, M.D. Del Pino y
Pino, A. Monies Puerta, A. Osuna Ortega, C. Asensio Peinado, CCSS
Virgen de las Nieves," Granada, Spain. Some of the most serious
adverse effects of the rHuEPO treatment, like coronary and encephalic
vessels and arteriovenous fistula thrombosis, are related to the im-
provement in hemostasis caused by this hormone. Relative to this fact
is the need to increase the doses of heparin during hemodialysis to avoid
clotting in the extracorporeal circuit, as has been observed in 70.5% of
our patients (average dose increment after 6 months of treatment: 980
lU/session; P = 0.02). The aim of this study is to establish the
differences in several coagulation parameters between ESRD patients
treated with rHuEPO and untreated ones. Methods: Group I: 11
patients with rHuEPO (9 intravenous, 2 subcutaneous) and hematocrit
= 27.9 3.8%. Group 11: 11 untreated chronic hemodialysis patients
with hematocrit = 23.2 3.7% (P I-Il < 0.01). Group III: 11 healthy
individuals (hematocrit = 43.3%). From the 14th to the 23rd week of
hormone treatment (155 94 lU/kg/week) platelet count, fibrinogen,
prothrombin and thromboplastin times, clot retraction, platelet aggre-
gation (Aggrecoder PA-3210 and Menarini reagents) and bleeding time
(Surgicutt Ortho-diagnostic) have been determined simultaneously in
each group. Results:
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Group I Group II
P
(I—Il)
GroupIII
P
(11—111)
ADP 5 LM 84.8 77.5 NS 90 0.01
ADP 2 M 58.15 68.4 NS 70
1 NS NS
Epinephrine 10 iLM 80.9 75.7 NS 75 NS
Collagen 5 LM 86.5 83.3 NS 90 NS
Collagen 2 M 73 72.8 NS 70 NS
A 23187 20.2 .tM 61.22 52,92 0.07 60 NS
Arach.Ac. 14.3 M 90.83 83.7 0.051 90 NS
Bleeding time 578
mm
619
mm
NS — —
There were no differences in platelet count, fibrinogen, clot retraction,
prothrombin and thromboplastin times between groups I and II. No
correlation to hematocrit, thrombocytes and rHuEPO dosage have been
observed. Conclusions: (1) In ESRD there is a decrease of platelet
aggregation induced by 5 ADP. (2) The effects of rHuEPO upon
hemostasis are not related to the parameters studied here. Neverthe-
less, platelet aggregation induced by calcium ionophore A 33187 and
arachidonic acid seems to be better in the treated group, but the
difference with the untreated group does not reach statistical signifi-
cance.
Effects of immunosuppressive therapy on renal transplant hyperfiltra-
lion. R. Peces, M. Gorostidi, L. Sanchez, P. Escalada, J. Alvarez,
Nephrology Department, Hospital Covadonga, Oviedo, Spain. Exper-
imental findings in rats have demonstrated that cyclosporine (CsA) can
inhibit compensatory renal growth (CR0) following uninephrectomy.
Some renal transplants develop high glomerular filtration rates as an
expression of CRG. The aim of this study was to determinate the
influence of immunosuppressive therapy on renal transplant (RT)
hyperfiltration. We studied 106 RT, 61 on a triple therapy regimen
(including CsA 7 mg/kg/day initially—group CsA) and 45 on classic
immunosuppressive therapy (group Aza). Thirty-seven RT (35%) had a
creatinine clearance of 124 3 mI/mm/I .73 m2, being 21 from group
CsA and 16 from group Aza. There were no differences in the highest
clearance reached (group CsA 121 3 vs. group Aza 128 4, NS),
donor age (group CsA 30.0 2.9 vs. group Aza 23.7 2.8 years, NS),
and recipient age (group CsA 43.2 2.2 vs. group Aza 37.4 2.9 years,
NS). There were no differences between both groups in HLA compat-
ibility, ischemia times or acute tubular necrosis incidence. Mean time in
developing post-transplant hyperfiltration was lower in group CsA than
in group Aza (4.0 2.3 vs. 13.7 3.7 months, P < 0.05). Acute graft
rejection incidence was lower in the group CsA (P < 0.025). When
comparing the graft volume enlargement by ultrasonographic methods,
there was no difference between both groups (CsA 20,8 6.2% vs.
Aza 22.7 7.5%, NS). In conclusion, hyperfiltration can be observed
in about 1/3 of RT recipients with both immunosuppressive protocols.
The low-dose CsA therapy, while avoiding immediate nephrotoxicity
and diminishing acute rejection incidence, permits hyperfiltration de-
veloping even before using the Aza protocol. CsA, in such doses, does
not inhibit CRG in RT.
Sodium intake influences amino acid excretion on cystinuria. R. Peces,
M. Gorostidi, L. Sanchez, P. Escalada, J. Alvarez, Servicio de Nefro-
logIa, Hospital Covadonga, Oviedo, Spain. There is evidence that
cystine and dibasic amino acid resorption is closely coupled to sodium
flux across the luminal membrane in the proximal tubule. To charac-
terize the effects of sodium excretion on renal amino acid excretion in
cystinuria, we studied 4 homozygous patients and 4 heterozygous
subjects at various levels of sodium intake, In homozygous patients, the
decreasing sodium intake from 242 33 to 50 9 mmol/day (P < 0.005)
led to a fall in the excretion of cystine from 1,737 276 to 759 247
zmol/g of creatinine (P < 0.01). There was a significant correlation
between individual excretion rates of sodium and cystine (r = 0.80, N
15, P <0.001), sodium and lysine (r = 0.59, N = 13, P < 0.005), and
sodium and ornithine (r = 0.60, N = 13, P < 0.05). There was also a
significant correlation between the urinary concentration of sodium and
amino acids. Two patients followed during 4 and 34 months, respec-
tively, on a low sodium diet remained free of lithiasis. No correlation
was observed between urinary excretion of sodium and amino acids in
heterozygous subjects. These results suggest that a sodium diet re-
stricted to about 50 mmol/day with a high fluid intake can maintain
cystinuric patients in a safe range of cystine excretion. This simple
maneuver can provide a long-term approach to the treatment of
cystinuria.
Percutaneous transluminal angioplasty (PTA) in patients with renal
artery stenosis in a solitary functioning kidney (SFK). J.M. Galceran, A.
Martinez-Amenos, H. Rama, X. Sarrias, J. Montana, J. Alsina,
Departments of Nephrology and Radiology, Bellvitge Hospital, Barce-
lona, Spain. PTA is now considered by many to be the procedure of
choice for patients with renovascular hypertension. Patients with renal
artery stenosis in a SFK constitute a special group not only because of
the severity of their hypertension, but because of the quick impairment
of their renal function. These patients, in whom PTA has been thought
to be relatively contraindicated, also present a major risk to surgery.
Between 1981—1989 we performed PTA in 10 patients with renal artery
stenosis in a SFK, 7 males and 3 females, with a mean age of 53.8 16.1
years, a mean blood pressure at admission of 201/112 mm Fig and a
mean serum creatinine of 236. 1 96.5 mol/liter. The etiology was
ateroma in 8 cases and dysplasia in 2 cases. The procedure was effective
in 8 cases, which showed a significant improvement of systolic (P =
0.0018) and diastolic blood pressure (P = 0.013) with a reduction in
dosage or a withdrawal of their antihypertensive medication. The 2
cases in which PTA was not successful were referred to renal auto-
transplantation with success. We found no complications but had an
acute renal failure in one case due to contrast nephrotoxicity which
required one session of hemodialysis, the patient improving afterwords.
In 2 patients, renal function continued to worsen and they had to begin
dialysis at 14 and 24 months, respectively, after PTA. In the rest of
them, renal function remained stable and so did blood pressure during
a mean follow-up time of 57 35.7 months. We conclude that PTA is
an effective procedure for renovascular hypertension in patients with a
SFK, with few complications, and that in the majority of cases the
procedure can stop the impairment of renal function,
l,25(OH)2D Production after 25.OH-D administration in CAPD dia-
betic patients. I. Ubeda, A. Sanchez, L. Hidalgo, F. Tornero, M.
Borque, A. Cruceira, A. Barrientos, H. Clinico, Madrid, Spain. 25-
OH-D Administration in uremic patients reaching supraphysiological
levels leads to an increase in serum I ,25(OH)2D concentrations. We
tested this effect in 9 CAPD diabetic patients, receiving 0.266 mg of
25-OH-D orally every other day for 4 weeks. There were no changes in
the regular diet or in (01-1)3 Al intake during the study. We evaluated
Ca, F, 25-OH-D, l,25(OH)2D and iPTH (intact mol.) levels, basely and
after 2 and 4 weeks of therapy. Results are in mean SEM using a paired
f-test for statistical analysis:
Basal 2 Weeks 4 Weeks
Ca' mEq/iiter 1.8 0.2 1.4 0,la 1.5 0.2
P mg% 5.7 0.5 6.3 0.5 6.4 0.3
25-OH-D ng/ml 19.3 4.9 55.2 7,7b 52.5 5,2k'
l,25(OH)2D pg/mI 8.7 2.4 12.6 1.5 339 8,3bc
iPTH pg/mi 232.0 83.4 243.9 114 109.3 46.5a.
a p < 0.05, b p < 0.01 for statistical differences from basal and C p <
0.05 from 2 weeks.
After 4 weeks of therapy, serum 25-OH-D and I ,25(OH)2D increased
significantly with a reduction in iPTH levels. We found a tendency of
Ca to decrease and of P to increase without statistical significance.
There was no correlation between I ,25(OH)2D vs. 25-OH-D levels, nor
iPTH vs. l,25(OH)2D. In conclusion: (1) In CAPD patients, with oral
25-OH-D administration we can reach supraphysiological levels of this
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metabolite, even considering the loss through peritoneal dialysis. (2)
The increase in serum 25-OH-D is enough to produce normal levels of
l,25(OH)2D and a fall in PTH production. (3) With regard to 25-OH-D,
there is a delay in the increase of I ,25(OH)2D that may be the time for
extra I a-hydroxylase stimulation. (4) Individual responses in I a hy-
droxylation intensity and different levels of hyperparathyroidism could
be the reasons for the lack of correlation between 25-OH-D,
1 ,25(OH)2D and iPTH.
Postexercise hematuria and proteinuria in 213 healthy volunteers. G.
Fernandez. Zatarain, E.T. Gonzalez Garcia, R. Diaz-Tejeiro Izquierdo,
J.E. Garcia DIaz, F. Ahyado Hormigos, E. Gomez Tejada, T. Sierra
Yébenes, Hospital del Insalud Virgen de Ia Salad," Toledo, Spain.
Subjects and methods: To determine the frequency of post effort
proteinuria and hematuria, a group of 213 healthy males with ages
between 18 and 38 years old (23 3.5) were studied after running
(outside track) a distance of 4 to 10km (7.5 1.4). Samples of urine in
basal conditions, immediately after exercise and after rest of 24, 48 and
72 hours were collected to determine proteinuria and hematuria by
colonmetric methods and microscopic examination of urinary sedi-
ment. Results: The frequency of postexercise proteinuria was 55.4% (N
= 118); none of the cases were above level "++ "- and proteinuria
disappeayed in direct relation to time exponential, becoming negative in
100% of the runners 72 hours after the effort. Men under 25 years old
had higher incidence of proteinuria than older ones (61% vs. 29%; P <
0.001), the latter needing a longer time to become negative (P < 0.05).
The incidence of proteinuria varied by function of covered distance: it
was 84% among men who ran a distance longer than 9 km (a); 60% if
they ran between 7 and 9 km (b), and 28% when less than 7 km (C), (a
vs. b, P < 0.05; b vs. c, P < 0.001; a vs. c, P < 0.0001). Postexercise
hematuria was found in 19.3% (N = 41) with different intensities (7
cases with macroscopic hematuria), disappearing in 95% of them 72
hours later. No relationship was found between the frequency of
hematuria and age or covered distance. Postexercise hematuria and
proteinuria were produced independently from one another, not always
repeating in the same man after attempting the same effort again.
Conclusions: Hematuria and proteinuria are frequent and transient
findings after physical stress in a healthy population. The proteinuria
seems be related to age and covered distance, however, we did not find
a correlation between hematuria and these two factors.
Hemodialysis with double lumen catheters (Fermcath) in the internal
jugular vain: Experience with 27 catheters. E.T. Gonzalez Garcia, G.
Fernández Zatarain, J.E. Garcia DIaz, R. DIaz-Tejeiro, E. GOmez
Tejada, F. Ahijado Hormigos, T. Sierra Yébenes, Hospital del Insalud
"Virgen de Ia Salud," Toledo, Spain. Methods: 27 double-lumen
silicone catheters, Permcath (C), were surgically inserted with silicone
into the internal jugular vein (21 right, 6 left), in 23 patients aged
between 38 and 72 years old; the survey time was 48.6 months (2—137).
Results: (a.) Only one postsurgical complication was reported, a
cervical hematoma that needed surgical treatment. (b.) A total of 3.517
hemodialysis sessions were performed with this access, and the flow
was higher than 200 mI/mm in the 94.4% of them; the problem was
resolved with postural changes (3%), fibrinolytic infusions (2.1%), and
with the use of other vascular accesses. (c.) There were 1.67 infections
of the exit site or subcutaneous tunnel and 1.07 sepsis episodes (Staph.
aureus: 78.7%) every 1000 catheter days. (d.) The cumulative survival
rate was: 100% in the first month, 84% in the sixth, 65.5% in the first
year and 17.3 in the second year. (e.) Fourteen catheters were removed;
in 7 of them the complication was related to the catheter (I septic shock
with origin in the catheter, I sepsis without response to treatment, 2
with sepsis probably related to catheter, 2 with subcutaneous tunnel
infections, and I with thromboses). Conclusions: The double lumen
catheters seem to be a good alternative vascular access for hemodial-
ysis. The infection rates, fulfilling sepsia and antisepsia rules in the
catheter management, is low. We did not observe mechanical, hemor-
rhagic nor hemodynamic complications.
Duplex Doppler (D.D) detection of intrarenal changes induced by
Captopril (C). R. Diaz-Tejeiro, J. Longo, F. Maduell, N. Esparza, L.
Bolanos, P. Errasti, A. Purroy, ClInica Universitaria de Navarra,
Pamplona, Spain. It is known that C could be useful to slow diverse
nephrologic disease progressions to ESRD by reducing intraglomerular
pressure. This treatment has been suggested based on animal model
studies with direct measurements of renal plasma flow (RPF) and renal
vascular resistance (RVR). Those techniques are invasive, laborious
and expensive, and have not been useful in daily practice. Recently,
D-D has made possible noninvasive studies of renal vessels. The
purpose of this work was to determine if D-D was successful in II
healthy controls in basal situation and after administration of 25 mg of
C, measuring: sistolic peak (SP) (in relation to RPF) and resistivity
index (RI) (RVR index). Mean arterial pressure (MAP), cardiac fre-
quency (CF), creatinine clearance (Car) and net and fractional sodium
excretion (NENa, FENa), were also measured. MAP, CF, Na, Cr and
C did not modify after administration of 25 mg of C. NENa and FENa
rose significantly (6.5 0.9vs. 11.2 2.1; P < 0.05and 0.54 0.08 vs.
0.94 0.14; P <0.01). D-D post-C administration detected an elevation
of SP(l.l 0.05 vs. 1.3 0.07; P < 0.01) and a decline of RI (56.2
0.7 vs. 54.2 0.7; P < 0.05), those parameters being a representation
of RPF and RVR, respectively. We conclude that D-D is useful for
detecting captopril-induced intrarenal changes, and that the increase of
natriuresis is probably the consequence of those changes.
Response to recombinant hepatitis B vaccine (Engerix) (RVBV) in
hemodialysis (HD) patients: Associated factors. R. Diaz-Tejeiro
Izquierdo, E. T. Gonzalez Garcia, G. Fernandez Zatarain, J.E. Garcia
Diaz, F. Ahijado Hormigos, E. Gomez Tejada, T. Sierra Yébenes,
Nephrology Service, H. "Virgen de Ia Salad," Toledo, Spain. The
purpose of this work is to study the response to RVBV in HD patients
on a three dose protocol (0, 1 and 6 months) of 40 g given i.m. (deltoid
muscle) and to study possible factors associated with a positive
response. Forty-two patients aged 15 to 76 years old (53.7 2.5; mean
SEM) with ESRD who were on HD between I and 156 months (57.4
7.2) were included in the study. Anthropometric, hematometric,
biochemical and hormonal parameters, aluminium and associated dis-
eases and treatments were analyzed. The seroconversion rate was
71.4% (N = 30). The age of seropositive patients was significantly lower
than seronegative ones (50.8 vs. 60.9 years; P < 0.5). Patients younger
than 35 years (a) had a 100% seroconversion rate, between 35 and 60
years old; (b) it was 68.7%; and patients older than 60 years (c) had a
56.2% immunization rate (a vs. b, P < 0.01; a vs. c, P < 0.0005). The
seroconvertion rate was not significantly different when sex, time on
HD, cause of ESRD and analytical parameters (hematometric, bio-
chemical and hormonal) were studied. We conclude that the response to
RVBV in a HD population is excellent, advanced age being the only
negative factor for seroconvertion.
A new, disposable non-disconect Y.system (ANDY) for CAPD. J.
Montenegro, R. Gonzalez, 1. Martinez, R. Saracho, Nephrology Dept.,
Galdakao Hospital, Galdakao, Vizacaya, Spain. In addition to simpli-
fying the dialysis techniques, recent advances in connector technology
have resulted in a decrease in the incidence of touch contamination in
continuous ambulatory peritoneal dialysis (CAPD). We have used a
new disposable Y CAPD system by Fresenius that features a clamp that
seals the catheter connection after the dialysate inflow has been
completed, and allows the cutting of the set, thus eliminating the
diconnection step of the dialysis exchange, on 19 patients, (12 male, 7
female) mean age 57 yrs, for a combined total of 153 months (2—14
months). The mean training time required was 3 days and the peritonitis
incidence has been 6 episodes, (1 episode per 25 patient months), as
follows: 3 episodes with S. Epidermidis; 2 episodes with P. Aeruginosa;
I negative culture. One episode followed the accidental disconnection
at the catheter adaptor site. The two gram negative infections occurred
concomitant with infections of the catheter tunnel and exit site. This
new non-disconnect Y system (ANDY) has great patient acceptance, is
easy to learn and has lowered the incidence of peritonitis in our Center.
(I episode per 16 patient months with conventional systems).
Recombinant human erythropoietin (EPO) for chronic renal failure
anemia before dialysis. C. V. Valverde, C. Garcia Aparicio, M. Torre-
grosa, L.A. Liopis, Nephrology, Hospital SVS Elda and Perpetuo
Socorro, Alicante, Spain. Progressive deterioration of renal function
goes with worsening of anemia. To evaluate the effect of EPO treatment
on this stage, we treated 10 patients: previous follow-up 11.9 months
(rank 4 to 24), with symptomatic anemia and transfusion requirements
on 8 of 10. Starting EPO dose was 120 U/kg administered once week
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subcutaneously. Iron was proscribed according to requirements. Later
EPO doses were adjusted to Hb levels. Results:a
Age Nephropathy Cr0 Ht0 Cr12 Cr48 Ht12 Ht48 BP0 BP48
54 Rejection 5,1 21 4,8 4,9 28 32 + +
56 Interst. 7,2 18 7,6 8,3 27 30 0 0
72 GN 5,8 17 6,7 6,9 26 31 0 0
33 Rejection 4,7 17 5,2 5,9 29 34 + +
59 lnterst. 7,4 16 7,1 8,4 23 31 0 +
37 GNIgA 7,8 17 8,1 8,3 21 33 + +
57 GN 8,1 19 7,9 8,4 24 35 + +
61 GN 7,9 16 8,4 9,1 22 32 + +
64 Amyloid. 6,8 16 6,1 6,9 21 29 0 0
66 Interst. 7,1 19 6,7 7,7 23 31 0 0
a Symbols are: o = zero; 12, 48 = weeks; 0 = normotension; + =
slight/moderate.
The response to EPO treatment was good with a symptomatic improve-
ment. No transfusions were needed further. Weekly subcutaneous
administration was comfortable and the response suggests adequate
EPO levels. EPO s.c. could be used as an alternative to intravenous
administration. There were no complications from this technique, only
local slight pain and there was no worsening of blood pressure control
(but, there was a new case of slight hypertension). We did not find renal
function deterioration (I/Cr decreasing slope was similar on both
periods). We conclude that weekly subcutaneous EPO administration
has been useful to treat symptomatic anemia in cases of advanced renal
failure, without further deterioration of blood pressure control or
residual renal funtion.
Surgical release or medical treatment for carpal tunnel syndrome
(CTS) by amyloidosis related to chronic hemodialysis. C. V. Va/verde,
AC. Garcia, M.J.L. Perez, L.A. Llopis, Nephro/ogy, Hospital SVS
Elda and Perpetuo Socorro, A/icante, Spain. Symptoms from median
nerve (MN) compression by amyloid deposits improve quickly on
affected patients who receive a renal transplant and steroidal treatment.
This improvment is not related to graft function and has been attributed
to steroidal action, We prospectively studied at 12 and 18 months, 3
groups of patients with CTS who had histological evidence with Congo
red deposits. Age (58.2), /32m levels (68 mgldl), time (8.5 years) and
technique of dialysis were similar for all 3 groups. Group A and group
B had a surgical release of MN going on HD with Cuprophan (Cup)
group A, and high permeability membrane (HPM) group B. Group C
received steroids 25 mg day for four weeks and then 15 mg every other
day, and 11PM dialysis. Results:
Symptomatic
Group 0 m
f32m
12 m 18 m
improvement
12 m 18 m Recurrence
GroupA 68 71 70 6 4 7
GroupB 72 51 31 9 7 5
GroupC 70
m = months.
49 33 9 9
Conclusion: Recurrence of CTS is frequent with Cup HD. Though /32m
levels decreased in patients treated with HPM, recurrence of CTS is yet
high. Late perineural fibrosis could be an explanation for this. On no
operated patients and those treated with steroids, symptomatic improv-
ment is the rule, though we only saw disappearance or improvement of
MN compression in 3 patients, and 6 of the remaining had improvement
of symptoms without NVC worsening or anatomical deterioration
(atrophy). Five of the operated patients have had funtional deterioration
with atrophy. We conclude that furter follow-up is needed to get
definative conclusions.
Citric acid metabolism in the different clinical forms of primary
hyperparathyroidism. M. V. Alvarez Arroyo, M.L. Traba, M. Diaz
Curiel, A. Rapado, Laboragorio de Ia Unidad Metabólica and Servicio
de Medicina Interna, Fundación Jiménez Diaz, Madrid, Spain. In-
creased bone resorption diseases produce a high release of citrate from
bone. It is known that citrate is an inhibitor of spontaneous nucleation
and crystal growth of calcium salts. The aim of this work was to study
the citrate metabolism in patients with primary hyperparathyroidism
(HPP) in order to evaluate its influence on the development of several
clinical forms of this disease. Eighty patients affected by HPP were
studied under standard clinical and laboratory protocol. Urine and
serum citrate levels were analyzed. Patients who had renal failure and
a secondary metabolic disease associated with nephrolithiasis were
excluded from the study. HPP was diagnosed by the presence of
hypercalcemia associated with high immunoreactive PTH serum val-
ues. In a reduced group of patients the diagnosis was assessed surgi-
cally. Bone activity was measured by alkaline phosphatase, by osteo-
calcin serum levels, by urinary hydroxyproline creatinine ratio, and by
bone mineral content determined by a dual photon absorptiometry.
Forty HPP patients developed renal lithiasis (RL) and 12 of them
presented hypocitraturia. Among the patients without RL only four
presented hypocitraturia. None of the patients affected by HPP with
hypocitraturia presented bone alterations. Moreover, patients with
bone alterations presented higher citrate serum levels than those
without bone alterations. Hypocitraturic patients had a greater increase
of citrate tubular resorption than normocitraturic ones. Conclusions:
We found that most of the patients who had HPP and RL, without bone
alterations, had hypocitraturia. Our results suggest that an increase in
osteoclastic activity prevents the development of RL in patients af-
fected by HPP. We propose an oral administration of citrates as a
prophylactic measure in HPP patients with RL.
Renal transplant and hepatitis C. J.L. Rocha, M.A. Gentil, R.
Torronieras, L. Gil, P. Pereira, G.R. Algarra, J. Aguilar, C. Rey, J.
Mateos, Servicios de Nefrologia, MicrobiologIa y Digeslivo, Hospital
U. Virgen del RocIo, Sevilla, Spain. This study analyzed the presence
of antibodies against hepatitis C virus (anti-HCV) in 191 renal trans-
plants with a graft functioning before the transplant, and its evolution
afterwards, simultaneously studying the signs of hepatitis B (HB) and
the biochemistry and the hepatic histology in the cases of those were
there was a biopsy. A total of 25% of the patients tested positively for
the anti-HCV pretransplant, compared to 27% testing anti-HCV-posi-
tive of the postransplant study. Ten percent of the total anti-HCV-
negative before the transplant tested positive afterwards, while 35% of
those who tested anti-HC V-positive pretransplant tested negative after
the transplant. No age or sex differences existed between the groups.
Those tested anti-HC V-positive had received more transfusions (29 vs.
15, P < 0.01). There was a relationship between the HB and the cases
of anti-HCV-positive tests in the pretransplant samples (P < 0.001),
that didn't offer statistical importance for the ensuing samples. A
relationship was found between the cases of anti-HCV-positive in the
postransplant and the discovery of prolonged hypertransaminasemia (P
< 0.001), without previous notice of whether or not there was an
infection for hepatitis B virus; however, the existence of anti-HCV-
positive antibodies pretranspiant didn't correspond with the subsequent
presence of changes in the hepatic biochemistry which existed after-
wards. In conclusion, the infection caused by hepatitis C virus through
transfusions can be the cause of some non-A non-B hepatitis cases in
pre- and postranspiantation, making further studies necessary to clarify
the exact significance and importance.
Acute renal failure and nonlonic radiocontrast media: The role of renal
ischemia and calcium antagonists.'. New nonionic radiocontrast
media (NIRC) do not seem to be free of nephrotoxicity although their
pathogenic mechanisms are still under discussion. We studied: (I)
variations in renal function in patients undergoing cardiac catheteriza-
tion with NIRC; (2) variations of urinary sodium concentration and
fractional excretion of sodium (FENa) and (3) influence of premedica-
tion with calcium antagonists within these parameters. Methods: We
studied 34 males; eman age 54 13 years, who were undergoing cardiac
catheterization with NIRC (Iopamidol). Blood pressure, heart rate
frequency, serum creatinine, uric acid, proteins and baseline serum
glucose were obtained before catheterization (basal) and subsequently
24 and 48 hours later. Acute renal failure (ARF) was defined as an
increase in serum creatinine of at least 0.5 mg per deciliter above the
baseline value. Twenty patients, 11 treated with calcium antagonists
and 9 without were measured for urinary sodium, creatinine, glucose,
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proteins and FENa. Results: We observed a significant increase of
serum creatinine level maximum at 24 hr after the infusion of radiocon-
trast media that persisted 48 hr afterward (baseline creatinine: 1.7
0.4; creatinine 24 hr: 1.9 + 0.4; creatinine 48 hr: 1.79 0.8; P <0.05).
Four patients, 3 with pre-existing renal insufficiency developed ARF; 2
of them were in treatment with calcium antagonists and 2 were not. We
found a significant decrease of urinary sodium and FENa.
FENa-pre FENaPO5t P
Total 0.56 0.05 0.29 0.04 <0.001
With calcium antagonists 0.51 0.05 0.31 0.04 <0.050
Without calcium antagonists 0.62 0.10 0.26 0.10 <0.050
Calcium antagonists did not prevent the decrease of FENa althought this
decrease was less in the treated patients (37% vs. 58%; P = NS). Other
physical or biochemical parameters did not change. Conclusions: (I)
NIRC induced a significant increase of serum creatinine and ARF in
13% of the cases, but only 6% if we are dealing with patients without
pre-existing renal insufficiency. (2) They caused renal ischemia with
decrease in FENa. (3) We found a decrease of FENa in patients without
treatment with calcium antagonists and in those patients pretreated,
although in the latter the decrease tended to be smaller, the difference
wasn't significant.
Incidence and risk factors of stenosis after catheterization of jugular (J)
and subclavian veins (S) veins for hemodialysis (HD). C.F. Rivera, M.
Marini, M.P. Fontán, M. Cao, J. Castro, F. Valdés Cañedo, Nephrol-
ogy and Radiology Departments, Juan Canalejo Hospital, La Coruna,
Spain. To know the incidence of stenosis as a late complication of
catheterization, the results of 44 venographies on 33 patients [17 women
(F) and 16 men (M)] with terminal chronic renal insufficiency, average
age of 54 13, was analyzed 4.24 4.6 months after last catheter was
removed. The risk factors examined were: age, sex, catheter infection,
duration and number of catheters per vein. Four stenosis levels were
established as per the percentage of light reduction: Level 1(30—60%),
Level 11(30—60%), Level III (60—90%), Level IV (+90%). Student's
t-test and X2 were used for the statistical analysis. From 44 studies (S
= 26 and J = 18) stenosis was found in 21, 12 of which were in S
(57.14%) and 9 in J (42.85%). The stenosis occurred in the place of the
puncture in 14 occasions (66%), in the brachiocephalic trunk in 6 (28%)
and in both in I occasion (4%). In one case, J stenosis caused an
obstruction within the venous return of the subclavian vein. Stenosis
level and risk factors are shown in Tables I and 2.
Table 1.
Vein
Stenosis level
I II III IV Total
5
J
Total
3
4
7
4
1
5
3 2
1 3
4 5
12
9
21
Table 2.
Risk
factors Stenosis No stenosis P
Age
No. of
catheters
Duration
Infection
Sex
56.61 9.46
1.4 0.75
25.23 15.06
8 (39.09%)
lOFvs. II M
54.34 16.96
1.21 0.42
15.13 8.09
8 (34.78%)
II Fvs. 12M
NS
NS
<0.05
NS
NS
The stenosis incidence was high (47%) and similar for J and S, with light
occlusion superior to 60% in almost half of the cases. The sole risk
factor was the length of time the catheter remained in place. Stenosis of
the J vein may determine the viability of a possible fistula in the
ipsilateral superior member.
Acute complications of the central venous catheters (Civ) for hemodi-
alysis (HD). C.F. Rivera, M.P. Fontán, M. Cao, J. Saavedra, J.F.
Daza, A. Alonso, F. Valdés Canedo, Juan Canalejo Hospital, La
Coruña, Spain. To establish the incidence and risk factors for acute
complications associated with Civ for HD, the result of 204 processes
on 94 patients with HD (SI men, average age 58, has been analyzed
prospectively for acute complications associated with Civ for HD. The
following has been compiled: technical complications, infections (de-
fined as fever with no clear focus conducting Civ removal), sepsis
bacteriemia Btc (equal to the previous + hemocultures and positive Civ
point culture), endocarditis (echocardiography), and as possible risk
factors: the age, basic disease, type of technique, number of punctures
and how much time Civ remains, immunosuppression and kidney status
(chronic renal insufficiency IRC or acute FRA). Student's t-test, and
variance analysis were used for statistical analysis. A total of 196
femoral Civ F(2/technical), 53 subclavian S, and 48 internal J jugular
were implanted. The kidney status was FRA (N = 90), IRC (N = 192),
transplant (N = 95) and plasmapheresis (N = 6). The number of
punctures was 2.8 1.8 for 2 Civ F; 1.8 1.3 for S and 2.3 2.2 for
J. The duration was 6.3 6.4 days in F vs. 14.4 10.9 in J (P < 0.001)
and II 8.8 in S (P < 0.01). The technical complications have been:
arterial puncture (7 in F vs. I in J and 5, P < 0.05), serious hematoma
(2 in F, I in J), femoral thrombosis (N = 2), malposition of S (N = 3)and
retroperitoneal hematoma (N = I). No acute mortality occurred.
Twenty-nine infections occurred, of which 18 were bacteremias. A total
of 18% of the S (7 Bct), 16% of J (5 Bct) and 10% of F (6 Bct) (NS),
suffered complication with infection. The isolated germs were cocos G
+ (St aureus 39%, St coagulasa 61%). Four endocarditis (3 St aureus +
I St epidermidis) occurred with 2 exits. No mortality occurred in the
absence of endocarditis. The only significant risk factor of infection has
been IRC vs. FRA (P 0.05). Technical complications are rare, though
potentially dangerous, and are of similar incidence in the different
techniques. The infection incidence is high and significantly major in
IRC. The Bct due to St aureus and St epidermidis implied 66% of the
infections. Endocarditis has been the most serious complication and the
cause of patient mortality.
Erythropoietin and cardiac function. P. Torguet, A. Serra, E. Lar-
rousse, M. Borràs, J. Bonal, J. Bonet, R. Lauzurica, J. Teixidô, R.
Romero. A. Caralps, Servicios de Nefrologla y Cardiologá, Hospital de
Badalona Germans Trias i Pujol", Barcelona, Spain. The administra-
tion of erythropoietin (EPO) in hemodialysis patients improve their
quality of life increases effort capacity. The ascent of basal hematocrit
can determine significant changes in cardiac functional parameters.
Seventeen patients (Ii M 6F) in a hemodialysis program, whose
average age was 55.8 years old (range 23—70), were studied while doing
an isotropic ventriculography (17 cases) a echocardiogram (12 cases)
and ergometry (7 cases) before the start of erythropoietin treatment
(Htc X 19.9%) and a few months later (3.67 mon) when they had
hematocrit similar to normal patients (Htc 30.8%). With isotopic
ventriculography we evaluated the ejection fraction (EF) teledyastolic
volume (TDV) telesystolic volume (TSV), beat volume (By), stroke
volume index (SVI), and cardiac index (CI). We saw an increase of
VTD from 116 to 159.6 ml (P < 0.05) and the VTS (NS). The EF did not
change. BV changed from 56.8 to 79.6 ml (P < 0.05). The SVI changed
from 4045 to 5788 mI/mm (P < 0.05) and CI modified from 2596 to 3271
mi/min/m2 (P < 0.05). With echography examination we did not find
significant changes of parameters evaluated. The teledyastolic and
telesystolic diameters of left ventricle, the ejection fraction and short-
ened fraction experienced a slight decrease. The thick posterior left
ventricle wall and thin wall didn't change. About ergometry, we found
a significant increase in their duration, from 3.45 to 5.01 minutes. We
had to stop the test in 6 patients for physical exhaustion and 1 for anger.
So we conclude that erythropoietin improves cardiac function in
general terms, evaluated by ventriculography, increasing the By, SVI
and CI, with parallel increase of TDS and TSV. Also the longer duration
in ergometry test can express a better functional capacity of those
patients. Echography did not show significant changes probably due to
short time between the first and second evaluations.
Effect of low dose erythropoietin (EPO) on cardiac size and function. C.
Gómez Roldán, M. Gómez Sanchez, A. Vigil, P. Gallar, f.M. AlcOzar
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de Ia Ossa, C. Saenz de Ia Calzada, Nephrology Div., H. "Severo
Ochoa", Cardiology Div., H. "Doce de Octubre", Nephrology Div.,
H. "Doce de Octubre," Madrid, Spain. High doses of EP worsen
hypertension in 40% of patients. We treated 7 normotensive (NT) and
15 hypertensive (HT) patients undergoing hemodialysis with EP 31.5
U/k, 3 times per week, during six months. Mean value of hematocrit
rose from 21.4% to 28.1%. Nine of the fifteen HT required an increase
of hypotensive treatment. No hypertension was observed in NT pa-
tients. Mode M and Doppler echocardiography studies were performed
in five NT and nine HT patients prior and after EPO treatment.
Ventricular mass index (VML) was found elevated in both groups and
was significantly reduced with treatment, more in NT group. Dyastolic
left ventricular diameter index (DLVDI) was also reduced. Left ven-
tricular dyastolic function, measured as E/A peaks quotient, showed a
significant amelioration.
MAP VMI DLVDI CO E/A peak
Baseline 101 12 202 28 3.2 6.8 0.89
After EPO 98 10 173 40 3.0 5.7 1.11
P NS <0.01 NS NS <0.05
Mean arterial pressure (MAP) did not change significantly, although
cardiac output showed a nonsignificant trend to decrease, suggesting a
parallel increase in total peripheral resistances. Conclusions: Correc-
tion of anemia with EPO decreases cardiac mass and improves ventric-
ular dyastolic function in patients on chronic hemodialysis. These
changes are more patent in normotensive than hypertensive patients.
Carpal tunnel syndrome (CTS) effect on hemodialysis and CAPD. A
comparative study on characteristics and risk factors. K. Lopez Re-
vuelta, C. Perez-Conde, J.L. Miguel, R. Se/gas, G. Caparros, A.
Ferrer, T. Gonzalez, A. Cruz, Hospital La Paz, Madrid, Spain. CTS is
a complication of /32-microglobulin (/32m) amyloidosis both on hemodi-
alysis (HD) and CAPD, but there is little information on comparative
studies. We studied 72 patients on HD and 59 on CAPD, excluding any
pathology which could give a predisposition of patients suffering from
amyloidosis. Epidemiologic characteristics were respectively: age (HD
and CAPD) NS; months on treatment 79 59 vs. 37 31; diuresis (cc)
55.8 145 vs. 444 507, Cr 0.3 I vs. 1.4 1.7, S,m (mg/liter) 65
16 vs. 37 19; intact PTH 359 557 vs. 144 148 (P < 0.05). We
performed electronmicrographic studies for CTS. We searched for the
presence of osteolytic lesions, peritonitis incidence and peritoneal
function parameters. Our results are as follows: Prevalence of CTS is
similar on both groups, 16.9% on HD and 13.5% on CAPD, with no
differences about age, sex or nephropathy. Similar values are main-
tained when we consider time on dialysis and 132m serum levels. The
time of detection, clinical severity and EMG findings were significantly
increased in HD group with 25% of the patients involved in surgical
treatment against 0 pts on CAPD. Time on dialysis and age are risk
factors in HD (P < 0.01). We did not confirm this influence nor that of
previous peritoneal injuries in the CAPD group. The incidence of
osteolytic lesions was significantly higher in HD: 44.1% vs. 9.5% on
CAPD (P <0.01, being affected in 80% of the subjects with CTS on HD
and only 14% of the CTS on CAPD. Conclusions: Carpal tunnel
syndrome occurs with a similar frequency in hemodialysis and CAPD
patients. A striking finding on CAPD patients is its early appearance in
relationship with arthropathy. Further studies about the role of age as
an etiologic factor in this disorder and the evolution of these lesions
require further studies.
Carpal tunnel syndrome effect on CAPD. Characterization of the 2m
peritoneal transference and its relationship with this clinical syndrome.
K. Lopez-Revuelta, R. Se/gas, J. Molano, C. Rihon, A. Bajo, F.
Borrego, L.S. Sicila, Hospital La Paz, Madrid, Spain. Carpal tunnel
syndrome is the most representative clinical manifestation of amyloi-
dosis /32m related among dialysis patients. Its real prevalence is not
clear, and other mechanisms could be involved in its formation. We
studied 19 patients (12 male and 7 female), average age 55.7 years, mean
time on CAPD 41.7 31 months, 6 of them affected by CTS. The study
was aimed at characterization of the peritoneal transport of 2m and its
relationship with the CTS. We evaluated the peritonitis incidence, renal
function, serum /32m, effluent concentrations of Na, K, P, Ca and
proteins, the MTC (peritoneal mass transfer coefficient) for urea,
creatinine, f32m and f32m peritoneal clearance (/32mPC). Calculation of
132m-MTC was realized through a mathematical model based on the
adjustment of equilibriation curves in four different points (0.60, 120,
180 mm of peritoneal dwell time) with a volume distribution of 2/7 body
weight and a sieving coefficient of 0.3. Results: The level of 132m had an
inverse correlation with the urinary output, creatinine clearance and a
statistically borderline significance with lost proteins on the peritoneal
effluent. Furthermore, it showed a direct correlation with effluent /32m
concentration but not with the other epidemiological parameters. f32m-
MTC and /32m-PC were not related to small molecules MTCs, epidemi-
ological characteristics, peritonitis incidence or CTS incidence. Finally,
we emphasize that the f32m mass transfer did not show any relationship
(with either the epidemiological and peritoneal characteristics) and did
not appear to be related with that of the small molecules. /32m
concentration on peritoneal effluent was highly representative of its
serum level, which indicated that small benefits can be expected from a
high peritoneal dialysate flow. Peritoneal clearance of f2m does not
protect against carpal tunnel syndrome.
Subcutaneous recombinant human erythropoietin (rIluEPO) on ane-
mia management in a CAPD program: Two different dosage approaches.
B. Miranda, M.A. Bajo, R. Selgas, A. Fdez-Zamorano, F. Borrego,
J.R. Romero, L.S. Icilia, Hospital La Paz, Madrid, Spain. We have
studied two homogeneous groups of patients treated with CAPD, every
one of them with Hgb < 8 g/dl. The first group included 12 patients who
received EPO at initial dose of 20 U/kg/day. This dose was progres-
sively diminished when the patient reached Hgb > 10.5 g/dl. The
second group was integrated with 7 patients who received EPO at dose
of 2000 U. twice weekly. All patients showed an evident improvement;
for that reason there were not subsequent increments in any of the two
groups. By the third month, group I showed an Hb increment from 7
I g/dl to 11.08 1.2 (P < 0.01), decreasing the requirement of EPO
from 9122 2340 U/week to 4463 2337 (P <0.01). Group 2 showed
the following data: Hb from 7.6 g/dl to 10.3 1.1 g/dl (P < 0.05) and all
maintained stability in dose requirement (4000 U/week). By the 6th and
9th month, the Hb levels maintained stable values 10.6 2.5 g/dl and
10.3 1.1 gIdl, respectively, with weekly requirements of 3450 2110
U and 3758 1804 U in the 1st group. The values for 2d group were: Hb
11.1 1.2 g/dl and 10.5 1.1 g/dl, and EPO 3330 707 U and 3440
766 U/week, for similar periods. After 12 and 15 months group 1 was
evaluated again: Hb 10.7 0.9 g/dl and 10.2 0.6 g/dl, and EPO
requirements of 3612 1161 U and 3132 1591 U, respectively. High
blood pressure was difficult to control in two patients from group I. We
did not observe any other clinical or biochemical disorders. We
conclude that we could achieve the same result in Hb increment by
prescribing rHuerythropoietin in lower doses at the beginning of
therapy in CAPD patients, expecting a delay of 2—3 months with respect
to higher dose schedules. Economic saving compensates for the small
clinical differences.
Long-term follow-up of peritoneal function during rHu-erythropoietin(EPO) treatment in CAPD patients. B. Miranda, M.A. Bajo, R. Selgas,
G. Caparros, F. Borrego, C. Riñon, L.S. Sicilia, Hospital La Paz,
Madrid, Spain. We studied the following peritoneal functional param-
eters in 19 patients under subcutaneous EPO treatment: urea and
creatinine MTCs (peritoneal mass transfer coefficients), peritoneal
clearances of P, K and CO2 both in 24 hours and in a 4 hr exchange with
1.5% dextrose dialysate. Ultrafiltration capacity was calculated in a
standard manner: 6 liters x 1.5% and 2 liter 4.25% dextrose with 5 hr
dwell time. The following Table shows our results:
Basal
N=l9 3 MonthsN=8
6 Months
N=19
12 Months
N=12 ANOVA
Stan UF 1694 730 1539 632 1691 814 1850 644 NS
cc
Creat. 10.9 4.3 10.9 3.2 10.3 3.3 10.7 404 NS
MTC
rn//mm
Urea MTC 24.1 8 20.5 5 20.4 2 23.8 10 NS
rn//mm
Hemoglob 7.2 0.9 10.6 1.1 10.6 1.8 10.6 0.7 0.01
g/dl
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Peritoneal clearance (4 and 24 hr) of P and CO2 did not change.
Peritoneal clearance of K (24 hr) did not suffer variations, but peritoneal
clearance of K (4 hr) showed an increment after 6 and 12 months (7.02
I vs. 8.03 1.1 at 6 months and 7.5 I at 12 months (P < 0.05).
Serum potassium did not show any change at the same periods. We
conclude that hemoglobin increment following EPO s.c. treatment does
not induce any change in the pentoneal transport capacity for water and
solutes.
Influence of demography on the incidence of peritonitis in CAPD
patients using a Y-disconecting system without disinfectant. A multicenter
study during 4 years. R. Se/gas, R. Madero, C. Miguelez, V. P-Diaz, A.
R-Carmona, M. Casares, A. Vigil, F. Sousa, Hospital La Paz, Madrid,
Hospitales Rio Ortega y Clinico, Va//ado/id, Hospital General, Seg-
ovia, Hospital Cruz Roja, Madrid, Hospital Severo Ochoa, Leganes,
Hospital dePalencia, Spain. Quality control in CAPD is related to the
incidence of peritonitis. Desconecting systems have been enthusiasti-
cally introduced in the majority of CAPD programs with variable
results, always improving those of the former systems. To covalidate
any method for CAPD exchanges it seems necessary to evaluate it in
different Centers. Eighty-eight new CAPD patients from 7 Spanish
Centers were included in this study. Mean age 53 16 years. CAPD
mean time: 14 8 months. CAPD method: Y desconecting system
without disinfectant (Baxter). Statistical analysis: we analyzed data
around the first episode by survival techniques (Kaplan-Meier and
Breslow tests). The survival curve to the first episode was: at 6 months:
79% patients free of peritonitis; 12 months: 64% free; 18 and 24 months:
46%. Conclusions: (1) Overall peritonitis incidence, 53% before the 2nd
year on CAPD. (2) Women showed lower incidence than men. (3)
Unfavorable living conditions induce a negative effect in peritonitis
incidence. (4) Urban or country environment do not induce influences.
(5) Mechanical troubles were only referred by patients beginning CAPD
therapy and not after completing the training period. (6) No other type
of complications related to the system were registered. We consider
that DCN systems for CAPD improve the incidence of peritonitis and
the quality of life of patients because of the bagless method.
Effects on mitogenic activity of peritoneal effluent by in vitro addition
calcitriol, erythropoietin (EPO) and interferon alfa-2b (IFN). R. Se/gas,
A. Lopez-Rivas, B. Miranda, F. Borrego, C. Rinon, M.A. Bajo, 5.
Mo/ma, Muñoz, F. Vara, Hospital La Paz y CSIC, Madrid, Spain. The
presence of cellular growth factors under identification process in
nocturnal peritoneal effluent of CAPD patients has been demonstrated.
Several drugs which could maintain any relationship with this activity
are being researched. Calcitriol is able to modify the inmune response
through effects on macrophages and EPO has some characteristics of
cellular growth factors. Finally, IFN has antiproliferative activity and
could decrease growth of peritoneal fibroblasts when administered
topically. To test the effects of these three drugs on cellular growth
induced by peritoneal effluent, we used mice (Swiss 3T3 line) and
human fibroblasts in culture. Cellular growth was quantified by tritri-
ated thymidine incorporation after adding 50 .d of peritoneal effluent
from 13 CAPD patients under baseline conditions and after adding in
vitro several doses of the three drugs: EPO 4000, 500 and 1000 iJliter;
1,25 calcitriol 0.5, I and 20 pg/liter; IFN from 1200 to 1500000 iJml.
Every activity is referred to that of fetal serum which represents the
maximum activity. At the in vitro doses administered neither EPO nor
calcitriol showed any influence on the peritoneal effluent-induced
capacity for stimulating fibroblast growth. Consequently, their intra-
peritoneal use does not seem contraindicated by these reasons. On the
other hand, in vitro added alfa-2b-interferon showed an antiproliferative
effect quite evident in the experiments performed in human fibroblasts;
its clinical use in fibroblastic peritoneal hyperactivity could be investi-
gated.
Hands and uremic erosive arthropathy (UEA) in hemodialysis and
CAPD patients. Hyperparathyroidism or amyloidosis? A. Cruz, T.
Gonzalez, A. Balsa, R. Se/gas, K. Lopez-Revue/ta, MA. Bajo, C.
Riñon, •. Muñoz, J.L. Miguel, Hospital La Paz, Madrid, Spain. We
evaluated 74 patients (36 m and 38 f), 53 on hemodialysis (HD)
treatment and 24 on CAPD, for the presence of erosive arthropathy
lesions (EAL) with evidence of non-affected joint space on metacarpo-
falageal (MCP) and proximal interfalangeal (PIP) joints. Median age was
54 12 years; mean time on HD was 80 55 months; intact PTH was
291 440 pg/mI, serum /32-microglobulin was 65 17 mg/liter. We
found 9 patients with UEA (4 m and Sf), 7 on HD and 2 on CAPD, mean
age 58 7.6 years, mean time on dialysis 81.4 40.8 months, i-PTH
344 386 pg/mI, /32-microglobulin 56 5 mg/liter. Other interesting
findings were: carpal tunnel syndrome in 5 patients, tenosynovitis on
flexion tendons, accelerated destruction of MCP and PIP joints in I
patient, large osteolytic lesions in 5 patients, knee joint effusions in 2
patients, with positive amyloid stain test in I patients and destructive
spondiloarthropathy in one other. The secondary biochemical hyper-
parathyroidism degree was similar for those with UEA and the control
group. Although there was a significant relationship (P < 0.05) between
UAE and carpal osteolytic lesions, there was a striking association with
other lesions that suggest amyloid etiology. We conclude that uremic
erosive arthropathy on hands could be included among osteoarticular
pathology provoked by amyloid deposition in dialysis patients.
Cyprofloxacine role in the therapy of CAPD catheter-related skin
infections. MA. Bajo, M.T. Naya, R. Se/gas, B. Miranda, G. Caparros,
J.R. Romero, F. Texeira, C. Riñon, Hospital La Paz, Madrid, Spain.
CAPD catheter-related skin infections can lead to peritonitis, and most
of the time to the loss of the device. Until today, different antibiotic
schemes have shown poor efectiveness. Cyprofloxacine is a quimio-
therapic drug that fulfills the necesary conditions (wide spectrum, easy
oral dosage administration . . .) to be involved in a clinical study in a
group of patients with this type of infection. Now, after 1½ years, we
have evaluated the outcome of this group of patients, so we can firmly
establish a definitive role of cyprofloxacine in the management of
exit-site skin infections (1—1.5 g p.o.qd). The initial results reported
were: 18 episodes, 7 of them were failure of the previous therapeutic
regimens. Their etiology were as follows: St. aureus = 8, P. mirabillis
= 2, M. morgagni = I, Ps. aeruginosa = I, another gram negative strain
= 6. We have realized 1—2 rounds of per oral treatment, three weeks of
duration each; eleven patients experienced good tolerance to the
medication. With these preliminary results there was: (a) total useful-
ness = 12 cases (67%); (b) partial usefulness = 3 cases (17%); (c)
therapeutic failure = 3 cases, all of them caused by gram positive
bacteria. On a second analysis of the outcome: 12 patients were
followed for 18—24 months and were classified as previously stated: 10
patients with evidence of total cure (83%) and 2 other patients with
partial response. From these 10 very last patients, three of them have
not experienced related problems. Only one was involved in a St.
aureus recidivant episode, that was succesfully treated with a new
round of cyprofloxacine therapy. Two other patients (St. aureus af-
fected) have presented recidivant infections that have led to catheter
removal. Finally, 4 patients have been reinfected by other bacteria.
From this group, 3 cases had a good result after being treated again with
cyprofloxacine. We conclude that cyprofloxacine has had a usefulness
of 53% in a long lasting outcome of this group of patients, especially for
gram negative strains, and on the other side of the spectrum, a poor
response for S. Epidermidis infections and a moderate success for S.
Aureus infections.
A multicenter randomized study on treatment of CAPD peritonitis:
Cyprotloxacine vs. vancomycine + tobramycine. M. A. Bajo, M. T.
Naya, M. Casares, F. Coronel, R. Se/gas, J.R. Romero, F. Teixeira, C.
Rinon, Grupo de Estudios Multihospitalarios CAPD-Centro, Spain.
Forty-five episodes of peritonitis in CAPD patients have been treated
by a randomized therapeutic regime consisting of: cyprofloxacine (C)
(200 mg.ip.followed by 500—750 mg/12 hr p.o., 10 days) vs. vancomy-
cine (V) (1—2g. i.p., 1st and 5th days) + tobramycine (T) (100 mg.i.p.,
followed by 6 mg/liter, JO day). Nineteen episodes were treated with
with C and 23 with V ÷ T; the rest were catheter dependent episodes
and were excluded from the study. The results were as follows:
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No normalization
fluid citol symptoms
S. epidermidis
V+T 9 64±36 64±36 35±24
C 8 39±17 45±23 30±21
S. aureus
V+T 4 156 216 156 216 156 216
C 3 64±13 64±13 48±24
Gram neg.
V+T 1 48 48 48
C 5 62±21 67±20 43±10
S.B-hemolitico
V+T 1 48 48 48
S. viridans
V+T I 48 48 48
C 1 48 48 48
Mixed infections
V+T 1 72 72 72
C 1 48 48 48
Negative culture
V+T 5 43±20 48±13 9±13
C 2 48 48 36±16
UF Recov Evolution
Hours Initial Relapse
S. epidermidis
V+T 56 20 Good No
C 45±8 Good I
S. aureus
V+T 156 216 1 Bad I
C 64±13 Good 2
Gram neg.
V+T 48 Good No
C 72±24 Good I
S.B-hemolitico
V+T 48 Good No
S. viridans
V+T 48 Good
C 48 Good
Mixed infections
V+T 72 Bad
C 48 Good No
Negative culture
V+T 38 13 Good No
C 48 Good 1
Cyprofloxacine showed efficacy in 13 cases (68.5%) with an incidence of
relapses of 31.5%; 21% of patients referred some degree of gastric
intolerance. Vancomycin + tobramycin showed efficacy in 20 cases(87%); 2 cases caused by St. Viridans failed to cure. We conclude that
vancomycine + tobramycin as a blind initial therapeutic regimen for
CAPD peritonitis is a better regime than oral cyprofloxacine because of
the high frequency of relapses related to the last agent.
Isolation of a kidney growth factor from plasma of uninephrectomized
rats. A. GarcIa-Ocaña, P. Esbrit, R. GarcIa -Cañero, A. Rivero, and J.
Egido, Laboratorio de Ia Unidad Metabólica and Servicio de Nefrolo-
gIa, Fundación Jiménez DIaz; and BioquImica Experimental, Cilnica
Puerta de Hierro, Madrid, Spain. A kidney growth factor (KGF) has
been purified to apparent homogeneity from plasma of Sprague-Dawley
rats (200—300 g body wt), obtained at 24 hr after uninephrectomy
(UNX). Starting material was a crude KGF preparation, partially
purified as described previously (Nephrol Dial Transplant 4:334—338,
1989). Purification involved hydrophobic interaction (alkyl-Superose)
and reversed-phase (Bondapak C18) HPLC. KGF elutd from the last
chromatographic step as a UV-absorbing peak that appeared to be
homogeneous by thin layer and reversed-phase chromatographies. The
factor, which eluted close to the salt volume (1.5 kDa) on Sephadex
G-50, was sensitive to proteinase K treatment. KGF stimulated DNA
synthesis in quiescent LLC-PK1 cells, a cell line displaying proximal
tubule features. This activity was dose-dependent, so that maximal
activity was observed at 0.5 ng/ml protein. The factor also increased the
rate of (3H) thymidine incorporation into DNA of renal tubules from rat
kidney removed at 24 hr after UNX. This stimulation was brought about
within a range of KGF concentration which is 10-fold lower than that
found in LLC-PK1 cells. Moreover, KGF within a similar dose range as
in renal tubules, also increased DNA synthesis in rat mesangial cells in
primary culture. Our results suggest that in the rat, this renotropic
factor might play an important role in the renal compensatory growth
following UNX.
Multi-center prospective study of swan neck peritoneal catheters with
intraperitoneal segment straight or coiled. Multicentre Group of Study of
Continuous Ambulatory Peritoneal Dialysis. We have studied by means
of a prospective questionnaire the evolution of 137 double-cuffed Swan
neck peritoneal catheters with skin exit pointing downward, with
intraperitoneal segment straight (92, 67%) or coiled (45, 33%), in 128
patients of 9 hospitals, from June 1988 to February 1990. Details on
catheter type, insertion technique (surgical 78, 57%, bedside by means
trocar 59, 43%) and early (first 30 days) or late complications were
recorded. Patients were 70 men and 58 women aged between 15 and 79
years (54.3 15.2). Twenty-four percent were obese and 41% diabetics.
Mean permanency of catheters was 7.1 5.6months (range, I day to 21
months). Cumulative permanency was 968 months/patient. All patients
received general antibiotic prophylaxis, and local prophylaxis (cuff
impregnation) was added in 20% of catheters. Early and late complica-
tions with respect to number of catheters are shown in the Table:
Early
compl.
Late
compl.
Poor inflow or drainage 32 (24%) 8 (7%)
Hemoperitoneum 12 (9%) 8 (8%)
Dialysis solution leak IS (11%) 5 (5%)
Cuff extrusion 5 (4%) 2 (3%)
Exit site infection 19 (14%) 26 (25%)
Tunnel infection 4 (3%) —
Peritonitis 19 (14%) 32 (29%)
Any complication 77 (57%) 55 (50%)
No complications 59 (43%) 55 (50%)
The study was too short to allow definitive conclusions but from our
results, it seems clear that: the insertion technique does not affect
evolution; the external cuff must be fixed at 2 cm of skin exit site;
antibiotic impregnation of cuffs do not protect against infection or
dialisis fluid leak; a wide exit side hole is a risk factor of local infection;
coiled intraperitoneal segment diminishes the consequences of migra-
tion or omental capture of cateter tip that produces slow or poor dialysis
fluid flow, and; the skin exit pointing downward does not seem to
reduce the incidence of exit site infections as previously suggested. We
need to follow the future evolution of these catheters to confirm these
preliminary conclusions.
Cyclosporin A (CsA) chronic nephrotoxicity in heart transplant (HT).
S.G. de Vinuesa, E. Gallego, J. Luflo, F. Fdez, Avilés, P. DomInguez,
F. Ahijado, F. ValderrObano, R. Arcas, Hospital General "Gregorio
Maranon", Madrid, Spain. CsA-induced renal toxicity was analyzed in
15 heart transplant recipients (13 male and 2 females, ages ranging from
20—64 years); the mean follow-up period was 13 months (5—22 months).
Renal and cardiac functions were prospectively analyzed: Crs, Cr,
glomerular filtration rate (GFR), renal blood flow (RBF), measured
using isotopic methods; renin, aldosterone, and microalbuminuria were
determined every 3 months. Three months after transplant, cardiac
function was normal, and no histologic rejection signs were found. Crs
was normal in all patients (Crs = I 0,3 mg/dl). CsA doses ranged from
5.2 1.4 mg/kg/day three months after transplant to 3.8 1 mg/kg/day
after one year, keeping serum levels (RIA) at 149 94 and 70 40
ng/ml, respectively. During follow-up, neither variations in Crs (1 0.3
at 3 months vs. I 0.2 mg/dl at 18 months) nor in Cr were observed.
However, a significant decrease in GFR and RBF showed during the
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first year (113 10 vs. 74 27 mI/mm and 485 55 vs. 313 178
mi/mm, respectively). The filtration fraction (FF) remained unchanged,
0.23. No patients developed proteinuria, and microalbuminuria was 12
10 mg/liter 18 months after HT. C03H, C1 and K serum levels
were normal. The uric acid serum level increased (7.3 2 mgldl) after
12 months, although only one patient manifested gout. Hypertension
appeared in four cases (27%), even though renin and aldosterone
decreased progressively (6.6 to 2.3 ng/ml and 239 to 164 pg/mI,
respectively, after 3 and 18 months). We conclude that CsA nephrotox-
icity is not a limiting factor in the evolution of HI using doses between
3 to 5 mg/kg/day. However, GFR measured using isotopic methods
decreases significantly (30% after 12 months), and C. overestimates it.
No hyperfiltration mechanism seems involved in CsA induced nephro-
toxicity, since FF remains constant and no significant proteinuria
shows. Patients receiving CsA often show hypertension and it seems
independent of renin levels.
Hemostasis and platelet aggregation in patients on continuous ambula.
tory peritoneal dialysis (CAPD) and hemodialysis (lID). E. Ga//ego, E.
Junco, J. Luño, A.R. Huerta, M.S. ChacOn, F. Ahijado, F. Va!derrá-
bano, Hospital Genera! Gregorio MarahOn, Madrid, Spain. Patients
with chronic renal failure (CRF) present impairment in hemostasis
manifested by prolonged bleeding time. We studied 21 patients with
CRF 12 on HD and 9 on CAPD treatment to evaluate the possible
influence of the dialysis method in hemostasis. Ivy test and platelet
adhesion induced by ADP, collagen, epinephrine arachidonic acid and
ristocetion at different concentrations were assayed before HD and
before the first daily exchange in CAPD. Coagulation tests: PT!',
prothrombin activity; WBC, platelets Htc, Hgb, iron and ferritin were
determined simultaneously. Bleeding time was prolonged in patients on
HD (21 8 mm). This value was significantly higher than the one from
patients on CAPD (8.6 9.5 mm; < 0.05). Only one patient on CAPD
presented a prolonged bleeding time, over 30 mm. Platelet adhesion was
normal in patients on CAPD except for one patient who presented
impaired response to arachidonic acid. On the other hand, all but one
patient on HD had impairment in platelet adhesion, especially in ADP
and arachidonic acid tests. Coagulation tests were normal in all pa-
tients, Htc, Hgb and platelet counts were significantly lower in patients
onHDthanintheonesonCAPD: 24.2=4.l;7.9± 1.1; 162,000± 7,000
vs. 31.5 7.4; 10.8 2.2; 289,000 44,000, respectively. We conclude
that patients on CAPD presented better hemostasis and platelet adhe-
sion than patients on HD. This fact could be secondary to the difference
in Htc values found in the two groups.
Fenoldopan and progression of chronic renal insufficiency. R. Jofré,
f.M. Lopez GOmez, E. Ga!/ego, A. Ga/an, F. Va!derrábano, S2Nefro-
logIa, Hospital Genera! Gregorio Marañon", Madrid, Spain. With
the aim to slow the rate of renal function deterioration, treatments like
protein and phosphate restriction, rigorus hypertension management
and drugs to decrease the intraglomerular pressure are frequently used.
Fenoldopan is a selective DA1 receptor agonist that increases renal
blood flow and decreases renal vascular resistence, without a-adrener'
gic activity, DA2 agonist or central action. Thirteen chronic renal failure
(CRF) patients were included in a double-blind study with 300 mg daily
of oral Fenoldopan (6 patients, group A) controlled against 7 patients
with placebo (group B). Ten of them were male and 3 were female aged
between 30 and 70 years (49.8 14.2 years). The etiology of CRF was
glomerulonephritis in 5 cases, polycystic disease in 3, interstitial
nephropathy in 3, diabetic nephropathy in I and nephroangiosclerosis in
one. We used the slope of the regression line of 1/serum creatinine with
time to assess the progression of renal insufficiency. Mean duration
time was 10.8 3.7 months. All patients were controlled monthly.
Serum creatinine before treatment was 3.5 1.2 mg/dl in group A and
2.8 1.0 mg/dl in group B. After treatment, it was 4.7 2.0 and 3.2
6, respectively. The slope of progression of renal failure did not change
significantly in either group. Proteinuria did not modify. There were no
side effects, but a patient of group A had bleeding gastritis. We
conclude that oral Fenoldopan at doses used did not modify the
evolution of renal disease.
Clinical tolerance and efficiency of acetate free bioffitration (AFB).
Preliminary results of the Spanish Cooperative Study. Presented by E.
Junco. To evaluate the clinical results of AFB, 33 patients (l5M l8F)
have been studied prospectively of 60 14 kg body wt, who were
previously on conventional biofiltration or hemodialysis (pre AFB). The
patients underwent AFB in a prospective protocol: 3 hours 3 times a
week, Qb 350 mI/mm, capillary AN69 1.3 sqm and infusion post-dilution
of 2 liters/hour of NaHCO3 167 mmol/liter. The study was controlled
during 7 3 months, and recorded were body weight, blood pressure
and clinical tolerance. Before and during AFB the following were
measured at 1, 3, 6, 9 and 12 months: small molecule levels, lipid and
nutritional parameters, acid-base status and KTV and PCR were
calculated. The small molecule levels did not change during AFB with
respect to the previous data. The plasma HCO3 increased during one
session of AFB from 21.4 to 27.0 mmol/liter, which was significantly
higher than the values obtained previously in the same patients during
pre-AFB (from 20.2 to 22.8 mmol/liter). The KTV and PCR in AFB
were 1.10 and 1.17, whereas during pre-AFB they were 1.07 and 1.10,
respectively. There were no changes in blood pressure during AFB, and
the incidence of hypotensive episodes fell from 32% in pre-AFB to 9%
during AFB. Therefore we can conclude that the AFB is a biofiltration
procedure that is well tolerated, efficient and that provides a good
acidosis correction and without complications during this period of
study.
Hemostasis and platelet aggregation (PA) with erythropoietin (EPO)
therapy in hemodialysis (HD) patients. E. Junco, A.R. Huerta, MS. R.
Chacon, A. Aroca, D. Serrano, J. Luno, M. Renge!, E. Ga/lego, J.
Aya/a. F. Va/derrObano, Hospita! General Gregorio MarañOn, Madrid.
Spain. To investigate if correction of anemia may affect the hemostasia
and PA, we have studied the effect of EPO therapy in 12 HD patients
receiving 50 U/kg body wt i.v. post-HD. Before and during EPO we
measured hematocrit (Htc), Hb, platelet count (PC), prothrombin time,
PTT, fibrinogen, PA induced by ADP, collagen (Co), ristocetin (Ri),
arachidonic acid (Aa), and adrenaline (Ad). The i.v. time, anti-thrombin
111 (All!), protein C LDH and haptoglobmn were recorded. After 12
weeks on EPO, the Hb and Htc increased (7.9 1.! vs. 10.5 1.624
4 vs. 31 4) (P < 0.05). There was a nonsignificant increase in PC.
Coagulation test did not change. The i.v. time decreased (21 8 vs. 7
3 mm, P < 0.05) in all patients. ADP aggregation values were
decreased in 70% of patients, and normalized in 90% of them during
EPO. The PA by Co, RI and Ad were almost normal pre- and post-EPO.
PA by Aa was decreased in 90% of patients pre- and post-EPO. Protein
C levels decreased, and A!!! values were unchanged. During the study
one patient developed thrombosis of A-V fistula. In conclusion, the
correction of anemia with EPO therapy in HD patients is accompanied
by a significant decrease on i.v. time, and improvement of platelet
aggregation.
Urea kinetics in short dialysis with AN69 membrane. Modulating
factors of PCR. Cooperative Spanish study. E. Junco, Spain. One
hundred and sixty patients on 3 hours of dialysis with an AN69
membrane were retrospectively evaluated by the following parameters:
small molecule levels, acid-base status, clinical tolerance and urea
kinetic parameters KTV and PCR. The patients on AN69 were on
several dialysis schedules: acetate HD (HDAc), bicarbonate HD
(HDBi), biofiltration (Bio) acetate (BioAc) or bicarbonate (Bio Bi), or
acetate free biofiltration (AFB). The results were compared between
the differents groups on AN69 with the data obtained in patients in
Cuprophane (CU) hemodialysis (CUDBi). The predialysis BUN, creat-
mine, Na, K, uric acid and phosphate were similar in all patients on
AN69 treatment, and similar to the values observed during CU HD. The
HCO3 predialysis was significantly lower when the Ac was used as a
buffer in HD.
Membrane
KTV PCR
surface
m2
HCO3
mmo///iter
AN69
HDAc 1.18 1.03 1.57 19.2*
HDBi 1.13 1.17 1.55 21.2
BioAc 1.02 1.12 1.50 22.0
BioBi 1.11 1.22 1.54 22.6
AFB 1.12 1.12 1.30* 22.0
CUHDBi 1.15 1.00 1.65 20.6
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The PCR level was lower during HD with cuprophane membrane than
during HD with AN69 membrane. The utilization of bicarbonate as a
buffer provided higher PCR values than during acetate buffering. The
PCR in biofiltration techniques was also higher than in hemodialysis
techniques. Therefore, PCR may be dependent on the kind of mem-
brane, dialysis technique and of the absence of acetate in the bath of
dialysis. The biocompatibility of the AN69 membrane, its high hydrau-
lic permeability and the better clinical tolerance in HD bicarbonate or
biofiltration may be conditioning factors that provide better clinical
nutrition in dialysis patients.
Secondary hyperparathyroidism (SB) in patients with chronic renal
failure. Surgical options. J. M. Llovera, f.M. Campistol, J. Almirall, M.
Prados, L. Ferndndez-Cruz, Department of Surgery, Renal Transplant
Unit, Department of Nefrology, Hospital Clinic, University of Barce-
lona, Barcelona, Spain. Dialysis has increased the survival rate of
patients with chronic renal failure (CRF) who have several metabolic
disorders. One of the most important is the alteration in calcium
metabolism that causes compensatory hyperplasia of parathyroid
glands, with the consequent elevation of P'FHi levels. This leads to bone
and neurological disorders that will need surgical treatment in 5—15% of
cases, Patients and methods: 22 patients affected with SH (calcemia
levels > 12.5 mg% and PTHi values > 65 pg/mI) were operated on
between 1982—1989. Total parathyroidectomy with auto-transplant (PTx
+ A) was performed in II cases and subtotal parathyroidectomy (SPT)
in 11, Nineteen patients were in hemodialysis for 8—120 months.
Surgery was indicated in IS patients with persistent hypercalcemia, in
13 affected with bone disease and in 7 with neurologic disorders.
Results: hypercalcemia persisted in I patient, but reached normal levels
when kidney transplantation was performed. Another case presented
hematoma of surgical wound and was reoperated. In the early postop-
eratory period 7 patients required sustitutive treatment because of
hungry bone sd." up to 3 months. Twelve months follow-up was
possible in 19 patients. Three patients died of CRF complications. The
other patients are normocalcemic, with improving clinical and radio-
logic alterations. No recurrence of the disease was observed. Conclu-
sion. Both PTx + A and SPT are successful surgical options in the
management of biochemical and clinical aspects of SH. Occasionally,
oral calcium supplements are needed for short periods of time.
Efficacy of intraoperative P'FHI determination in the surgery of hyper-
parathyroidism. J.M. LLovera, L. Fernández-Cruz, Department of
Surgery, Hospital Clinic, University of Barcelona, Barcelona, Spain. In
hyperparathyroidism surgery there is still a controversy: the distinction
between adenoma and hyperpiasia glands. Recently, intraoperative
PTHi (1—84) determination has been used to quickly and securely
evaluate the efficacy of surgery. Matherial and methods: between April
1989 and May 1990, 25 patients were operated: 8 primary hyperpara-
thyroidism (PHP), 9 secondary hyperparathyroidism (SHP), 6 post-
kidney transplantation and 2 parathyroid carcinoma. The technique of
primary hyperparathyroidism was only done as a resection of an
adenoma in 12 patients, a subtotal parathyroidectomy in 8 patients, and
in 5 a total parathyroidectomy with autotransplant. Before surgical
exploration, peripheral and right and left internal jugular vein blood
were obtained for calcium and PTHi determinations. The same proce-
dure was done 15 minutes after resection of the affected glands. Results:
1.) In the group of PHP with a single gland affected, the PTHi values in
the ipsolateral territory were higher than the contralateral one; in the
cases of hyperplasia, the value was similar on both sides. Surgery
allowed a decrease in PTHi values less than 50% of basal values. 2.) In
the group of SHP, the PTHi values were similar in both sides of jugular
zone and were less than 50% of basal values after both total or subtotal
resection. 3.) In the post-kidney transplantation group the secretion of
the affected glands showed a decrease less than 40% of basal values. 4.)
The curative resection of parathyroid neoplasms implied a decrease of
PTHi values from 2900 pg/mi to 23 pg/mI in one patient, in the other, no
modification was seen. Conclusion: PTHi determinations allow the
surgeon to know immediately the successfull resection of the affected
parathyroid glands. A lack of this modification in postresection values,
or a decrease not more than 40—50% in basal values, might rule out a
persistent hyperparathyroidism because of insufficient gland resection.
Evaluation of the immune reaction in renal transplant rejection using
monoclonal antibodies: Analysis of 21 cases. R. Garcia Del Moral, A.
Montes, R. Lopez Gigosos, N. Navarro, M.D. Del Pino, P. Lardelli, J.
Bravo, J.M. Osorio, C. Asensio, Departament of Pathology, University
Hospital, Service of Nephrology, Virgen de las Nieves, Hospital
S.A.S., Granada, Spain. The diagnosis of renal allograft rejection is
currently based on the characterization of infiltrating leukocytes on
biopsy material or fine needle aspiration cytology. In the present study,
25 biopsies obtained from 21 cases of acute rejection were analyzed.
Out of a total of 76 renal transplantations performed from 1988 to 1990,
34 cases of acute rejection were registered, from which 25 biopsies were
available. In 4 patients who suffered a second episode of rejection or in
whom the initial one was resistant to treatment, two consecutive
biopsies were obtained. Besides the routine processsing for optical and
electronic microscopy and immunofluorescence detection of immune
deposits, frozen sections of each sample were immunostained for the
following markers: CD45 (pan leucocyte antigen); CD2, CD3 (pan
T-cells); CD4 (helper T-cells); CD8 (cytotoxic/suppressor T-cells);
CDIO (CALLA); CD1 lb (granulocytes/monocytes/macrophages);
CD 14 (monocytes/macrophages); CDI 5 (granulocytes, proximal tu-
bule); CD22 (pan B-cells); CD25 (IL-2 receptor); CD35 (C'3b receptor);
HLA-Dr; class I HLA; EMA (distal tubule); vimentin (podocytes/
regenerating cells); Leu 7 (NK cells) and Ki-67 (proliferating cells).
Evaluation of the cellular composition included the enumeration of the
different types of cells with the help of an ocular grid. Data were finally
subjected to a statistic analysis. Histologically, 19 cases were classified
as cellular interstitial rejection, 3 resulted of the mixed vasculo-
interstitial type, I was predominantly vascular and 2 corresponded to
interstitial cellular rejections associated to transplant glomerulopathy. 2
additional cases aiso presented initial toxicity to CsA. Immunohisto-
chemically, CD8+ cells constituted the predominant subset in 14 cases,
while CD4+ cells predominated in II, in all of them co-existing with an
abundant component of infiltrating macrophages. Furthermore, a pop-
ulation of B-lymphocytes comprising more than 10% of the cellularity
was observed in 8 cases. Regarding the therapy, 21 patients were
treated with corticosteroids, S of these resulted corticorresistant being
further rescued with Mo Ab OKT-3, and the remaining 4 received
exclusively this latter agent. Statistical analysis of the data showed that
the predominant populations in corticorresistant cases consisted of
CD8+ lymphocytes and macrophages: 94.8 26.3 cells/5 glomeruli vs.
34.3 8.2 in corticosensitive patients, the infiltrate being more evident
in glomeruli than in the interstitium. According to the results presented
here, we have developed a clinicopathological protocol for the manage-
ment of renal allograft rejection patients which proposes the use of Mo
ab OKT-3 as an initial therapy, instead of as a rescue agent, in those
cases exhibiting a prominent CD8+ cells infiltrate.
1gM mesangial proliferative glomerulonephritis. Immunohistochemical
analysis of 11 cases. V. Cortes, R. Garcia Del Moral, M.L. Aguayo, R.
LOpez-Gigosos. A. Navas, P. Lardelli, A. Osuna, D. Barajas, C.
Asensio, S. Cerezo, Departaments of Pathology and Nephrology,
University Hospital, Department of Nephrology, Virgen de las Nieves,
Hospital S.A.S., Granada, Spain. 1gM type mesangial proliferative
glomerulonephritis (1gM MPGN) exhibits a diffuse proliferation of
mesangial cells as well as the presence of 1gM in mesangium, with or
without accompaning granular deposits of this immunoglobulin subtype
along the capillary walls. Clinically, patients present with either a
classical nephrotic syndrome or persistent proteinuria. Recent analysis
of leucocyte subpopulations on biopsy material have emphasized the
pathogenic relevance of glomerular leucocytes in idiopatic nephrotic
syndrome, opposite to what occurs in IgA nephropathy, which shows a
prominent interstitial infiltrate. The aim of the present study was the
immunophenotypic characterization of the reactive inflammatory pop-
ulation in 11 cases of 1gM MPGN, and the investigation of a putative
correlation between the nature of the infiltrating component, the
histologic appearance and the clinical course of the patients. Renal
biopsies from each case were analyzed by light and electronic micros-
copy, immunofluorescence and immunoperoxidase techniques with a
panel of Moabs specific against the following markers: CD45 (pan
leucocyte antigen); CD3 (pan T-cells); CD4 (helper T-cells); CD8
(cytotoxic/suppressor T-cells); UCHL-l (pan T-cells), monocyte/mac-
rophage antigens and CDI5 (granulocytes). Positive cells were quanti-
fied by enumeration under a grid placed on the eyepiece of the
microscope. Statistical analysis of the data demonstrated a significant
correlation between patient's age and initial values of creatinine (r =
0.71, P < 0.05). In addition, a significant correlation was observed
between initial proteinuria and glomerular infiltration by macrophages
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(r = 0.71,P < 0.05), as well as between the mesangial cellularity and the
number of intraglomerular T-cells (r = 0.85, CI. = 0.47—0.96, P <
0.05). We conclude that in 1gM MPGN the prognosis becomes poorer
with age and as the glomerular infiltrate increases. On the other hand,
the presence of proteinuria is probably due to a lesion produced by
T-cells and macrophages, and not to the effect of a circulating lympho-
kine, as proposed for minimal change glomerulonephritis. Furthermore,
glomerular colonization by T-cells could be the result of the secretion of
IL-I by proliferating mesangial cells and glomerular macrophages.
Tubulointerstitial lesions induced by cyclosporin A. N. Navarro, R.
Lopez Gigosos, R. Garcia Del Moral, P. Lardelli, A. Montes, A.
Navas, M. GOmez, M. Cámara, M. Garcia Cones, S. Cerezo, Depar-
laments of Pathology and Nephrology, University Hospital, Depart-
ment ofNephrology, Virgen de las Nieves, Hospital S.A.S., Granada,
Spain. Since the introduction of cyclosporin A (CsA) as a major
immunosuppressor agent in post-renal transplantation therapy, typical
features of renal allograft rejection have been replaced by new morpho-
logical and clinical manifestations. In this sense, tubulointerstitial
lesions have been recognized, frequently overlapping with those pro-
duced by the intrinsic toxic effect of cyclosporin A. Pathogenetic
mechanisms of the nephrotoxicity produced by CsA include a main-
tained decrease of renal blood supply as well as a direct effect on
stromal fibrogenetic cells. Furthermore, several abnormalities in the
synthesis and expression of intermediate filaments by tubular cells have
been described in a variety of forms of pharmacologically-induced
nephrotoxicity. In consequence, vimentin expression could become an
useful marker of the regenerative potential of the damaged tubular
epithelium. A comparative analysis of the tubulointerstitial lesions in
two series of 20 renal allograft recipients each, treated with azathioprine
and CsA, respectively, is presented. Jointly with the routine examina-
tion of standard histologic parameters, an evaluation of changes in the
phenotypic expression of renal tubules was carried out. Tissue speci-
mens were processed for immunoperoxidase staining with monoclonal
antibodies directed against: vimentin (usually absent in normal condi-
tions), EMA (apical border of distal tubule cells), and CDI5 (leu-Ml)
(brush border of proximal tubule cells). Among all morphologic features
previously related to CsA nephrotoxicity (band-like fibrosis, peritubular
capillary congestion, artenolopathy, calcifications, global tubular atro-
phy and presence of tubular megamitochondria), only this latter one
showed a statistically significant association with the effect of CsA,
being detected in 7 CsA treated individuals versus I patient from the
series in which azathioprine was administered. In addition, when
considering the group of patients treated with CsA who also exhibited
intratubular megamitochondria, a strong correlation was found between
tubular atrophy and presence of immunohistochemical markers (r =
0.87, P < 0.05), particularly due to vimentin expression. However, no
correlation was observed when the entire population of patients treated
with CsA was taken into account. As a result of this study, we propose
that, in late post-transplantation stages, overexpression of EMA, CD 15
and vimentin by proximal tubular epithelium may reflect, in the absence
of an active acute rejection, an early injury caused directly by CsA and,
in consequence, susceptible of periodical surveillance and/or modifica-
tions in the therapy protocol (replacement of CsA by azathioprine)
when possible, according to patient's clinical condition.
Leucocyte subsets as markers of tubular lesions in post-transplantation
renal biopsy. R. Garcia Del Moral, A. Monies, N. Navarro, R.
López-Gigosos, F. O'Valle, P. Lardelli, D. Aguilar, J. Aneiros, C.
Asensio, Depantaments of Pathology, University Hospital, and
Nephrology, Virgen de las Nieves, Hospital S.A.S., Granada, Spain.At present, accurate diagnosis acute rejection of renal transplant relies
mainly on the in situ identification of the infiltrating reactive subpop-
ulations either on needle aspiration biopsy or cytology. The important
role of reactive lymphocytes and macrophages in the pathogenesis of
acute rejection, is well-recognized except in those cases of hyperacute
vascular rejection due to prior hypersensitivity. Also, the type of
infiltrating population is a determining factor of the putative degree of
the rejection process and, probably, of the patient's initial response to
the therapy. We present a diagnosis and treatment protocol of choice
for the management of renal allograft rejection patients, based on our
experience obtained from histological examination and subsequent
follow-up of 23 allograft recipients with history of one or more acute
rejection episodes. An immunohistological study was performed on
frozen tissue sections with the use of monoclonal antibodies specific for
the following markers: CD45 (pan-leucocyte antigen); CD2 and CD3
(pan T-cells); CD4 (helper T-cells); CD8 (cytotoxic/suppressor 1-cells);
CDIO (CALLA); CDI lb (granulocyte/monocyte/macrophage); CDI4
(monocyte/macrophage); CD 15 (granulocyte/proximal tubule); CD22
(pan-B cells); CD25 (IL-2 receptor); CD35 (C'3b receptor); HLA-Dr;
HLA class I; EMA (distal tubule); vimentin (podocytes/regenerating
cells); LeuMi (NK cells), and Ki-67 (proliferating cells). Vimentin and
Ki-67 expression by proximal tubule cells is associated with histological
images of cellular regeneration and, therefore, therapy abstention is
advisable in an early post-transplantation stage. However, the presence
of macrophage infiltration, even to a mild degree (>5 macrophage/
glomerulus), is indicative of an initial acute rejection. These particular
cases, jointly with those showing a prominent infiltration by CD4+
cells, deserve corticosteroid therapy, while cases with a predominance
of CD8+ cells are submitted to a rescue treatment with Mo ab OKT-3,
provided that this form of acute rejection is persistently steroid resis-
tant. Finally, no correlation was found between the expression of
HLA-Dr antigen by distal tubule epithelium and the density of the
cellular infiltrate.
Is the incidence of dialysis-associated pericarditis decreasing? E. Her-
nandez, C. Campo, C. Montoyo, M. Praga, f.M. Alcazar, f.M.
Morales, J.L. Rodicio, Hospital 12 Octubre, Madrid, Spain. It has been
reported that acute pericarditis (AP) can complicate the course of
20—30% of dialysis patients. We have decreased the appearance of AP
in 210 chronic hemodialysis (HD) patients treated in our hospital
between January 1975 and December 1989. This interval of time was
divided in 3 periods: A (1975—1979), B (1980—1984) and C (1985—1989).
The incidence of AP was expressed as AP episode per patients-year on
HD. We also classified the AP episodes as early AP (EAP), those
appearing in the first six months after the initiation of HD, and late AP
(LAP), those remaining. The total number of AP episodes in the studied
period (1974—1989) was 33. In period A there was I AP/27.8 patients-
year, 60% of them being EAP. In period B there was I AP/l8
patients-year, 66% being LAP. Finally, in period C, 1 AP/ 54 patients-
year was detected, with 50% of EAP and 50% of LAP. The incidence of
AP in period C was significantly lower than in periods A and B (P <
0.05). The most frequent clinical presentations in period A were
precordial chest pain (77%) and fever (38%), whereas in period C
dyspnea (66%), fever (50%) and dialysis-associated hypotension (50%)
were the most frequent initial symptoms. Four episodes of AP (3 LAP,
1 EAP) were associated with minoxidil treatment, all of them in period
B. Acute tamponade appeared inS cases of LAP, 3 of them in period C.
In summary, the incidence of AP has significantly decreased in the last
years in our HD unit. A tendency for LAP presentations with subacute
evolution to increase was also observed in the last period.
Proteinuria and focal glomeruloscierosis (FGS) in adult polycystic
kidney disease (APKD) with renal insufficiency (RI). C. Montoyo, C.
Campo, A. Mazueco, M. Praga, T. Ontuño, A. Andres, J.L. Rodicio,
Hospital 12 Octubre, Madrid, Spain. It has been demonstrated that
cysts develop in less than 1% of nephrons in APKD. The mechanisms
leading to progressive RI in the remaining nephrons remains unknown;
it has been suggested that glomerular hyperfiltration can play a role and
that angiotensin-converting enzyme inhibitors (ACEI) could halt the
progression of RI. We studied 66 patients (34 females, 32 males, mean
age 53.5 11.3 years) with APKD and RI. The creatinine clearance
(Ccr) oscillated between 2.7 and 40 mI/mm (X 11.4 8.9 mI/mm). In ten
of these patients, previous uninephrectomy had been performed; we
investigated the presence of FGS in the removed kidneys. Only one
case showed nephrotic range proteinuria (13 g/day); this patient had a
Cr of 22 mI/mm and frequent FGS lesions were observed in the
removed kidney. With captopnl treatment, his proteinuria decreased to
less than 3 glday. In the remaining cases, 27% had proteinuria between
1—2 g/day, 59% proteinuria <I g/day and 17% had no proteinuria.
Patients with arterial hypertension had a mean proteinuria significantly
higher than those with normal blood pressure. No correlation was found
between proteinuria range and renal function. The histologic study
showed FGS lesions in 7 out of 10 kidneys studied, but the percentage
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of involved glomeruli was scarce. In conclusion, most of the patients
with APKD and RI have moderate ranges of proteinuria and isolated
FGS lesions. Nephrotic-range proteinuria is exceptional and it can
partially decrease with ACEI treatment.
The measurement of the peritoneal function by means of the test of
peritoneal equilibrium (TEP). Clinical correlation. C. Montilla, A.
Guerrero, J. Molina, R. Montes, C. Rios, J.L. Rocha, J. Mateos,
Hospital Universitario Virgen del Rocio, Sevilla, S.BioquimIca and
S.Nefrologia, Spain. The pentoneal equilibrium test (PET) seems to be
an easy and reproducable method to measure the peritoneal clearance
of different solutes. Periodically carried out at an early stage of disease,
we could establish the prescription of peritoneal dialisis (PD) and
individualize the treatment for each patient. This study was carried out
with the objective of creating reference curves for our hospital and their
immediate clinical correlation. Twenty-five patients were given the PET
according to the technical descriptions of Twardowski. With the
quotients D/D0 and D/P at I, 2, 3 and 4 hours and the volume of
drainage, a linear correlation was made to determine the most repre-
sentative solutes. Glucose and creatine correlated the most. With the
objective of proving whether there was a correspondence between
these values with clinical parameters, the patients were divided into
three groups according to whether their D/P relation to Cr measurement
at the 2nd and 4th hour was superior, inferior, or was within the average
+ I SD. Analysis of the variance were made with: hematocrit, nerve
motor velocity, urea, creatinine, rehabilitation level and PD time. No
statistical importance was obtained for any of these parameters. After
the correlation of these clinical parameters with determinations at all
the hours specified was determined, it was found that hematocrit values
were significant for all the determinations carried out in the third hour.
Effect of angiotensin conversion enzyme inhibitors (ACE!) on protein-
uria and renal function in various nephropathies with chronic renal
failure (CRF). J. Bonet, M. Borrâs, R. Romero, J. TeixidO, J. Bonal, R.
Lauzurica, A. Serra, A Caralps, Service of Nephrology, Hospital
Universitario de Badalona, "Germans Trias i Pujol", Barcelona,
Spain. It has been proposed that ACE! can modify intrarrenal hemo-
dynamics with changes in proteinuria and renal function. Taking the
hypothesis as baseline we did the following study. Material and
methods. A retrospective study of 23 patients, 18 male and 5 female,
during a period of 12—36 months, who were diagnosed with CRF (7 IgA,
6 hyalinosis, 5 end-stage glomerulonephritis, 3 mesangial proliferative
and 2 membranous glomerulonephritis) was performed. They were
receiving ACE! between 50—200 mg/day (x = 105 39). The sodium
intake was between 40—60 mmol, and during the period of study the
T.A. was under 160/95 mm Hg. Student's t-test was used to assess
proteinuria and plasma creatinine (Per) before and after receiving
treatment with ACE!; the linear correlation was calculated with per-
centage variations of proteinuria and pc, Results. We observed that in
5 of 17 patients receiving other hypotensors at the beginning of the
study had hypertensive lesions (EKG and funduscopy) and that 5
patients presented proteinuria of nephrotic range. Proteinuria de-
creased in 20 patients, remained stable in 2 and increased in I.
Prot B 2.01 1.73 g/day P Cr B 343 184.2 mmol/liter
Student's t P < 0.02 P < 0.01
Prot E 1.56 1.59 g/day 1Cr 456 283.9 smol/liter
The percentage variations of proteinuria were not significantly corre-
lated with Cr Conclusions. The patients with ACE! treatment reduced
their proteinuria significantly, but this reduction was accompanied by a
significant deterioration of renal function. The variations of proteinuria
were not correlated with Cr'
Tc-" Dimercaptosuccinic acid (DMSA) in acute pyelonephritis: a
study of 55 children over the age of 3. L. Espinosa, M.J. Martinez
Debora, J.A. Coya, f.M. Avilla, M. Navarro, A. Peña, Pediatric
Nephrology Section and Nuclear Medicine Service, Hospital La Paz,
Madrid, Spain. We studied 55 children over 3 years old (12 males and
43 females) with clinical evidence of a first episode of acute pyelone-
phritis (APN), in whom DMSA imaging was performed during the acute
phase. Their ages ranged between 3 an 13 yr (mean: 7.4 yr). All but one
received parenteral fluid therapy and i.v. antibiotic therapy (cephalo-
thin, gentamicin ora combination of both) for 2—15 days (mean: 4 days),
followed by oral treatment for a mean of 8.3 days (0—28 days). Within
the first month after the onset of symptoms (mean: 9.5 days; range: 3—29
days), posteroanterior and oblique projections were made 3 hr after
injection of 1.5—3 mCi of Tc-DMSA. We found deficient uptake in 67%
of the children, with bilateral involvement in 9%. Fifty underwent
echography during acute phase, which revealed alterations in 54%. Of
the 45 subjects in whom IVU was done, 44% showed some kind of
alteration. Voiding cystography (VC), performed in 52 patients one
month after APN, revealed unilateral VU reflux in 13 (25%), bilateral in
5 (10%), and bladder and/or ureteral alteration in 3 (6%), while the
remaining 31 were normal. There was no statistically significant corre-
lation between the existence of reflux and anomalous DMSA uptake (
0.346); of the 21 children with reflux, 16 (76%) had deficient DMSA
uptake, but 20 subjects with altered DMSA uptake had normal VC.
However, when the assessment was based on the number of kidneys,
the correlation was significant ( 9.4; P < 0.01). We found no
significant differences in the incidence of DMSA uptake alterations with
respect to age (> and < 5 yr) ( 0.088) or sex ( 0.08). Reflux was
more frequent in males (58%) than in females (35%) ( 1.23; NS). In 20
patients, DMSA imaging was repeated one year after APN, showing
scars in 40%. When compared to the previous findings, we found that 6
patients (30%) had normalized, 3 (15%) had improved, 1(5%) was
worse and 10(50%) remained the same. Conclusions: 1) DMSA imaging
is the most sensitive test for selecting patients at risk of developing
scars; 2) 40% of patients present scars after a single episode of APN,
even beyond the age of S yr; and 3) aside from reflux, there are
additional factors which predispose the patient to renal scar formation.
Efficacy of erythropoietin at low doses in the treatment of anemia in
hemodialysis. C. Solozábal, F. Maduell, F. Fonseca, J. Unzué, J. Asin,
S. NefologIa, Hospital Virgen del Camino, Pamplona, Spain. Recom-
binant human erythropoietin (rHuEPO) has been shown to be effective
in correcting renal anemia of uremic patients. The initial intravenous
dose used to increase the hematocrit (Hto) to a target level 30% higher
varied from 40 U/kg body weight to above. This treatment, although
well tolerated, also has complications, the more severe of which are
blood pressure control and hypertensive encephalopathy. To minimize
medical complications, we have used rHuEPO at low-doses (10—16
U/kg body weight). Fourteen hemodialysis patients were studied, 6
males and 8 females, with an average age of 58.4 16.5 years, who had
moderate to severe anemia, and whose transfusional requirements were
6.3 2.1 concentrates/patient/year. They were treated with rHuEPO
intravenously, three times a week, at the end of every hemodialisis
sesion, for 5 months at a constant dose of 13.6 1.7 U/kg body weight.
All patients responded to the treatment. It was enough to slowly
increase hematocrit and hemoglobin (Hb) (Table). No blood transfusion
was required. After 5 months, 8 patients had good responses (Hto >
30%), and 6 had partial responses (Hto 25—30%). No hypertension was
observed, nor was increased antihypertensive medication necessary in
any case.
Basal
After
1 month
After
5 months
Hb, g/dl 7.53 0.67 8.75 1.08a 9.76 0.9"
Hto, % 23.61 2.31 26,16 2.91a 30.27 2.8"
(Data are mean SD, N = 14) P < 0.01, b p < 0.001, vs. Basal.
In summary, low-dose rHuEPO could be an effective and safe alterna-
tive treatment for renal anemia in hemodialysis patients.
Renal transplant: Comparative renal histopathology and clinico-patho-
logic correlations between cyclosporin A and azathioprine treatment. P.
Iglesias DIaz, E. Vazquez Martul, A. Alvarez Garcia, A. Alonso
Hernández, S. Pita Fernández, Hospital Juan Canalejo, La Coruna,
Spain. We examined 146 kidney transplant biopsies, from 61 patients
(93 biopsies) with conventional immunosuppression (C!S) and 33 pa-
tients (53 biopsies) with cyclosporine A+ corticosteroid therapy (CsA).
All biopsies were evaluated in a semiquantitative method by three
pathologists who were unaware of the clinical data and immunosup-
pression therapy. The parameters for the evaluation of biopsies in-
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eluded glomerular, tubular, interstitial, and vascular pathology. In the
final evaluation, the following clinical data were included: days of
biopsy after transplantation, total time of ischemia, serum creatinine,
hypertension (>140/90), CsA levels in whole blood, early function of
allograft and clinical signs of rejection in the moment of biopsy. The
biopsies were allocated into groups on the basis of treatment with CsA
and CIS. Comparisons of the frequency of each morphological feature
were made between these groups by statistical methods. None of the
morphologic parameters was specific for CsA treatment. Isometric
tubular vacuolization was more frequent in CsA treated patients, and
there were significant differences between CsA levels and vacuoliza-
tion. No statistical differences were found between vascular, tubular or
interstitial parameters and blood CsA levels, serum creatinine or
arterial hypertension in the two groups. In CIS treated patients vascular
intimal fibrosis and interstitial diffuse fibrosis were correlated with long
intervals between the time of transplant and the date of biopsy (>120
days).
Study of cellular and humoral immunity in dialysis patients suffering
from j32-microglobulin amyloidosis. J. Fort, J. Aliaga, J. Rossello, J.
Camps, A. Olmos, L. Piera, Nephrology, Pneumology and Preventive
Medicine Departments, Hospital General Vail D'hehrón, Barcelona,
Spain. Although the pathogenesis of dialysis amyloidosis is still un-
known, seeming to be multifactorial, several authors have suggested its
relationship to a greater deterioration of immune status of patients who
have been on dialysis for a long time. The different incidence of this
pathology in patients of similar age and similar length of time on dialysis
and its infrequent occurrence in young dialysis patients encouraged us
to carry out this study. We studied 36 patients who had been on dialysis
for an average of 10 years; they were divided into three groups: Group
1, patients with dialysis-related amyloidosis and pathologic evidence of
amyloid deposition who had an average age of 61.5 years. Groups 2 and
3 were patients without amyloid arthropathy who had an average age of
62.2 and 44.3 years, respectively. For controls we studied two groups of
healthy patients from the Plastic Surgery Department who had an
average age of 60 yr. and 39.3 yr. We tested serum levels of immuno-
globulins, lymphocyte subpopulations with monoclonal antibodies and
we carried out skin tests with five different antigens. Results: When we
compared lymphocyte subpopulations in groups I, 2, 3, first separately,
then together with the control group, patients from group 1 had a T4/T8
ratio of 1.1 which was significantly lower, P: 0.04, than that of patients
from group 2, F: 1.71, and group 4, P: 1.62. No differences were found
either in T4/T8 ratio or in absolute number of T3, T4, 18 cells between
patients from groups 3 and 5. We did not find any differences in the
immunoglobulin levels. Higher levels of 1gM were found in patients
from group 5 than from group 3. Skin tests: We found a greater
cutaneous reaction in control groups related to PPD, Varidase and
Staphylococcus Toxoid. A greater cutaneous reaction to PPD was
detected in asymptomatic patients (groups 2—3) (P = 0.01) in compari-
son with amyloid arthropathy patients (group I). In summary, in our
patients for the same length of time on dialysis, those who developed
amyloid arthropathy had a greater worsening of the cellular immunity in
comparison with patients of similar age or younger, who remained
amyloid-symptom free.
Treatment of uremic growth failure with biosynthetic growth hormone.
Study in S children. M. Heras, J.A. Castillo, A. Ferrandez, C. Loris,
Unidad de Nefrologia Pediatrica y Endocrinologia Pediatrica, Hospital
Infantil "Miguel Serve!", Zaragoza 50009, Spain. The objective was to
investigate the effect of recombinant human growth hormone treatment
on five children with uremic growth failure. The patients received 30
pJm2/week for 1 year. Material and methods: 3 males and 2 females.
Age between 2 years 10 months and 14 years 8 months. Parameters
studied were: somatomedin, hydroxyproline, glucemia, cholesterol,
HbA1C, Hb, 14, GOT, GPT, uric acid, GFR, TRP, FENa, FEK,
FE0 acid, Ua/Ur, as well as weight, height, height velocity (HV),
triceps skinfold (TS), sum of the cortical thickness (CT) and sum of the
smallest diameter of the 2, 3, and 4 metacarpal bones (SD) in SDS, and
bone age as per Tanner and Greulich-Pyle, initially at 6 and 12 months
of treatment. Results: A patient showed impairment of the renal
function at 6 months of treatment. The remainder did not present any
variations of their parameters except for:
Initially 6 months 12 months
Somatomedin 0.49 0.26 1.44 0.89* 1.87 1.25*
Alkaline P. 456 177 502 241 599 159*
FErc*cd 15.4 7 16.7 8.6 11.0 4.42*
Weight SDS. —1.47 0.82 —1.03 0.7* —0.81 0.81*
Height SDS. —2.14 1.05 —1.84 1.32 —1.2 0.76*
H.V. SDS. —1.62 0.96 +3.86 3.8* + 1.38 1.56*
CT. SDS. —0.17 1.39 —0.04 1.33 +1.22 1.06*
S.D. SDS. —1.65 1.34 —1.67 1.19 —0.89 1.5*
IS. SDS. —0.18 0.06 —0.46 1.96 —1.43 0.53*
Conclusions: Growth hormone improves height velocity and height
without advancing bone age more than chronologic age and with no
modifications in renal function. The growth hormone resistence ob-
served in uremic patients is more severe at end-stage renal failure;
therefore it is necessary begin to treat before a large growing potential
has been lost.
Survival of patients with diabetic nephropathy before and after their
inclusion in programs of renal replacement. A. Oliveras, J. Aubia, A.
Orfila, I. Liorach, J. Lloveras, J. Masramon, Hospital G.M.D. l'Es-
peranca, Barcelona, Spain. It is a well known fact that diabetics with
nephropathy (DN) have a high mortality once they are included in the
programs of renal replacement treatment (DN-RRT). The survival of
diabetics with nephropathy is much lower than in those without
nephropathy, as it is derived from the epidemiologic studies of the
l960s. There are very few recent studies about the survival of patients
with pre-terminal diabetic nephropathy (DN). Since the main causes of
death in both groups of diabetics, i.e. before and after the development
of end-stage renal disease, are cardiovascular ones, the index of
survival before and after being in dialysis program would be expected
not to be very different. Moreover, it would be expected that a
continuous control of the blood pressure would have a positive influ-
ence on survival as well. We present a survey of actuarial survival of 50
DN with an overall following of 141 patient-years compared with the
survival of another group of DN-RRT, who were under control in the
last six years. The curves have been analyzed by test of Green and the
comparison between groups by test of Hanzel-Mantel. The actuarial
survivals at 24, 36 and 78 months were, for the DN, 96.3, 86.5 and 72%,
and for the DN-RRT 72.7, 51 and 20.8%, respectively (w = 4.08, P <
0.02). A subgroup of IS patients with a good control of blood pressure
during the preterminal stage was segregated from the group ND-RRT,
and it was compared to the remaining 53 ND-RRT without control,
being the survivals in such subgroup 78.6, 68.8 and 68% ( = 9.05, P
< 0.05). In conclusion, it seems that the intensive treatment of blood
pressure during the preterminal stage of the DN improves the survival
of diabetics in dialysis programs.
Vascular access for hemodialysis. M. Mir, R. Martinez-Cercos, J.
Aubia, 1. Llorach, F. Vidai-Barraquer, F. Castro, J. Lioveras, J.
Masramon, Hospital G.M.D. L'Esperanca, Barcelona, Spain. We
describe surgical techniques, results and complications obtained on
2300 vascular access (AV) (164 grafts PTFE). We analyzed these results
comparing different techniques, materials localizations, clinical situa-
tion and risk factors of patients and their influence on AV survival. We
did not detect any difference between techniques on duration of the
distal arm AV (45—50% survival two years). But longer survival might
be observed in proximal AV (70% 2 years) with respect to the distal
ones even when PTFE were considered (60% in arm and 71% in leg).
After 10 years the survival in those groups has been 31%—45%, 18% and
45%. respectively, with significant differences. The most frequent
complication has been edema in patients with previous subclavial
catheter, thrombosis in patients with vascular stenosis, in diabetics with
PTFE, and in those treated with erythropoietin. Finally, we stress the
necessity to proceed in a gradual and successive use of patient's own
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vessels in AV construction, sparing the graft to use it only when all the
possible direct anasthomosi have been attempted.
Rapid diagnosis of cytomegalovirus infection with DNA hybridization
in renal transplants. E. GOmez, S. Aguado, S. Melon, R. Cimadevilla,
E, Gago, M. de Ona, A. Martinez, J. Alvarez-Grande, Hospital
Covadonga, Oviedo, Spain. The appearance of new antiviral drugs
emphasizes the convenience of researching new diagnostic methods,
which allows us a more accurate and sensitive diagnosis. With this aim
a prospective study was done to compare the diagnostic utility of
conventional viral cultures with a hybridization assay performed on
shell vial centrifugation cultures. A total of 266 urine specimens were
tested simultaneously with both methods. The specimens were donated
by 45 consecutive renal transplant patients who were studied weekly
during the first 3 months after renal transplantation, and monthly
afterwards. Briefly, the specimen was inoculated on shell vial, centri-
fuged during 45 minutes at 150 g and then incubated for 48—72 hours in
MRC-5 monolayer cells. Lastly, a DNA hybridization assay was done
with an immunoperoxidase labeled probe (Color Gene, Enzo Diagnostic
Inc.). A total of 61 (23%) specimens were positive by conventional
culture, hybridization assay, or both simultaneously. Of these positive
samples, 53 (87%) were detected by hybridization assay, and 41(67%)
by conventional culture. Results of hybridization assay was available in
48—72 hours, whereas that of conventional culture were delayed for
several days or weeks. In conclusion, for diagnosing cytomegalovirus,
shell-vial centrifugation culture followed by hybridization assay, be-
sides its rapidity, seems to have better diagnostic sensitivity than
conventional cultures.
Clinical variability of cytomegalovirus infection with different levels of
immunosupression. S. Aguado, E, GOmez, M. Gorostidi, S. MelOn, R.
Cimadevilla, E. Gago, M. de Oña, A. Martinez, J. Alvarez-Grande,
Hospital Covadonga, Oviedo, Spain. Due to the appearance of new
diagnostic methods, clinical course of cytomegalovirus infection was
prospectively followed in our renal transplant unit with the aim of
following their clinical evolution. From 24/2/87 to 15/11/89, 59 consec-
utive renal transplant patients with graft surviving more than 6 months
were followed. During this period 34 patients were conventionally
treated whereas 25, with the aim of reducing the incidence of cyclos-
porine toxicity, received lower doses of this drug, this being the only
difference in clinical treatment. All the patients were studied weekly
during the first 3 months post-transplant and monthly afterwards.
Cytomegalovirus antigenemia, hybridization assays in centrifugation
cultures, and conventional viral cultures were done in peripheral blood
and urine, as specified, and determinations of anticytomegalovirus
antibodies, IgG and 1gM, were done in serum. Patients in the conven-
tional group had a higher incidence of infections (85% vs. 28%, P <
0.001) and symptoms (9 vs. 1, P < 0.001). They also had a higher
incidence of viremia and antigenemia (25/34 vs. 1/25, P < 0.001). In
contrast the predominant pattern in the group with less treatment was
one of viruria and seroconversion. Conclusions: Viremia and or anti-
genemia usually precedes development of clinical symptoms. Presence
of viremia or antigenemia might express severe infection or appearance
of clinical disease.
Anti-hepatitis C virus (HCV) positive donors for renal transplants. E.
GOmez, S. Aguado, R. Cimadevilla, S. MelOn, E. Gago, A. Martinez,
M. de Oña, J. Alvarez-Grande, Nephroloogy and Microbiology Serv-
ices, Hospital Covadonga, Oviedo, Spain. Recent availability of a
serological test for detection of antibodies against HCV allows us to
investigate the posibility of transmission of this virus from donor to
receptor through the graft. With this aim we tested (Ortho Diagnostic)
the serological status of the last 47 consecutive kidney donors with an
ELISA system. A total of 45 (96%) were seronegative for anti-HCV
antibodies and 2 (4%) were seropositive. These seropositives kidneys
were implanted in four different recipients, and all of them survived for
at least 8 months. All the patients postoperatively received blood
products which were tested for anti-HCV antibodies, which were
negative in all cases. Clinical and serological evolution of these four
patients were as follows: one previously seronegative patient serocon-
verted 7 months after transplant and developed chronic hepatitis which
has continued for 24 months after renal transplantation. Two more
seronegative pretransplant patients remained seronegative 7 and 27
months after transplant, and had normal hepatic function tests. The
fourth patient was already seropositive pretransplantation, and so it
remains, but the hepatic function tests have been always normal.
Conclusions: 1.) In one patient HCV might have been transmitted
through the graft. 2.) The absence of seroconversion in the other two
patients provokes further questions about the quantitation of risk of
transmission and the convenience of new confirmatory tests.
Hypoprotein diet decrease proteinuria and glomerular production of
tumoral necrosis factor (TNF) and of platelet activating factor (PAF) in
experimental nephrotic syndrome. J,L. Lerma, M. GOmez-Chiarri, E.
Gonzalez, A. Ortiz, L. Hernando, J. Egido, Fundación Jiménez DIaz,
Madrid, Spain. Glomerular damage mechanisms in minimal change
nephropathy must be clarified. It was recently demonstrated that
platelet activating factor (PAF) and tumoral necrosis factor (TNF) were
able to induce proteinuria. In adriamycin nephropathy, an experimental
nephrotic syndrome model similar to minimal change nephropathy, we
studied the effect of two isocaloric diets with different protein contents
on clinical evolution, histology and glomerular mediators. Rats from
group I were nourished with a standard diet containing 20% protein and
rats from group H with hypoprotein diet (9% of proteins) during 15 days
before adriamycin injection and during the study. Group III rats, not
injected and nourished with standard diet, were considered to be
controls. Animals from group II had presented, in relation to that of
control rats (group III), decrease of proteinuria (32 + 6 vs. 135 + 26
mg124 hours the day 14 after injection), decrease of cholesterol (62 0.5
vs. 317 0.8 mg/dl) and increase of serum total proteins (6.3 0.8 vs.
4.8 0.2 mg/dl). Glomerular cells from animals of group I incorporated
H-acetate into H -PAF and generated TNF activity in a significantly
greater amount than those from control rats (group III). The major
production of these mediators preceded or coincided with maximal
proteinuria and with important lesions of glomerular epithelial cells.
Animals from group II (hypoprotein diet) did not present an increase in
the production of glomerular PAF and TNF in relation to the control
group. These results suggest that hypoprotein diet prevents the devel-
opment of nephrotic syndrome induced by adriamycin in rats, probably
as consequence of diminution in glomerular mediator synthesis, as PAF
and TNF.
Role of platelet activating factor (PAF) in the nephrotoxicity induced by
cisplatinum. M. Guerra, A. Rivero, J.L. Lerma, E. Gonza/ez, A. Barat,
J.F. Escanero, L. Hernando, J. Egido, FundaciOn Jiménez D(az,
Madrid, Facultad de Medicina, Zaragoza, Spain. Cisplatinum is a
widely used drug in the chemotherapy of several tumors. The major
limitation of therapeutic use in adequate doses is nephrotoxicity. At this
study we verify the hypothesis that PAF could be responsable of
functional vascular alterations and of renal damage induced by cisplat-
mum. Rats from group I received a single intraperitoneal injection of
cisplatinum (6 mg/kg). Rats from group II received a similar dose of
cisplatinum and 10 mg/kg/day of BN52021, a specific PAF receptor
antagonist, during the time of study. Rats from group III received
cisplatinum and 10 mg/kg/day of verapamil intraperitoneally. Group IV
was considered as the control. At the 4th day of cisplatinum injection,
7/12 rats from group I developed acute renal failure (serum creatinine
4.2 1.8 mg/dl). All animals from group II (N = 6) had serum
Creatinine in normal values (Cr 0.62 0.12). In group III, 4/5 rats
developed renal insufficiency, but the creatinine levels were lower than
those from group I (Cr 2.7 0.9). Renal histology of ill rats from group
I showed tubular vacuolization, epithelial desquamation and absence of
cellular infiltrates. The kidneys from group II were normal or showed a
moderate tubular vacuolization, Histological lesions in rats from group
III were generally less intense than these from the group I. Glomerular
cells of rats from group I incorporated H -acetate in a lipid with
physicochemical characteristics of PAF. In addition, PAF was deter-
mined on glomerular supernatants at the bioassay of marked rabbit
platelets. PAF synthesis by glomerular cells of rats from group II was
normal or discretly increased. In vitro studies showed that glomerular
cells of normal rats incubated with different cisplatinum concentrations
produced PAF in time and dose-dependent way. In conclusion, the data
suggest that PAF could be an important mediator in renal damage
induced by cisplatinum. The use of PAF antagonists is useful in
prevention of cisplatinum nephrotoxicity.
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Intravenous calcitriol pulse therapy in hemodialysis patients with
severe osteitis fibrosa. MA. Frutos, J. Fernandez-Gal/ego, B. Ramos,
E. Perez-Miranda, and E. Lopez de Novales, Servicio de Nefrologla y
Laboratorio de Hormonas, Hospital Regional de Málaga, Spain. To
evaluate the effects of intravenous calcitriol in seven hemodialysis
patients (7 females, mean age: 43 years, HD treatment: 88.7 months),
diagnosed with severe osteitis fibrosa by iliac cresta biopsy, none had
aluminum deposits in mineralization front and their iPTH levels were
more than 10 times higher that upper normal values. Treatment with i.v.
calcitriol started with I g day, administered at the end of each dialysis
session. The calcitriol dosage was adjusted depending of serum calcium
and phosphorus levels in order to avoid high calcium-phosphorus
products. The calcitriol dose was increased monthly to a maximun of 3
g, and continued during 2 to 6 months (X = 4.8). The most noticeable
results were as follows:
iPTH
pg/mi
Alkaline
phosphatasa
mU/mi
Serum Ca
mg/di
Serum P
mg/di
Basal End B E B E B E
1089 611 969 648 9.7 9.2 6.1 6.6
a P < 0.05, paired t-test between B and E
All patients experienced a clinical benefit with improvement in muscu-
lar weakness and with less bone pain. Four hypercalcemic episodes
were detected, needing intermitent stopping of calcitriol. All patients
showed a increase in serum phosphorus levels, needing more phosphate
binders, and frequently it was neccesary to discontinue calcitriol
administration by high peaks of serum phosphate. Therefore, calcitriol
pulse therapy has proved to be useful in dialysis patients with severe
osteitis fibrosa, proportioning a significatine decrease in iPTH and AP.
This analytical improvements reflects a minor reabsortive and forming
bone activity. We recomend a test of calcitriol response in any patient
with severe secondary hyperparathyroidism before doing a subtotal
parathyroidectomy.
Peritoneal behavior in patients treated with erythropoietin. N. Vega,
A. Fernandez, L. Hortal, C. Plaza, J.C. Rodriguez, M. Perdomo, L.
Palop, H.N.S. Pino, Las Palmas, Canary Islands, Spain. In evaluating
the possible modifications that treatment with erythropoietin infers in
peritoneal behavior, we have studied: dialysate to plasma ratio; mass
transfer area coeficient (CTM) for urea (U), creatinine (Cr), glucose (G)
and protein (P); ultrafiltration volume (UV); protein catabolism ratio
(PCR) and protein losses (EP) into dialysate, in thirteen patients in
CAPD treated with erythropoietin before starting the treatment and
three months later when the Hb level reached 10 g/dl or higher. We
found no significant difference in these parameters in all the patients.
CTMU CTMCr CTMG CTMP
pre
post
19.1 3.7 7.2 2.5
20.8 7.8 7.9 4.7
8.0
8.2
1.3
2.5
2.4 0.9
2.2 0.8
UV PCR EP
pre
post
676.9 216.6
596.2 207.6
64.9 11.7
65.0 16.3
7.9 3.7
7.8 2.8
However, there were significant differences (P < 0.05) in pentoneal
difusion in the second study between the patients with Hb higher or
lesser than II g/dl for CTMU (15.47 3.55 vs. 24.ll 7.97) and
CTMCr (5.36 l.76 vs. 9.43 5,36). In conclusion, treatment with
rHuEPO could modify the peritoneal difusion by decreasing it when the
level of Hb is the same or higher than 11 gIdl.
Relationship between levels of anti-ETO IgE and cutaneous test with
albumin+ETO in dialysis patients. L. Hortal, N. Vega, A. Fernandez,
T. Carrillo, A. Losada, J.C. Rodriguez, C. Plaza, M. Perdomo, L.
Palop, S. NefrologIa, S.Aiergia, S.A. Clinicos, Hospital N.S. del Pino
Las Paimas, Canary Island, Spain. We studied 96 patients (Pats) with
chronic renal failure (CRF) on dialysis, 29 on DPCA and 67 on
hemodialysis (HD), 8 with PAN membrane, and 59 with cuprophan
(CU), with 4.6 3.4 years in the technique and an age of 45.8 14
years. Total IgE (T-lgE), anti-ethylene-oxide-IgE/ETO-IgE) and blood
cell count were determined on all patients. HD Pats also had cutaneous
tests (prick) to pneumoallergens, histamine and specific of albumin
incubated with ETO: 1, 2, 10 and 20mg of albumin and 24, 48 and 72
hours after ventilation. We did not find any difference in T-IgE between
HD and DPCA (49.1 vs. 66.8 107 U/liter, P = NS); ETO-IgE was
1.9 3.4 in HD vs. 0.99 0.41 in DPCA (P < 0.05). A significant
correlation was obtained between the number of eosinophils (EO) and
T-lgE (r = 0.69, P < 0.01), EO and ETO-IgE (r = 0.6, P < 0.01). Pats
dialyzed with PAN had a T-IgE of 11.6 13 vs. 53.7 110 in pats with
CU (<0.05), andETO-IgE of 0.87 0.3 vs. 1.8 3.3 (P <0.05). All the
patients were positive to histamine test. Nine Pats who were positive to
ETO prick had higher levels of ETO-lgE(7.5 7.4 vs. 1.1 0.4; P <
0.01) as well as higher levels ofT-IgE (l79 192 vs. 29 46; P <0.01).
All these patients were dialyzed with CU. Those Pats positive to ETO
prick were all positive with I mg, and a positive correlation was
obtained between the level of ETO-IgE after 72 hr of ventilation and the
popular area produced by the prick (r = 0.7). Conclusion: I) Pats on
CAPD presented levels of T-IgE similar to those on HD. 2) Pats on HD
have ETO-IgE figures higher than those on CAPD, and the Pats with
CU higher T-lgE levels than those with PAN. 3) Pats with positive
specific ETO-albumin cutaneous prick have significantly higher levels
of ETO-IgE, which allows hypersensitivity to ETO to be determined in
a simple way.
Lymphocyte subsets in bone marrow (BM) and blood sample (BS) in
patients treated with rIluEPO. A. Fernández, N. Vega, L. Hortal, T.
Molero, R. Mataix, M. Perdomo, J.C. Rodriguez, C. Plaza, L. Palop,
F. Hernández, H,Ntra, Sra. del Pino, Las Palmas, Canary Islands,
Spain. We studied 24 patients in treatment with rHuEPO (13 in HD and
II in CAPD) with a mean age of 42.7 15.6 years and a time on dialysis
of 55 40 months. Since T lymphocytes modulate erythropoiesis in the
first studies, we evaluated lymphocytes T, and B, T helper (T4),
T.suppressor (T8), helper-suppressor ratio, and natural killer (NK), (I)
before starting treatment with rHuEPO, (2) when the target Hb was
reached in 10 patients, and (3) six months after reaching target Hb in 14
patients.
LT% LB% T4% T8%
NK
BM1
P
BM2
P
BM3
5.9
NS
42.2
NS
30.4
8.5
NS
8
NS
7.8
23.1
NS
28.8
<0.05
15.5
26.1
<0.05
17.3
NS
19
5.3
<0.05
11.8
<0.05
3.1
LT LB T4 T8 NK
BSI
P
BS2
P
BS3
1330
NS
1073
NS
1122
198
NS
131
NS
164
705
NS
557
NS
662
583
NS
586
NS
692
223
<0.01
78
NS
147
rHuEPO modified T4 and T8 subsets in BM, without modification in
lymphocytes T and B. This could be due to the same modification in
antigenic expression in BM or changes in the helper-suppressor ratio.
Dialysis fluids: Quality control and likely sources of aluminium (Al)
contamination. P. Menéndez Fraga, M. Serrano, J.L. Fdez Martin, M.
Miguel, D. Lopez, M. Alonso, J.B. Cannata, Bone and Mineral
Research Unit, Hospital General de Asturias, Oviedo, Nephrology
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Services FundaciOn Jiménez DIaz, Madrid, Hospital Covadonga,
Oviedo, Spain. The present study was carried out with the collaboration
of 160 Spanish dialysis units. In a cross sectional study evaluated the Al
content of (A) tap water, (B) treated water, and (C) final dialysis
solution. The tubes to collect these samples were decontaminated for
trace element analysis and mailed to all participant centers with the
instructions to collect and handle the samples. Al was measured with
atomic absorption spectrometry (detection limit <I pg/liter). The mean
Al was: A, 80 64pg/liter; B, 7 18 pg/liter; and C, 7.68 21 pg/liter.
A total of 51% of the renal units had a final dialysis solution with Al
content lower than 2 pg/liter (ideal value), and 74% lower than 4 pg/liter
(safe and acceptable value). The remaining 26% of units showed results
between 4 and 200 pg/liter (mean higher than 10 pg/liter unacceptable
values) with a positive and significant relationship between tap water
and treated water (r = 0.36, P < 0.05), indicating a non-adequate water
treatment, despite the fact that all the included centers have deioniza-
tion or reverse osmosis. In this study the different concentrates used to
prepare the dialysis solution did not add a significant amount of Al to
the final solution (7 18 pg/liter vs. 7.68 21 pg/liter). Due to these
results we completed the study with an 18 month (monthly) follow-up in
6 renal units. We confirmed our previous analysis, as in many cases we
observed a wide range of variations in the Al concentration of dialysis
fluids (25% of analysis excceding the 10 pg/liter). These findings
emphasize the necessity of routine analysis of Al concentration in
dialysis fluids.
The role of aluminium in cellular uptake of iron (59Fe). M.J. Fernández
Menéndez, S. McGregor, J.H. Brock, J.B. Cannata, Bone and Mineral
Metabolism Unit, Hospital General de Asturias, Oviedo 33080, Spain,
and Immunology Department, Western Infirma,y, Glasgow, United
Kingdom. Aluminium could interfere with the hemobiosynthesis and
induce partial resistant to the effect of recombinant human erythropoi-
etin (rHuEpo). The purpose of the present study was to investigate the
role of aluminium in cellular uptake of iron (Fe) by measuring the
incorporation of 10 pg/mI of Fe [59Fe-transferrin (TO] at the cellular
level when it was administered with: a) 40 pg/mI of Apo-transferrin or
b) 40 pg/mI of transferrin bound to Al (Al-TO. The studies were carried
out using the rat intestinal epithelial cell line RIE I. Three groups of
cells were evaluated with different degree of iron overload: Group I: Fe
depleted cells; Group II: Fe normal cells; Group III: Fe overload cells.
Twenty days prior to performing any test, cultures I and III were Fe
overload by addition of 0.1 m of iron nitrilotriacetate or Fe depleted
with 5 pg/ml/48 hr of desferrioxamine. As expected, the administration
of 59Fe-Tf together with Apo-Tf showed higher incorporation ratios of
Fe in the iron depleted group of cells (DFO) when compared with the
normal and Fe overload groups: 6.8 X l0- 3.5 X lO vs. 4.01 XlO 5.01 x l0— and 5.75 x l0- 3.04 x l0 (log mean SD: P
< 0.05). When Tf was previously complexed with Al (Al-TO, we
observed a significant reduction in 59Fe uptake, the results in the DFO
group becoming very similar to those reported in the Fe overload group
when only Fe-Tf was given to the cells (5.2 x l0 vs. 5.75 X l0).
Results are shown as ng59Fe incorporated by pg of cell DNA. These
data suggest: a) the inhibitory efect of Al in 59Fe uptake at the cellular
level when Fe and Al are administered together and b) the role played
by transferrin as Al carrier when Al is presented to the cell as Al-Tf
complex. This interference in the 59Fe uptake induced by Al may justify
some of the responses observed in some people who lack response to
the hormone.
Evaluating the biochemical and histological hyperparathyroidism ob-
tained with an experimental model to induce chronic renal failure (CRF)
in rats. M.J. VirgOs, P. Menéndez Rodriguez, S. Braga, C. Gómez
Alonso, B. DIaz LOpez, J.B. Cannata, Bone and Mineral Research
Unit, Hospital General de Asturias, Biochemistry Service, Intituto
Nacional de Silicosis, Oviedo, Spain. When studying animals with CRF
and secondary hyperparathyroidism, we needed to know the degree of
hyperparathyroid function we achieved, this aspect being particularly
important when we work with rats because these animals have a
different pattern of bone metabolic behavior compared with other
species. We evaluated the biochemical and histological changes (bone)
observed in 25 rats with CRF obtained using 5/6 nephrectomy. The
study was performed after 7 weeks of surgery, measuring serum, Ca, P,
Cr, BUN, proteins, PTH, creatinine clearance (Car) and tubular reab-
sorption of P (TRP). We obtained 1/3 of the proximal tibia for histolog-
ical analysis after sacrificing the animals. We compared all the results
with 5 control rats with normal renal function. As the table shows, the
mean biochemical parameters demonstrated the existence of hyper-
parathyroidism. Bone histology showed an increase in osteoclasts,
osteoblasts, resorption surface and osteoid surface. We observed
minimal peritrabecular fibrosis.
Basal 7 weeks
Ccr mI/mm
BUN mg/dl
Proteinuria mg/24 hr
TRP%
P1'H pmol/liter
2.12 1.6
17.5 5.8
17 6
90±1
114 47
0.681 0.3
56.5
110 75
85±8"
342 l9l
a p < 0.01, b p < 0.001
This data confirm that after 7 weeks 5/6 nephrectomy is able to induce
a CRF with biochemical and histological changes of hyperparathyroid-
ism.
Aluminium (Al) transfer in hemodialisis (LW): Effect of Al transmem-
brane gradient, different membranes and desferroxiamine (DFO). M.
Alonso, I. Olaizola, P. Menéndez Fraga, R. Elorriaga, C. Caramelo,
J.B. Cannata, Bone and Mineral Research Unit, Hospital General de
Asturias, Oviedo, Nephrology Service, Fundación Jimenéz D(az,
Madrid, Spain. A high percentage (>90%) of Al is bound to transferrin
and is then "non-dializable". To obtain an effective transmebrane Al
gradient the Al concentration in dialysis fluids must be lower than the
ultrafilterable Al in serum (<10%). This transfer may be increase using
high efficient membranes with or without DFO. In this study we
evaluated Al removal in 8 HD patients who were dialyzed throughout 3
consecutive weeks using 3 different membranes (Cuphrophan, Polysul-
fone and Poliacrilinitrilo for 1 week each) with and without using DFO
(15 mg/kg), completing 48 studies and obtaining 144 blood samples (pre,
intermediate and postdialysis) and 528 samples from the dialysate in
different times. Al transfer results had a relationship with: a) Al
concentration in dialysate (P < 0.05, r = —0.58), b) serum Al levels
pre-HD (P < 0.05, r = 0.43), and c) in lesser and no significant degree
with different membranes and DFO, The percentage of Al eliminated
was similar with or without DFO (9.7 3.7 vs. 8.7 1.3). There was
a linear relationship between serum Al pre-HD and Al removal with or
without DFO (r = 0.75 vs. r 0.76, P <0.05), suggesting that 48 hrs
after the infusion of DFO (15 mg/kg) there was no significant increase of
the ultrafilterable Al. These preliminary data suggest that, although
DFO and high efficient membranes should increase Al removal, the
latter is not achieved in the desired amount if the Al in the dialysis fluid
is not low enough (Al in dialysate lower than 5 pg/liter).
Limitations when interpreting the desferrioxamine (DFO) test: Effect of
iron status. M. Alonso, I. Olaizola, P. Menendez Fraga, C. Caramelo,
E. Gago, E. Fernández, J.B. Cannata, Hospitales: General de As-
tunas, Covadonga, F. Jiménez DIaz, Spain, and M. Quintela, Uru-
guay. DFO is currently used as a non-invasive test to evaluate the Al
body burden. As DFO infusion would mobilize both Al and Fe, the
measurement of serum Al increments after the DFO test may be
influenced not only by the amount of Al load but also by the Fe
"status". Therefore, we evaluated the serum Al changes induced by
DFO test as function of the iron metabolism. We performed a DFO test
(40 mg/kg) in 76 patients dialyzed in three dialysis centers using reverse
osmosis water treatment and having a low Al(OH)3 consumption policy.
In addition, in the pre-DFO sample we also measured hematocrit,
hemoglobin, mean corpuscular volume, sferritin, serum Fe and Fe
transferrin saturation. The serum Al increments induced by DFO
correlates negatively with serum Fe and transferrin saturation (P <
0.05). The lower the serum Fe and transferrin saturation the higher the
serum Al increment after the DFO test. If we compare the DFO
response in those patients with Fe repletion (high ferritin, 697 874 and
high Fe transferrin saturation, 61.6 12%) versus those with Fe
depletion (low ferritin, 240 160 and Fe transferrin saturation, 21
5%), we observed a significant higher serum Al increments in Fe
depleted patients (ferritin: 240 160 vs. 140 104, P < 0.05) and
Abstracts 379
(transferrin saturation 160 130 vs. 87 48, P < 0.01). These results
suggest the Fe "status" (serum Fe transport and stores) might be
always considered when interpreting DFO test because patients with
similar Al body burden may have after the DFO test significant
differencies in serum Al increments as function of its Fe metabolism.
Comparison between the aluminium (Al) content in bone and the
"aluminon" results. P. Menéndez Rodriguez, P. Menéndez Fraga, M.J.
Virgos, A. Gonzalez Carcedo, M. Serrano Arias, V. Lorenzo, J.B.
Cannata, Bone and Mineral Research Unit, Hospital General de
Asturias, Oviedo, Nephrology Service, Hospital Universitario de Ca-
narias, Spain. The aim of this study was to evaluate the specificity and
sensitivity of "aluminon" compared with the concentration of Al in
bone measured with atomic absorption spectrometry. We evaluated 25
bone biopsies (6 from iliac crest from hemodialysis patients and 16 from
tibias of Al-intoxicated rats and 3 from Fe-intoxicated rats. We formed
three groups according Al in bone: Group I: (N = 6) Al < 20 gIg (6.5
7.6 g/g), Group 2: (N = 7) Al between 20—50 tg/g (38 8.6 sg/g),
Group 3: (N = 9) Al >50 g/g (78.1 16.4 g/g). The "aluminon" stain
was negative in all cases of Group I, negative in 2 out of the 7 cases of
Group 2 (the otherS were positive), and in one case of Group 3 ("false
negative"), in which the Al concentration was 78 pgIg but the biopsy
also showed severe signs of hyperparathyroidism. The iron stain (Perls)
was positive in three cases of Group 1 (mean of Al: 1.4 0.4 g/g). In
these 3 cases the aluminon stain was positive with a more brownish
stain (false positive). These results demonstrate both methods are
complementary and they can help to avoid the diagnosis of 'false
aluminon positive" due to iron. It is always advisable to complete the
studies of bone histology with an iron stain.
Hypertension in hemodialysis. Evaluation of therapeutics. M. Sanchez,
M.D. Jarillo, F. Garcia Martin, J. Nieto, L. Lozano, Hospital General
de Guadalajara, Universidad de Alcalá de Henares, Spain. We retro-
spectively studied control of arterial hypertension (HTA) in HD and the
progress of the therapeutic needs in 43 patients, with a mean age of
58.18 12.53 years (23—79) and a mean time on HD of 46.67 40.4
months (3—132). A total of 83.72% of patients had HTA subsidiary of
treatment before HD. Of these a 62.7% still needed treatment after
starting HD and 37% normalized their tensional ciphers with ultrafil-
tration (UF). Of the patients requiring pharmacological treatment,
39.5% diminished their needs, 20.93% increased them and 18% required
the same treatment. The HTA was controlled (TA pre-HD < 160/90) in
the 97.67% of the all patients. Of these, 41.8% were controlled
exclusively with UF, 44% needed the addition of one drug, 11.62% two
drugs, and in one case we used three or more drugs in therapy. The
drugs used were: 25% ECA inhibitors and 30% Ca antagonists as
monotherapy, 25% both of them, and in 20% beta-blockers alone or
associated with hydralacine. We did not need to withdraw any medica-
tion chosen as first option due to side-effects. There was no relationship
between control of HTA, age or etiology. The plasmatic renin activity
(PRA) was found high in the 57% of the patients in whom we
determined it; there wasn't a relationship with a better response to ECA
inhibitors nor duration of HD, there was only a negative correlation
found with residual diuresis. Before HD 40.47% of patients had cardiac
repercussion (ECG/ECO), during HD in 45.23%, there not being a
significant increase. A total of 46.5% of the patients had cardiovascular
complications with a elevated correlation with HTA (P < 0.05). A total
of 67.4% had symptomatic hypotension in HD, there was relationship
with age (P < 0.001), and not with weight increase with inter-HD nor
drugs; 37.2% of the patients started treatment with human recombinant
erythropoietin (rHuEPO), of which 46.6% worsened their HTA control(P < 0.01), needing an increase of drugs. Conclusions: HTA is
controlled in 97% of patients in HD. Control is achieved frequently with
UF or monotherapy at low dosage. Bad controlled HTA influences in
cardiovascular morbility in HD. (rHuEPO) worsens HTA, with simple
control increasing medication.
Evaluation of the incidence of C hepatitis in dialysis. L. Lozano, J.
Nieto, M. Sanchez, i.E. Martin, V. Granizo, M.D. Jarillo, S. de
Nefrologia, Hospital de Guadalajara, Universidad de Alcala de
henares, Spain. Virus C (VCH) has recently been identified as an
etiological agent of the majority of no-A no-B postransfusional hepatitis
and of those that occur in drug addicts, there being a correlation
between the incidence of B and delta hepatitis and the presence of
anti-VHC antibodies (Ab). Because there are not many recent studies
concerning hepatitis C and hemodialysis (HD), we decided to study the
incidence of Ab anti-VHC in these patients as well as the different
factor implied. We studied 35 patients on HD, 17 females (48.6%) and
18 males (51.4%); their mean age was 58.8 2 years (23—79). The mean
time of HD was 47.7 7 months (4—37). They had a mean of 10.4 2
blood transfusions (0—50), of which there were was 7.1 I months
(1—20) before testing Ab anti-VCH. In all of them we determined the
title of Ab IgG anti-VCH in sera by ELISA (test was positive when the
S/CO index was > 1.00). Of the 35 patients studied, 20% had Ab
anti-VCH (VCH +) which remained positive all along the study. Com-
paring VCH + with VCH— patients, we observed that VCH+ were
older (61.3 2 vs. 58.2 3)and had been longer in HD (76.3 12 vs.
40.5 7, P < 0.005). The mean transfusion received was higher (17.4
6 vs. 8.6), this difference not being significant. Two patients, who only
received I and 3 blood transfusions during their 123 and 23 months of
HD, were VCH+. As far as alterations in hepatic biochemistry is
concerned these were only present in 28.6% of the VCH+ patients, a
similar proportion to VCH—, although the values in the VCH+ group
were higher (GGT 92 58 vs. 42 17, ALT 51.4 25 vs. 16.8 + 2 and
AST 44.1 25 vs. 20.3 3). Finally, we tried to find a relationship
between VCH and hepatitis B Ab and we saw that the patients VCH+
had a similar percentage of HBs Ab (28.6% vs. 25%), as those VCH—,
but lower in HBc Ab (14.2% vs. 21.5%) and of HBe Ab (0 vs. 13%).
Conclusions: The incidence of Ab anti-VHC in our HD patients was the
20%. Patients VCH+ had been significantly longer in HD and were
older. We did not find significant differences in the number of transfu-
sions in both groups. There seems to be an inverse relationship between
positivity against anti-VCH and presence of Ab anti-HBc and anti-HBe.
The effect of human recombinant erytropoietin (rHuEPO) over hemo-
stasis in patients under hemodialysis. J. Nieto, M.D. Jarillo, B. Pinedo,
M. Sanchez, I. de Ia Villa, L. Lozano, S. Nefrologia, Hospital de
Guadalajara, Universidad de Alcala de Henares, Spain. It has been
postulated that anemia plays an important role in primary hemostatic
problems in patients undergoing hemodialysis. In this work we studied
the effect of the rHuEPO over diverse biochemical and hematological
parameters in 8 uremic patients (4 m and 4 f) with a mean age of 59
10 years. The possibility of hepatopathy was ruled out, and of them
none had a blood transfusion in the three previous months. The dosage
of rHuEPO was 40 U/kg/session, which was doubled if Hb was < 10
g/dl. In all of them we determined both initially and after 20 weeks the
following parameters: 1) hematological: Hto, Hb; 2) platelet function:
Ivy's hemorrhage time, platelets, adhesivity and aggregation induced
by ADP, collagen (COL), adrenalin, araquidonic acid (AA), and risto-
cetin; 3) coagulation: prothrombin, TCK, fibrinogen, antithrombin III
(AT Ill) and protein C (PC); 4) fibrinolysis: plasminogen (PG), PG
tissule activity (t-PG), antiplasmine (a2AP) and inhibitor of the PC
activator (PA!); and 5) biochemical: iron, ferritin, creatinine, K, Ca, P,
AST, ALT, gammaGT, and alkaline phosphatase. Twenty weeks after
the beginning of treatment we saw a significant increase of Hb (P <
0.001) and Hto (P < 0.01), ADP (P < 0.01), ADR (P < 0.05), ATIH (P
<0.001), PC (P <0.05), FMB (P < 0.05), Fe (P <0.01), and ferritin (P
< 0.05) showed a significant decrease. There were no significant
variations in the rest of the parameters although Ivy time, ADS and
platelets tended to increase their value. We did not find a correlation
between Hto and Ivy time, but we did find correlation between Hto and
FBN and ADS. Conclusions: I) rHuEPO is effective in the treatment of
the uremic patient. 2) The correction of anemia with rHuEPO does not
improve the hemostatic disease in this group of patients. 3) The
tendency to improve adhesivity and fibronectin could be due to the
small increase in the platelets, induced by direct action of rHuEPO.
Incidence and progress of glomerulonephritis (GN) associated to neo-
plasms. L. Lozano, P. de Sequera, M. Sanchez, J. Nieto, P. Quijano,
F. Garcia Martin, J. Cuevas, J. Sanchez, M.D. Jarillo, Hospital
General de Guadalajara, Universidad de Alcalá de Henares, Spain.
Glomerular injuries associated with neoplasms have recently been
reviewed, and it has been estimated they are the cause of 10% of
nephrotic syndrome in adults. Our purpose was to verify the incidence
of GN associated with neoplasm as well as the progress and prognosis
of GN. We studied 27 patients who had clinical and histological
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evidence of GN and neoplasm. Eighteen of them (67%) were males and
9 (33%) females. Found were IgA nepropathy in 37.7%, focal sclerosis
ON in 21.4%, minimal change disease in 21.4%, crescentic GN in 14.2%
and membranoproliferative GN in 7.1%. No membranous ON was
found, although the majority of the neoplasms were carcinomas
(72.7%), and 28.3% hematological neoplasms. As far as ON is con-
cerned the mean age of clinical start was 64.4 2 year, and in 75% of
the cases progressed to the neoplasms (mean 4.8 3 year) with
microhematuria, non-nephrotic proteinuria (1.98 2 glday) and in 23%
with hypertension. The appearance of the neoplasm was related to a
clear increase of the proteinuria (20.8 9 g/day) and a worsening of
renal function (Cr 1.2 0.3 vs. 3.2 I mg/dl). The chemotherapy or
surgical treatment bought a diminution of the proteinuria (1.1 0.4
g/day) which in 11.4% of the cases disappeared, and there was no
improvement in renal function (mean Cr 3.12 0,9 mg/dl), which
supposed the inclusion of 4 patients in hemodialysis in complete
absence of tumoral relapse. Circulating immunocomplexes were found
in 65.4% of the patients, and 15.4% had IgO-anticardiolipin antibodies,
a clear predisposition to thromboembolism phenomena. Conclusions:
In our study ONs are more frequently associated with carcinomas than
hematological neoplasms. IgA nephropathy is the ON most frequently
associated with neoplasms, and is not reported in the literature. ON
proceeded to neoplasm, and the clinical presence of the neoplasm
bought an increase of proteinuria and a worsening of renal function.
Treatment of the neoplasm was accompanied by a clear reduction of
proteinuria but no improvement of renal function. Patients with LgG-
anticardiolipin antibodies had thromboembolic phenomena.
Long-term monotheraphy in old patients with moderate hypertension.
M.D. Jarillo, U. Rodriguez, L. Lozano, F. Huget, M. Sanchez, F.
Garcia Martin, J. Nieto, S. NefrologIa, Hospital de Guadalajara,
Universidad de Alcalá de Henares, Spain. The efficacy of hypotensive
treatment with monotheraphy has been demonstrated recently by
means of improving adherance treatment and decreasing the incidence
of secondary effects. The aim of our study was to compare the safety of
three hypotensive drugs (enzyme converting inhibitors, calcium antag-
onists and diuretics), in 90 moderately hypertensive patients (P) (35
males and 55 females) with a mean age of 75 5 years old, during a
period of two years. We divided P in three similar groups (with 30 P
each), and they were treated with: A) enzyme converting inhibitor
(25—100 mg/day); B) calcium antagonists (20 mg/day); C) diuretics (50
mg/day). A blood pressure (BP) of 160/100 was indicative of good BP
control. Biochemical parameters were analyzed at the beginning and at
the end of the study. Results: BP was reduced in the three groups of P:
A) 182± l9vs. 160±15 I l04±7vs.89±8 (P<0.00l)
B) 188 l6vs, 153 20 I 106 6vs. 85 10 (P<0.OOl)
C) 180 IS vs. 148 11 I 105 7 vs. 84 7 (P < 0.001)
At the end of the study, BP was significantly lower in group C versus A.
We obtained a good BP control in 23 (76%), 21(70%), and 19 (63%) P,
respectively. Secondary drug effects caused withdrawal of treatment in
2 P of group A (irritative cough), 4 P of group B (flushing, edema and
tachicardia), and 6 P of group C (cramps and orthostatic hypotension).
Compliance was excellent and only 9 patients (10%) left the medication.
We only found serum biochemistry alterations (glucosa, Ca, uric acid
and K) in group C. Conclusions: Hypotensive drugs are effective in P
who are older than 65, to control BP. Compliance in the treatment of
these patients is good. Mild secondary drug effects were observed,
mainly in patients taking calcium antagonist and diuretics. Biochemical
alterations were found more frequently in the group treated with
diuretics.
